Glucocorticoid access to the brain: involvement of the efflux transporter P-glycoprotein by Karssen, A.M.
  
 
GLUCOCORTICOID ACCESS TO THE BRAIN 
INVOLVEMENT OF  THE  EFFLUX  TRANSPORTER  
P-GLYCOPROTE IN  
 
 
 
 
 
 

  
 
GLUCOCORTICOID ACCESS TO THE BRAIN  
INVOLVEMENT OF  THE  EFFLUX  TRANSPORTER  
P-GLYCOPROTE IN  
 
 
 
 
 
PR O E F S C H R I F T  
 
ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden, 
op gezag van de Rector Magnificus Dr. D.D. Breimer, 
hoogleraar in de faculteit der Wiskunde en Natuurwetenschappen 
en die der Geneeskunde, 
volgens besluit van het College voor Promoties 
te verdedigen op donderdag 30 oktober 2003  
klokke 16.15 uur 
 
 
 
 
door 
 
 
AD R I A A N  MA R T I J N  KA R S S E N  
 
geboren te Delft in 1972 
 PR O M O T I E C O M M I S S I E  
 
Promotor : prof. dr. E.R. de Kloet 
 
Co-promoter : dr. O.C. Meijer 
Referent : dr. A.H. Schinkel (Netherlands Cancer Institute, Amsterdam) 
 
Overige leden : prof. dr. D.D. Breimer 
  prof. dr. F.G. Zitman 
  prof. dr. A.F. Cohen (CHDR, Leiden) 
  prof. dr. G.J. Mulder 
  dr. J. van Gerven (CHDR, Leiden) 
  dr. A.G. de Boer 
  dr. E.C.M. de Lange 
  dr. R.H. de Rijk (Rijngeestgroep, Oegstgeest) 
 
 
 
 
 
 
 
The research described in this thesis was conducted at the division of Medical Pharmacology 
of the Leiden/Amsterdam Center for Drug Research, Leiden University, The Netherlands.  
 
Financial support for the printing of this thesis was kindly provided by: 
− Corcept Therapeutics Inc. 
− J.E. Jurriaanse Stichting 
− LACDR 
− Leids Universiteits Fonds 
− Dr. Ir. van de Laar Stichting 
 
Glucocorticoid access to the brain; involvement of the efflux transporter P-glycoprotein / A.M. Karssen 
 2003 A.M. Karssen 
printed by Ponsen & Looijen BV, Wageningen 
 
Van dit proefschrift is ook een handelseditie verschenen bij uitgeverij Omen Malum 
Litterarum te Drachten onder ISBN 90-805415-7-5. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aan Henk 
 
  
 
 
 
 
 
 
 
Wetenschap zet onze ervaringen in een prachtig 
geordend perspectief, maar is ijzingwijkend stil 
over alles wat ons hart echt raakt.  
(Erwin Schrödinger (1887-1961), fysicus, winnaar Nobelprijs 1933) 
 TABLE  OF  CONTENTS  
Abbreviations 8 
Chapter 1 Introduction and Objectives 9 
 Glucocorticoids 10 
 P-glycoprotein 27 
 P-glycoprotein and glucocorticoids 36 
 Scope of the thesis 40 
Chapter 2 mRNA expression of multidrug resistance P-glycoprotein in brain 45 
Chapter 3 The multidrug efflux transporter P-glycoprotein hampers the access of cortisol 
but not of corticosterone to mouse and human brain 59 
Chapter 4 The role of the efflux transporter P-glycoprotein in brain penetration of 
prednisolone 79 
Chapter 5 Exclusion of dexamethasone from the brain leads to a selective central 
hypocorticosteroid state 95 
Chapter 6 General Discussion 115 
Chapter 7 Summary and Main Conclusions 135 
Chapter 8 References 141 
Chapter 9 Samenvatting 165 
Addendum Efflux transporter P-glycoprotein, cortisol and uptake of the glucocorticoid 
receptor antagonist C-1073 (RU486) in brain 171 
Curriculum vitae 187 
Publications  188 
Nawoord  190 
 
 ABBREV IAT IONS  
 
ABC-transporter adenosine triphosphate (ATP) binding cassette transporter 
ACTH adrenocorticotropic hormone  
ADX adrenalectomy / adrenalectomised 
AVP arginine vasopressin 
BBB blood-brain barrier 
BCB blood-CSF-barrier 
CRH corticotropin-releasing hormone 
CSF cerebrospinal fluid 
CTRL control 
DEX dexamethasone 
DST dexamethasone suppression test 
GFAP glial fibrillary acidic protein 
GR glucocorticoid receptor 
HPA-axis hypothalamus-pituitary-adrenal-axis 
MDR multidrug resistance 
MR mineralocorticoid receptor 
MRP multidrug resistance-associated protein 
Pgp P-glycoprotein 
POMC pro-opiomelanocortin  
PVN hypothalamic paraventricular nucleus 
 
 
  
 Chapter 1 
INTRODUCTION 
AND 
OBJECTIVES 
Chapter 1 
 10
Numerous functions of glucocorticoid hormones have been extensively studied in both clinical 
and animal research. Such research has particularly focussed on the role of these hormones in 
the response to stress and in pathogenesis of stress-related disorders. From these studies, 
glucocorticoids have emerged as important modulators of brain function. To reach their 
diverse target areas in the brain they have to enter the brain by passing the blood-brain barrier 
(BBB), a dynamic barrier that protects the brain from peripheral influences. Although the 
importance of the actions of glucocorticoids in brain is commonly accepted, modulation of 
glucocorticoid access at the BBB level has hardly been a subject of research as these 
hormones are considered to readily pass this barrier. Now that it has been demonstrated that 
transmembrane proteins are able to transport glucocorticoids (Bourgeois et al., 1993; 
Thompson, 1995; Ueda et al., 1996), this issue becomes an increasingly interesting subject to 
study. Dysfunction of the central glucocorticoid signalling system might be related to changed 
efflux of glucocorticoids from the brain.  
 
The research in this thesis is aimed at revealing the importance of glucocorticoid transport at 
the BBB. It describes the impact of the presence of the efflux transporter P-glycoprotein on 
the uptake of glucocorticoids and it describes a way of targeting P-glycoprotein to affect the 
stress system. Knowledge about the role of the BBB in modulating glucocorticoid access to 
the brain might eventually provide clues for development of new drugs that might be able to 
restore aberrant corticosteroid functioning in stress-related disorders.  
GLUCOCORT ICO IDS  
Glucocorticoids belong to the class of adrenal corticosteroid hormones. Adrenal 
corticosteroids are essential for life, as they coordinate the responses of body and brain to 
changes in both the external and internal environment. They play a crucial role in homeostasis, 
which comprises the processes of maintaining the internal environment of the body in a 
condition consistent with survival of the individual (Fink, 2000).  
Generally, two subgroups of adrenal corticosteroids are recognised, mineralocorticoids and 
glucocorticoids. The subgroup of glucocorticoids comprises many structurally related 
naturally occurring and synthetic hormones (figure 1). The main naturally occurring 
glucocorticoids are cortisol and corticosterone. The most common synthetic glucocorticoids 
are dexamethasone and prednisone/prednisolone.  
Functions of Cort icosteroids 
The prime physiological function of mineralocorticoids (mainly aldosterone) is control of 
electrolyte homeostasis and blood pressure (Agarwal and Mirshahi, 1999). Glucocorticoids 
have more widespread effects. In fact, virtually every cell in the body is sensitive to their 
actions. These hormones act on a wide range of physiological functions, including those 
involved in energy balance and metabolism, immunity, circadian rhythmicity, cardiovascular 
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regulation, cognitive processing, behavioural adaptation and mood (Murphy, 2000). The 
actions of synthetic glucocorticoids are generally more potent than those of naturally 
occurring glucocorticoids. For this reason and because they are often devoid of 
mineralocorticoid (=salt-retaining) actions, they are commonly used as anti-inflammatory and 
immunosuppressive drugs.  
A major target of glucocorticoids is the brain (McEwen et al., 1986a; Belanoff et al., 2001). 
Their effects on the brain range from feedback inhibition of their own secretion (Keller-Wood 
and Dallman, 1984; Dallman et al., 1987a), and modification of neuronal integrity and 
function (Joëls and De Kloet, 1992; Magariños et al., 1997; Gould and Tanapat, 1999; 
McEwen, 1999), to modulation of memory and learning processes and behavioural adaptation 
to stress (Lupien and McEwen, 1997; De Kloet et al., 1998; De Kloet et al., 1999).  
Glucocorticoid secretion 
Endogenous glucocorticoids are secreted by the adrenal gland under tight control of the brain. 
The neuroendocrine system that regulates this secretion is known as the Hypothalamo-
Pituitary-Adrenal Axis or HPA-axis (figure 2). This system provides the link between the 
perception of physical and psychological stress and the regulation of key homeostatic 
mechanisms in brain and periphery.  
Upon activation by a large variety of stimuli, a specific set of neuroendocrine neurons in the 
paraventricular nucleus of the hypothalamus (PVN) secretes corticotropin-releasing hormone 
(CRH) into a portal vasculature to the anterior pituitary. In many species these parvocellular 
neurons, located bilaterally from the third ventricle, co-secrete vasopressin (AVP). Within the 
anterior pituitary, the peptidergic hormone CRH stimulates cells both to synthesise 
adrenocorticotropic hormone (ACTH) from its precursor pro-opiomelanocortin (POMC), and 
to release ACTH into the main circulation, whereas AVP potentiates the effect of CRH. Via 
the blood circulation ACTH reaches the adrenal cortex to stimulate the synthesis of 
glucocorticoid hormones from cholesterol. These hormones are immediately secreted into the 
systemic circulation to act elsewhere in the body.  
 
In mice and rats, corticosterone is the only active endogenous glucocorticoid hormone. In 
other species including humans the principal glucocorticoid is cortisol. However, in these 
species some corticosterone is also circulating e.g. in humans at 10 to 20 times lower levels 
than cortisol (Underwood and Williams, 1972; Kage et al., 1982). As most research is done in 
rats and mice, much is known about the actions of corticosterone in the rodent brain. Less is 
known about the central actions of cortisol in human and other cortisol secreting animals, 
although it is generally assumed that these actions are similar to -or at least comparable with- 
those of corticosterone (Lupien and McEwen, 1997). Indeed, no major differences have been 
described so far between the actions of corticosterone and cortisol. 
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FIGURE 1. Molecular structures of several naturally occurring and synthetic corticosteroids.  
Cortisol and corticosterone are the main active glucocorticoid hormones circulating in the plasma of 
mammals. Hydrocortisone is the common name of the synthetic form of cortisol. Cortisone and 
dehydrocorticosterone are inactive metabolites, that can be reconverted into cortisol respectively 
corticosterone in the body. Cortexolone (also deoxycortisol) and deoxycorticosterone are the 
immediate precursors of cortisol respectively corticosterone in the biosynthetic pathways of the latter 
hormones. Prednisolone and dexamethasone are synthetic hormones, whereas aldosterone is the 
main endogenous mineralocorticoid. Aldosterone mainly circulates in the hemiacetal form with a 
cyclic 11-18 hemiacetal bridge. RU486 (also named mifepristone, RU38486 or C-1073) is a 
synthetic antagonist of both the glucocorticoid and progesterone receptor. 
Circadian rhythm 
Basal glucocorticoid secretion follows a circadian pattern, with a peak at the start of the active 
period, which is in early morning for diurnal animals like humans and at onset of darkness for 
nocturnal animals like mice and rats. There is also an ultradian pattern with a rather constant 
pulse frequency (Follenius et al., 1987; Windle et al., 1998). The circadian rhythm is driven 
by the biological clock in the suprachiasmatic nucleus (SCN) which conveys excitatory and 
inhibitory activity to the PVN (Dallman et al., 1987a; Buijs et al., 1997). Furthermore, the 
SCN regulates adrenal sensitivity to ACTH and thus corticosteroid secretion directly via 
sympathetic neural input to the adrenal gland (Buijs et al., 1997; Jasper and Engeland, 1997).  
Stress 
Secretion of glucocorticoids is also manifold enhanced after stress. Basically any kind of 
disturbance of homeostasis, either real or perceived, or ‘stress’, will result in a stress response. 
This stress response comprises a spectrum of physiological and behavioural adaptations of the 
individual aimed to restore homeostasis. The stimulus that evokes the stress response is 
referred to as stressor. Stressors might be divided in systemic stressors, which directly disturb 
physiological integrity (e.g. infections, temperature or blood volume changes), and 
psychological stressors, which disturb or threaten to disturb mental integrity (e.g. fear, social 
conflict, traumatic life event). The latter require interpretation by higher brain centres and are 
particularly powerful stressors. Many stressors, however, have both systemic and 
psychological aspects.  
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FIGURE 2. The Hypothalamus-Pituitary-Adrenal axis or HPA-axis.  
After activation by other brain areas that are stimulated by e.g. stress the hypothalamic
paraventricular nucleus (PVN) secretes CRH and vasopressin into a portal system to the anterior
pituitary. Specific cells in this structure are stimulated to release ACTH, which reaches the adrenal
via the main circulation. Adrenal cortical cells are stimulated to secrete corticosterone in rodents or
cortisol/corticosterone in humans. These glucocorticoid hormones feedback to the brain and the
pituitary to suppress activity of PVN and pituitary. They also have effects on many aspects of brain
function. Except for the pituitary most of the feedback sites of glucocorticoids lie behind the
blood-brain barrier.  
The inset, added for figurative reasons, shows a coronal section of rat brain at the level of the PVN
(black area within circle represents parvocellular part of the PVN). 
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Stressors activate the brain, which via activation of the HPA-axis eventually results in 
glucocorticoid secretion. The central response is a highly integrated process in which diverse 
neuronal systems are involved (De Kloet, 1991; Herman and Cullinan, 1997). Distinct types of 
stressors differentially activate distinct neural and neuroendocrine systems involved in the 
stress response (Senba and Ueyama, 1997), each affecting neural and neuroendocrine activity 
in their own specific way (Pacak and Palkovits, 2001). Systemic (aspects of) stressors mainly 
affect brainstem or hypothalamic areas, while psychological (aspects of) stressors depend on 
processing in limbic areas (Herman et al., 1996). These different stress-responsive brain areas 
have direct or indirect projections to the PVN through which they orchestrate the HPA-axis 
activity (figure 3) (Keller-Wood and Dallman, 1984; Makara, 1985; Herman and Cullinan, 
1997). In addition, these neural pathways are subject to input from other regulatory centres, 
which are not directly involved in the stress response. These regulatory inputs affect the 
responsiveness of the stress system in general. The magnitude of the glucocorticoid response 
is thus clearly context-dependent, although the response itself seems to be rather non-specific 
as essentially any kind of stressor ultimately results in secretion of glucocorticoids.  
 
Although glucocorticoids are intimately linked to stress they do not mediate the rapid primary 
reaction of the individual. The initial phase of the stress response, occurring within seconds, 
typically consists of activation of the sympathetic nervous system bringing the individual in a 
state of arousal (‘fright-fight-flight’ response). This phase also includes the first part of 
endocrine cascades (i.e. adrenaline, ACTH), which eventually, within minutes, results in the 
rise of plasma glucocorticoid levels. As it takes minutes to increase glucocorticoids levels in 
response to stress, glucocorticoids rather play secondary, but critical, roles in concert with the 
sympathetic nervous system.  
Glucocorticoids prevent primary stress responses from overreaction, thus protecting the 
individual against the potential threat of homeostasis caused by its own defence systems, as 
was independently postulated by Munck et al. (1984) and Tausk (1951). For instance, 
suppression of the immune system during infection limits the inflammatory response, and 
stress-induced levels of glucocorticoids facilitate the formation of memory of potentially 
dangerous events giving an individual the ability to successfully cope with a subsequent 
stressful event. Thus, generally, glucocorticoids play a beneficial role in the adaptation to 
stress.  
 
The process of adaptation to stress may also be described as allostasis, which means active 
maintenance of homeostasis through change (McEwen, 2000). In response to stressors, 
changes in glucocorticoid secretion and in other parts of the stress system help to re-establish 
stability of body and brain function and to promote adaptation to and coping with the stress. 
The operational cost of allostasis is termed allostatic load, which implies the price to be paid 
to actively maintain stability when the allostasis response systems are excessively challenged. 
Repeated or prolonged challenges may lead to vulnerability to stress-related disorders.  
Chapter 1 
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FIGURE 3. Some of the brain areas involved in regulation of HPA-axis activity.  
Many different brain areas control the activity of the PVN and thus the activity of the HPA-axis. In 
turn, the activity of these areas is modulated by glucocorticoids. Each stressor, irrespective of the 
type, ultimately activates the CRH system in the parvocellular PVN, which results in stimulation of 
the anterior pituitary (AP) and subsequently in secretion of glucocorticoids from the adrenal. 
Systemic stressors mainly activate catecholaminergic systems located in the brain stem such as the 
locus coeruleus (LC), which may directly activate the PVN. Psychological stressors depend on 
limbic-forebrain circuits (e.g. prefrontal cortex (PFC), amygdala, hippocampus (HIP)) which via 
multisynaptic pathways converge on the PVN. Many of these areas project to GABA-ergic neurons 
near the PVN, which exert inhibitory influences on the parvocellular neurons. 
Glucocorticoids mainly exert negative feedback on the HPA-axis by suppression of CRH in the PVN 
and POMC in the anterior pituitary, but also by their actions via the hippocampus and prefrontal 
cortex. In contrast, glucocorticoids activate the CRH system located in the central nucleus of the 
amygdala (CeA), potentially forming a positive feedback loop. Particularly via the hippocampus and 
the amygdala, glucocorticoid hormones affect behaviour and cognition.  
Abbreviations: AP anterior pituitary; cc corpus callosum; CeA central nucleus of the amygdala; HIP 
hippocampus; LC locus coeruleus; PFC prefrontral cortex; PVN hypothalamic paraventricular 
nucleus. 
Glucocorticoid actions  
Glucocorticoids and stress are often considered to be harmful for the body and particularly for 
the brain (Sapolsky et al., 1986; Sapolsky, 1996). Indeed, prolonged or out-of-context 
elevations of glucocorticoids may be maladaptive, enhancing vulnerability to stress, and 
contributing to human psychopathologies (Holsboer and Barden, 1996; Pariante and Miller, 
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2001; Belanoff et al., 2001). However, as long as the glucocorticoid actions are confined 
within certain limits, the glucocorticoid response to stress is in fact crucial for healthy 
functioning of the brain (De Kloet et al., 1998; De Kloet et al., 1999; Lupien and Lepage, 
2001). Without glucocorticoids, the individual likely would not survive many events in daily 
life. 
Context- and time-dependency 
The actions of glucocorticoids induced by circadian activity or stress are diverse and 
complicated and depend on the context in which they are operating. Depending on the 
physiological endpoint in question, glucocorticoid actions can permit, stimulate or suppress 
ongoing primary responses to stress or can be preparative for a subsequent stressor (Sapolsky 
et al., 2000). However, glucocorticoids do not only affect various physiological functions but 
they also modulate behaviour. They do not cause behaviours, but they induce chemical 
changes in particular sets of neurons, making certain behavioural outcomes more likely as a 
result of strengthening or weakening of particular neural pathways. Thus, glucocorticoids can 
operate in a ‘proactive’ mode through anticipatory physiological and behavioural activity to 
prepare the organism for upcoming events in order to maintain homeostasis (De Kloet et al., 
1998; De Kloet, 2002). In the ‘reactive’ mode they operate to restore homeostasis from 
disturbances by stressors by terminating the primary stress response. The latter mode 
facilitates storage of behavioural strategies that have appeared to be successful in dealing with 
stressors and eliminates behaviour of no more relevance.  
The permissive actions controlling the sensitivity of the stress system are evident at low levels 
of glucocorticoids, whereas the suppressive or stimulating actions facilitating the adaptation to 
stress emerge only when glucocorticoid levels are raised as following a stressor (Sapolsky et 
al., 2000).  
 
Actions of glucocorticoids are mostly modulatory and conditional, as they can often only be 
detected in presence of other stimuli (De Kloet et al., 1998). Glucocorticoids change the state 
of the cell or animal making it more or less receptive for the actions of other subsequent 
stimuli. Basal neuronal activity of hippocampal cells does not change in presence of 
glucocorticoids, but glucocorticoids change neuronal excitability as exemplified by the effects 
of glucocorticoids on voltage-dependent calcium fluxes and aminergic responses of 
hippocampal neurons (Joëls and De Kloet, 1994). Furthermore, the activity of the affected 
gene or system at the moment of glucocorticoid action determines the way glucocorticoids 
effectuate their action. Stress levels of corticosterone immediately after a learning experience 
promote consolidation of memory, but if corticosterone is administered out-of-context 
memory storage is impaired (Oitzl and De Kloet, 1992). The repressive actions of 
glucocorticoids on c-fos expression can only be observed after stress (Imaki et al., 1995), 
whereas the presence of the apoE gene determines the way mice react on stress in a 
glucocorticoid dependent learning task (Grootendorst et al., 2001). Previous stress experiences 
like early life events or chronic stress can change this state affecting the way a cell or animal 
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will react on subsequent exposure to glucocorticoids (Akana and Dallman, 1997; Workel et 
al., 2001). Thus, the same hormonal signal can have differential, even opposing effects 
depending on the circumstances.  
Corticosteroid receptors 
By far most of the actions of corticosteroids involve altering the expression of target genes. 
Corticosteroids exert their genomic actions mainly via two types of intracellular receptors, the 
glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR) (De Kloet, 1991). MR 
and GR are structurally highly homologous. They belong to the protein family of nuclear 
receptors. Upon binding of hormone, the steroid-receptor complex dissociates from a large 
protein complex and translocates from the cytosol to the nucleus to function as transcription 
factors. MR and GR can subsequently enhance (transactivation) or repress (transrepression) 
gene expression (Truss and Beato, 1993; Beato et al., 1996). Transactivation generally occurs 
through binding of MR or GR as homodimers to the specific DNA sequences, known as 
glucocorticoid response elements (GRE) in the promoter regions of target genes. The term 
transrepression is often used to describe the ability of activated GR as monomer to interact 
with other transcription factors via protein-protein interactions but may, for both MR and GR, 
also occur via DNA binding. 
Distribution 
MR and GR differ in their distribution and in their affinities for corticosteroids (Reul and De 
Kloet, 1985; De Kloet, 1991). The GR is localised throughout the body, including thymus, 
anterior pituitary and brain. Within the brain, GR is present in almost every region. 
Particularly high densities are found in the parvocellular neurons of the PVN, where 
glucocorticoids regulate the expression of CRH and AVP, and in neurons of hippocampal 
formation, which is a brain region involved in regulation of the behavioural stress response 
(Van Eekelen et al., 1988; Chao et al., 1989; Spencer et al., 1990). The MR is mainly 
localised in the classical peripheral mineralocorticoid target tissues such as the kidney, and in 
some areas within the brain (Krozowski and Funder, 1983). Central localisation is restricted to 
limbic regions such as hippocampus, septum and amygdala (Arriza et al., 1988; Van Eekelen 
et al., 1988; Chao et al., 1989; Spencer et al., 1990; Ahima et al., 1991). In these areas MR is 
abundantly expressed. MR is also found, although at lower levels, in the anterior 
hypothalamus and subfornical area (Van Eekelen et al., 1991). Particularly in hippocampus 
glucocorticoids can activate two signalling pathways via both MR and GR, as high levels of 
both receptor types are colocalised here (Van Eekelen and De Kloet, 1992). 
Affinity 
Cortisol, corticosterone and aldosterone can all bind to MR with very high affinity (all Kd 
values~0.5nM), whereas synthetic glucocorticoids like dexamethasone and prednisolone have 
a much lower affinity to this receptor (table 1) (Moguilewsky and Raynaud, 1980; Veldhuis et 
al., 1982; De Kloet et al., 1984a; Reul and De Kloet, 1985; Arriza et al., 1987; Luttge et al., 
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1989; Spencer et al., 1990; Reul et al., 2000b). On the other hand, whereas cortisol and 
corticosterone have a ten times lower affinity to GR than to MR, synthetic glucocorticoids 
have a very high affinity to GR (Coirini et al., 1983; De Kloet et al., 1984a; Reul and De 
Kloet, 1985; Arriza et al., 1987; Spencer et al., 1990). Aldosterone hardly binds to GR. The 
best-known effective receptor antagonist of glucocorticoids is mifepristone (RU486; 17β-
hydroxy-11β-(4-dimethylaminophenyl)-17α-(1-propynyl))-estra-4,9-dien-3-one) 
(Moguilewsky and Philibert, 1984). This compound, originally developed as a progesterone 
antagonist, expresses a high affinity for the glucocorticoid receptor, but binding generally does 
not result in stimulation of transcription. RU486 antagonises glucocorticoid effects in vitro 
and inhibits the effect of dexamethasone on HPA activity in vivo, although it may still have 
agonistic properties in some in vitro (Heck et al., 1994) and in vivo settings (Bradbury et al., 
1991). 
Table 1. Some characteristics of common glucocorticoids. 
corticosteroid receptor affinity plasma binding 
a 
cortisol/hydrocortisone MR/GR 
b 
CBG/albumin 
f 
corticosterone MR/GR 
b 
CBG/albumin 
f 
dexamethasone GR 
c 
- 
prednisolone GR/(MR) CBG/albumin 
f 
cortisone - albumine 
dehydrocorticosterone - n/a 
cortexolone/deoxycortisol (GR) 
d 
CBG/albumin 
f 
deoxycorticosterone MR n/a 
aldosterone MR albumine 
g 
RU486/mifepristone GR antagonist 
e 
AAG 
h 
n/a not available 
a. Plasma binding in human plasma. 
b. Both cortisol and corticosterone have very high affinity to MR and a 10 times lower 
affinity to GR. 
c. In vitro, dexamethasone has affinity for MR, but due to the unstable dexamethasone-MR 
complex dexamethasone does not act via MR in vivo. 
d. Cortexolone has some affinity for the GR and may act as a partial GR antagonist. 
e. RU486 is an effective GR antagonist, but is also a progesterone receptor antagonist. 
f. CBG is the main corticosteroid binding protein in plasma, which binds about 70-80% of 
hormone; albumine binds another 10-20%; 5-10% circulates as unbound fraction. 
g. About 40% of aldosterone circulates bound to albumine. 
h. In humans (but not in most other species) 95% of RU486 is bound to α-1-acid 
glycoprotein (AAG). 
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In spite of the equal affinities of cortisol/corticosterone and aldosterone to MR (Krozowski 
and Funder, 1983; Coirini et al., 1985), there seems to be aldosterone-selective and 
glucocorticoid-selective forms of MRs. The predominantly aldosterone-selective MRs are 
found in classical mineralocorticoid target cells in peripheral tissues like kidney and colon, but 
also in brain areas involved in central regulation of sodium homeostasis and blood pressure 
like the anterior hypothalamus and circumventricular organs (McEwen et al., 1986b; Brody et 
al., 1991; Van Eekelen et al., 1991; Pietranera et al., 2001). Enzymatic conversion by 11ß-
hydrosteroid dehydrogenase (11ß-HSD) type 2 into the inactive 11-keto derivatives cortisone 
respectively 11-dehydrocorticosterone (figure 1), which have little or no affinity for MR or 
GR, largely excludes cortisol and corticosterone from these MRs explaining the ‘MR paradox’ 
(Edwards et al., 1988; Funder et al., 1988; Seckl, 1997). The apparent glucocorticoid 
selectivity of MR in the limbic brain is presumably mainly explained by competitive 
predominant occupancy by cortisol/corticosterone, since these hormones circulate in 100-1000 
fold excess to aldosterone (Kage et al., 1982; Reul and De Kloet, 1985; Yongue and Roy, 
1987). 
Occupancy 
The difference in affinity of MR and GR for corticosterone/cortisol has important implications 
for the occupancy of central receptors throughout the day and during stress. At basal trough 
levels limbic MR is already activated to a considerable extent; even at low plasma levels of 
glucocorticoids 80-95% of these MRs are still occupied (Reul and De Kloet, 1985; Spencer et 
al., 1990), although a recent study argued against this high proportion (Kalman and Spencer, 
2002). Occupation of GR is low at the nadir of the circadian rhythm, but is progressively 
increased when glucocorticoids levels rise during the circadian peak or, more pronounced, 
after stress (Reul et al., 1987a). Due to their differences in affinity for endogenous 
glucocorticoids and their differential localisation in neuronal structures both types of receptors 
form a dual receptor system able to mediate glucocorticoid action through different neuronal 
circuits in face of a wide hormone concentration range.  
Glucocorticoid feedback 
Glucocorticoids feed back to the brain through both MR and GR to suppress pituitary-adrenal 
secretion (Dallman et al., 1987a), but also to modulate behaviour (De Kloet et al., 1998). 
Based on the differential occupancy of MR and GR, it has been postulated that glucocorticoids 
exert their tonic, permissive influences predominantly via the hippocampal MRs, whereas 
feedback actions on activated brain areas are mainly mediated by GRs (De Kloet and Reul, 
1987; De Kloet, 1991; De Kloet et al., 1999). The MR-mediated proactive effects are involved 
in control of basal activity of the HPA-axis and selection of an appropriate behavioural 
response. MR activation might function to sensitise the stress system for upcoming challenges 
and to organise the response to stress. The reactive processes of glucocorticoid feedback 
actions mediated by GR contribute to restoration of homeostasis and facilitation of 
behavioural adaptation after stress or during the circadian rise.  
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Through their MR- and GR-mediated feedback on the HPA-axis, the actions of 
glucocorticoids are constrained within appropriate limits. Direct negative feedback is exerted 
through GR present in PVN and pituitary (Keller-Wood and Dallman, 1984). Indirect 
feedback operates through both MR and GR present in diverse brain areas(Dallman et al., 
1994) and suppressive as well as facilitatory effects can be exerted through various afferent 
multisynaptic neural pathways to the PVN (figure 3). Among these are those from limbic areas 
like hippocampus and amygdala, and different cortical areas but also from serotonergic and 
catecholaminergic brainstem systems and diverse hypothalamic areas (Dallman et al., 1995; 
Herman et al., 1996; Herman and Cullinan, 1997; Lopez et al., 1999; Laugero, 2001; Makino 
et al., 2002). Many of these areas project to GABA-ergic neurons just outside the PVN, which 
have inhibitory inputs to the parvocellular neurons (Herman et al., 2002). Like the stress-
initiating areas, these glucocorticoid feedback circuits operate in a stressor-specific manner 
(Herman and Cullinan, 1997).  
 
Consistent with the hippocampal MR specificity, intracerebroventricular (icv) administration 
of MR antagonist elevated basal trough levels of corticosterone (Ratka et al., 1989), whereas a 
corticosterone but not a dexamethasone implant in the dorsal hippocampus reduced ACTH 
levels after adrenalectomy (Kovács and Makara, 1988). Icv administration of the GR 
antagonist RU486 does not interfere with basal trough pituitary adrenal activity, supporting 
the sole involvement of MR during that period (Ratka et al., 1989; Van Haarst et al., 1996a). 
However, RU486 increases the basal peak and stress-induced activity (Gaillard et al., 1984; 
Ratka et al., 1989; Van Haarst et al., 1996a), consistent with a role of GR in feedback 
regulation at these periods of high circulating corticosterone levels. The GR involved in 
negative feedback is located at different brain sites including the PVN. After icv injection or 
local application within the PVN RU486 increased neuroendocrine activity at the circadian 
peak or after stress only (De Kloet et al., 1988; Van Haarst et al., 1996a; Van Haarst et al., 
1997). Only at even higher plasma levels corticosterone also feeds back via the GR in the 
pituitary (Dallman et al., 1987b; Levin et al., 1988).  
 
Synthetic glucocorticoids acting through GR are particularly potent in suppression of HPA-
axis activity. They suppress basal levels of ACTH and corticosterone during the circadian rise, 
and they reduce stress-induced rises in ACTH and corticosterone plasma levels. It is likely that 
the pituitary gland is the primary site of action of dexamethasone. In contrast to corticosterone 
which is preferentially retained by hippocampal neurons (McEwen et al., 1968; McMurry and 
Hastings, 1972; De Kloet et al., 1975; Coutard et al., 1987), dexamethasone is mainly retained 
in nuclei of pituitary corticotropes (De Kloet et al., 1974; De Kloet et al., 1975). The exact site 
of action of other synthetic glucocorticoids like prednisolone is not known, although 
prednisolone has been presumed to act more similar to cortisol (McEwen, 1997; Pariante et 
al., 2002). 
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In presence of endogenous glucocorticoids GR never acts alone. Moreover, both receptor 
types have to be activated for proper functioning of negative feedback (Bradbury et al., 1994; 
Spencer et al., 1998) and cognitive processing (Oitzl et al., 1997). Treatment with synthetic 
glucocorticoids, which mainly bind to GR, may therefore lead to an imbalance in MR and GR-
mediated actions, which could have detrimental effects on brain function. 
 
Glucocorticoids do not only exert equivalent actions through MR and GR. Opposing effects of 
MR and GR activation have also been described, both at the cellular (Joëls and De Kloet, 
1994) and at the systemic level. Hippocampal MR blockade results in a disinhibitory effect on 
CRH containing neurons in the PVN, whereas hippocampal GR blockade results in an 
inhibition of PVN function (Van Haarst et al., 1997). Although corticosterone-responsive MR 
is predominantly expressed in the limbic brain, opposing effects are not only restricted to 
single hippocampal cell types expressing both types of receptors. MR can influence many 
processes in the brain through the efferent projections of the hippocampus to various brain 
areas. Therefore, even when expressed in different brain areas, MR and GR can act in a 
dichotomous co-ordinate action on many neural circuits, ultimately affecting behaviour and 
HPA-axis activity. This dichotomy may provide the basis of U-shaped or bell-shaped dose 
response curves often seen in glucocorticoid action (Oitzl et al., 1994; De Kloet and Joëls, 
1996; Lupien and Lepage, 2001). 
 
The way many actions of glucocorticoids at the physiological level are ultimately linked to the 
actions at the levels of gene regulation is hardly understood. Obviously, the type of receptors 
involved, MR, GR or both, may underlie the differential effects of glucocorticoids on cellular 
function. Activated MRs and GRs differ in their potency to induce changes in gene 
transcription with GR generally as the more potent one (Meijer, 2002). Specificity at the 
cellular level in the way MR and GR influence gene transcription is achieved by receptor-
specific efficacy at certain regulatory DNA regions (Rupprecht et al., 1993) and receptor-
specific interactions with other proteins like the transcription factor AP1 (Bamberger et al., 
1996), or coactivators and corepressors (Meijer, 2002). On the physiological level, however, 
other mechanisms are involved as well, as apparently simple physiological functions often 
require interactions among many glucocorticoid regulated target areas, cells and genes, as well 
as interactions with other hormones and mediators.  
Aberrant glucocorticoid action 
Because of their differential sometimes even opposing effects, a proper balance between MR 
and GR mediated actions is critical for homeostatic control and behavioural adaptation to 
stress. A change in this balance may compromise the ability to maintain homeostasis and may 
progressively create a condition of disturbed neuroendocrine regulation and impaired 
behavioural adaptation (De Kloet, 1991; De Kloet et al., 1998; Lupien and Lepage, 2001). 
This condition may underlie enhanced vulnerability to disease and may eventually lead to 
stress-related disorders (Holsboer, 2000; Makino et al., 2002). It is therefore not surprising 
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that stress-related diseases are often associated with abnormalities in glucocorticoid plasma 
levels. Hypersecretion of these hormones is a consistent finding in various subtypes of major 
depression (Holsboer and Barden, 1996; Gold and Chrousos, 2002), whereas hyposecretion is 
found in atypical depression (Gold and Chrousos, 2002) and post traumatic stress disorder 
(Yehuda, 1998). These abnormalities might be related to malfunctioning of corticosteroid 
receptor signalling. Inadequate control of glucocorticoid action may severely threaten health 
and well-being of the individual. Glucocorticoid action, therefore, needs to be tightly 
regulated. 
Ligand availabil ity 
Central control of secretion is obviously one of the main regulatory mechanisms of 
glucocorticoid action, but its effect is rather general. Regulation of expression or function of 
corticosteroid receptors and/or regulatory proteins provides additional, more locally acting 
mechanisms. Yet, glucocorticoid action can also be influenced even before glucocorticoids 
reach their intracellular receptors through modulation of their access to the target cells. 
Binding of corticosteroids to plasma proteins can affect uptake into tissues and can dampen 
sharp fluctuations in glucocorticoid plasma levels. Furthermore, at the level of the cell 
membrane, transport of glucocorticoids can influence uptake into the cell. Finally, within the 
cell, binding to proteins and enzymatic conversion can affect receptor binding.  
Corticosteroid-binding globulin (CBG) 
Approximately 90-95% of circulating endogenous glucocorticoid is protein bound mainly to 
corticosteroid-binding globulin (CBG), a specific low-capacity high-affinity plasma protein, 
but also to serum albumin, a common carrier protein with low affinity (table 1) (Pardridge, 
1981). The synthetic glucocorticoid prednisolone is also bound to both plasma proteins (Jusko 
and Ludwig, 1992), whereas dexamethasone is not bound to CBG. CBG may regulate 
bioavailability and metabolic clearance of glucocorticoids (Breuner and Orchinik, 2002). In 
principle, only free glucocorticoids have ready access to their intracellular receptors (Dallman 
et al., 1987a; Breuner and Orchinik, 2002), but local mechanisms may locally promote 
glucocorticoid delivery by releasing corticosteroid from plasma proteins. These include 
biochemical or physical properties like the ratio between capillary transit time and dissociation 
rate (Pardridge, 1981), but also biological mechanisms like the presence of plasma membrane 
binding sites and enzymatic cleavage of CBG (Pemberton et al., 1988; Hammond, 1995). The 
former may also play a role in brain delivery (Pardridge, 1981; Pardridge et al., 1983), the 
latter probably not (Hammond, 1995). At the blood brain barrier, the albumin-bound fraction 
may also be available for transport into the brain probably due to physical properties, 
increasing the brain uptake to 20-25% of total plasma levels (Pardridge and Mietus, 1979). 
CBG is also found intracellular in some tissues including pituitary but not in brain (Hammond, 
1990) and may affect glucocorticoid actions by sequestering glucocorticoids (De Kloet et al., 
1977; De Kloet et al., 1984b). CBG levels can be downregulated by glucocorticoids and stress 
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due to suppression of hepatic synthesis (Dallman et al., 1987a; Smith and Hammond, 1992) 
relatively increasing the biologically active levels of glucocorticoids. 
11ß-Hydroxysteroid dehydrogenase type 1 
In addition to the aforementioned 11ß-HSD type 2, a genetically distinct isoform is 
ubiquitously present that can also potentially modulate the intracellular levels of 
glucocorticoids. This 11ß-HSD type 1 (11ß-HSD1) can also mediate the metabolic 
interconversion of cortisol and corticosterone into inert cortisone and 11-
dehydrocorticosterone respectively, although in vivo it acts as an exclusive reductase, thus 
locally reactivating glucocorticoids (Jamieson et al., 2000; Seckl and Walker, 2001). It is 
expressed in numerous tissues such as liver, lung, and adipose tissue and also in brain and 
pituitary (Seckl, 1997). The enzyme is often colocalised with GR, thus able to enhance 
glucocorticoid action by contributing to the intracellular supply of active glucocorticoids 
available for GR binding (Seckl, 1997). A role of 11ß-HSD type 1 in amplifying 
glucocorticoid action in the periphery has been demonstrated with 11ß-HSD1 (-/-) knockout 
mice (Kotelevtsev et al., 1997). These mice are unable to reactivate glucocorticoids. Despite 
compensatory adrenocortical hyperplasia and increased ACTH/corticosterone secretion, upon 
starvation they demonstrate diminished activation of glucocorticoid responsive hepatic 
gluconeogenic enzymes. They are further resistant to hyperglycaemia induced by obesity or 
stress (Kotelevtsev et al., 1997). This is consistent with impaired intrahepatic regeneration of 
glucocorticoids.  
Within the brain 11ß-HSD1 may also modulate glucocorticoid action, although there is no 
definitive evidence for this. High expression of 11ß-HSD1 in hippocampus, hypothalamus and 
pituitary suggests that it may influence negative feedback of the HPA-axis (Moisan et al., 
1990). Primary hippocampal cell cultures are able to convert 11-dehydrocorticosterone (DHC) 
into corticosterone (Rajan et al., 1996). However, the first in vivo studies are far from 
conclusive about the potential role of 11ß-HSD1 in normal hippocampal functioning. In 
presence of DHC adrenalectomised animals show an exacerbation of kainic acid induced 
hippocampal damage (Ajilore and Sapolsky, 1999). However, after corticosterone 
replacement, this effect disappeared, whereas also in intact rats receiving icv carbenoxolone, 
an inhibitor of 11ß-HSD no effects were seen on kainic acid induced hippocampal damage 
(Ajilore and Sapolsky, 1999). In another study using adrenalectomised rats carbenoxolone did 
not affect in vivo uptake and retention of 3H-corticosterone in neuronal nuclei of hippocampus 
(Van Haarst et al., 1996b). This lack of any effect of icv administered 11ß-HSD inhibitor 
seems to indicate the absence of any role of 11ß-HSD1 in hippocampal functioning in spite of 
its high brain expression. On the other hand, carbenoxolone is a rather nonselective drug 
inhibiting 11ß-HSD1 and possibly other enzymes as well. 
Recently, the 11ß-HSD1 knockout mouse model was used to further investigate a possible 
central role of 11ß-HSD1. Although the increased adrenal weight and sensitivity of 11ß-HSD1 
deficient mice (Kotelevtsev et al., 1997) may be explained by increased peripheral need for 
glucocorticoids due to increased metabolic clearance, the raised corticosterone trough plasma 
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levels would suggest that HPA-axis activity is also relatively increased (Harris et al., 2001). 
Enhanced corticosterone plasma levels after stress and the inability of a dose of cortisol, which 
is effective in wild type mice, to suppress the HPA response to a stressor in knockouts has 
been attributed to a blunted sensitivity to glucocorticoid feedback due to lack of regeneration 
of active glucocorticoid in the brain (Harris et al., 2001). However, the decreased expression 
of GR in PVN of 11ß-HSD1 null mice (Harris et al., 2001) may also underlie impaired 
feedback, and, in addition, the lack of regeneration of active glucocorticoid by hepatic 11ß-
HSD1 may result in increased clearance of cortisol.  
On the other hand, aged knockout mice do not show the age-related decline in hippocampal-
dependent cognitive function, as is shown by wild type mice, even in face of increased 
corticosterone levels throughout life (Yau et al., 2001). The decreased hippocampal uptake of 
chronically infused 3H-corticosterone in knockout animals has also been postulated to be in 
line with their inability to regenerate corticosterone (Yau et al., 2001), although this 
phenomenon may also be explained by increased clearance of 3H-corticosterone in these mice. 
The generation of tissue-specific 11ß-HSD1 knockouts will resolve the question whether 11ß-
HSD1 is an important amplifier of central glucocorticoid signalling or not.  
Brain penetration  
Regulating access of corticosteroids at the level of the cell membrane may be another 
mechanism regulating access to the receptor. Since corticosteroids are commonly believed to 
cross membranes with relative ease by virtue of their highly lipophilic nature and their small 
size, information on access of corticosteroids to neurons is still scarce. As all CNS active 
compounds, corticosteroids have to pass the blood-brain barrier (BBB) before they reach their 
target cells within the brain. The BBB is a dynamic physical and metabolic barrier consisting 
of specialised endothelial cells that protects the brain from blood-borne compounds, and plays 
a role in maintaining brain homeostasis (Bradbury, 1993) (figure 4). Just like the pituitary, 
some brain areas like the circumventricular organs lie outside this barrier (Gross, 1992), but 
most of the brain is shielded from the periphery by the tight junctions between brain capillary 
endothelial cells and other barrier properties of these cells. The latter features comprise the 
lack of fenestrations and pinocytotic vesicles and the presence of metabolic enzymes and 
special transporter proteins (Lee et al., 2001b). The BBB can strongly interfere with 
distribution to the brain of endogenous and exogenous compounds (De Boer and Breimer, 
1994). Generally, hydrophilic and large lipophilic compounds are not able to penetrate the 
brain, as they are not able to pass cell membranes, whereas small lipophilic compounds such 
as corticosteroids can easily cross the BBB by passive diffusion through the endothelial cells. 
Any process at the BBB that can influence the endothelial crossing of these hormones would 
directly affect central corticosteroid receptor occupancy and the magnitude of the central 
response to corticosteroids.  
 
Consistent with the assumption that small lipophilic compounds can easily cross endothelial 
barriers, the naturally occurring glucocorticoid, corticosterone, readily gains access to the 
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brain and accumulates in limbic brain areas expressing MR (figure 5) (McEwen et al., 1968; 
De Kloet et al., 1975; De Kloet, 1991). In contrast, the synthetic glucocorticoid 
dexamethasone, when administered in tracer doses to adrenalectomised rats or mice, is poorly 
retained in GR-containing areas in brain (figure 5) (De Kloet et al., 1975; Rees et al., 1975; 
McEwen et al., 1976; Coutard et al., 1978). Their diversity in receptor affinity can only 
partially explain this differential retention pattern (Reul and De Kloet, 1985; Reul et al., 
2000b), as the anterior pituitary which also expresses high amounts of GR, retains high 
amounts of dexamethasone. To explain this puzzling phenomenon the existence of a blood- 
brain barrier limiting the uptake of dexamethasone into the brain was postulated (De Kloet et 
al., 1975; Rees et al., 1975; Coutard et al., 1978).  
Several transporters have been identified in the brain capillary endothelial cells, which can 
facilitate the uptake or impede the entry of substrates (Tamai and Tsuji, 2000; Lee et al., 
2001b). Besides multiple, mostly specialised influx transporters like the glucose transporter, 
there are several, more general efflux transporters described of which the multidrug 
FIGURE 4. Schematic representations of the anatomy of a typical blood vessel in peripheral
and brain tissue, respectively.  
Unlike peripheral capillary endothelial cells, brain capillary endothelial cells are closely sealed by
tight junctions, they display no intercellular clefts and little fenestration or pinocytosis, and they
have a relatively high number of mitochrondia. Some of these characteristics are induced and
maintained by astrocyte foot processes that are closely attached to and extensively envelop the
brain endothelium. For simplicity, the supporting pericytes and the basal lamina, structural
connective tissue surrounding the blood capillaries and separating the glial endfoots from the brain
endothelial cells are not shown. 
The various BBB-specific transporters are not shown except for the efflux transporter P-
glycoprotein (indicated by the balls and arrows). This transmembrane protein is localised at the
luminal membrane of the endothelial cells and transports its substrates (back) into the blood in an
energy-dependent manner. Reprinted from Schinkel (1999) with permission from Elsevier Science. 
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transporter P-glycoprotein is the best studied (Schinkel, 1999). Pgp is an important functional 
component of the BBB. It acts like a “gatekeeper” at the BBB keeping a wide variety of drugs 
out of the brain (Schinkel, 1999). This active drug efflux transporter appeared to be 
responsible for the apparent low permeation of some compounds including dexamethasone 
(De Kloet, 1997) that should easily penetrate the BBB as expected based on their size and 
their sufficiently high lipid solubility. Pgp may protect the brain in two ways, by excluding 
potentially neurotoxic substances from the brain but also by preventing drugs, which can 
potentially disrupt the BBB, to enter the endothelial cells (Van der Sandt et al., 2001).  
P-GLYCOPROTE IN  
P-glycoprotein (Permeability-glycoprotein) plays an important role in multidrug resistance 
(MDR). This phenomenon is characterised by intrinsic or acquired resistance of cancer cells to 
a wide variety of structurally and functionally unrelated drugs (Gottesman and Pastan, 1993). 
MDR is a major problem in the chemotherapeutic treatment of cancer. Many efforts have been 
put into the characterisation of MDR and into the reversal of MDR. Being the first detected 
transporter that was implicated in MDR (Juliano and Ling, 1976), Pgp has been extensively 
characterised. 
FIGURE 5.  Cell nuclear binding of 3H-corticosterone and 3H-dexamethasone in hippocampus,
hypothalamus and anterior pituitary, at various time points after intravenous injection of 5 nmol
3H-glucocorticoid to adrenalectomised rats. Binding is expressed as fmol steroid/mg protein in
purified nuclei. Radioactivity per ml plasma is expressed as percentage of injected dose. Reprinted
from De Kloet et al. (1975) with copyright permission from The Endocrine Society.  
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Structure 
The multidrug resistance P-glycoprotein belongs to the subfamily B of the adenosine 
triphosphate (ATP) binding cassette (ABC) superfamily of transporter proteins. ABC 
transporters are ubiquitous with over 300 family members identified in all known organisms 
from bacteria to mammals. They are involved in transport of a great variety of substrates 
including sugars, amino acids, cholesterol, phospholipids, peptides, proteins, toxins, 
antibiotics and xenobiotics (Higgins, 1992). Besides Pgp, other members include multidrug 
resistance related proteins (MRP1-7), MXR/BCRP (mitoxantrone resistance/breast cancer 
resistance protein) and the cystic fibrosis transmembrane regulator (Dean and Allikmets, 
2001). Many of the members of this family are involved in MDR.  
Pgp’s are N-glycosylated 140-170 kDa proteins of about 1280 amino acids (figure 6). Like a 
typical ABC transporter Pgp is an integral membrane protein consisting of two homologous 
halves each containing six putative transmembrane α-helical domains and a large 
intracytoplasmic loop encoding an energy-coupling ATP-binding site. This topology, 
however, remains controversial and has been challenged by alternative topologies (Skach et 
al., 1993; Jones and George, 1998).  
Genes 
Genes overexpressed in MDR cell lines have been isolated and characterised. Extensive 
studies have identified three classes of mammalian P-glycoproteins (table 2). Only two 
classes, I and III, convey the MDR phenotype. Of the two human genes, primarily the MDR1 
(Roninson et al., 1986) confers drug resistance (Ueda et al., 1987), whereas out of three rodent 
gene products two have the MDR phenotype. The murine mdr1b (mdr1, pgp2) cDNA was 
cloned from a mouse pre-B cell library and confers resistance when transfected into drug 
sensitive cell lines (Gros et al., 1986), whereas the second MDR conveying gene, mdr1a 
(mdr3, pgp1), was subsequently cloned based on its high homology (Devault and Gros, 1990). 
FIGURE 6.  Putative two-dimensional topology of the human MDR1 P-glycoprotein based on 
hydropathy analysis of the amino acid sequence. Two putative ATP-binding sites are shown as 
grey circles, and N-linked glycosylation sites are represented as squiggly lines. 
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Both genes have overlapping but distinct transport properties (Devault and Gros, 1990). The 
mdr1b gene of rats was cloned a decade ago (Silverman et al., 1991), whereas the rat mdr1a 
gene was only recently cloned (Hooiveld et al., 2000).  
As with human MDR3, transfection studies indicated that mouse mdr2 was not capable to 
confer MDR. Systematic searches have never identified a human class II, suggesting that 
classes I and II represent a gene duplication occurring after the separation of murine and 
human speciation (Ng et al., 1989). The mammalian Pgp multigene families are clustered in 
tandem on a single chromosome, chromosome 7 in humans, chromosome 5 in mouse and 
chromosome 4 in rat. 
The coding sequences of the various MDR-conferring genes show high homology within and 
between species indicating evolutionary conserved roles (Table 3). The rodent mdr1a and 
mdr1b genes show 85% identity to each other. Sequence identity of rat mdr1a and human 
MDR1 genes is 83%, whereas rat and mouse mdr1a are more than 90% homologous. Human 
MDR1 and rat mdr1b are 80% identical. The homology at the amino acid level is even higher, 
at least 90% (Table 3). 
Biochemistry  
The drug transport mediated by Pgp depends on ATP hydrolysis. Interaction of the two halves 
of Pgp, specifically the proper interaction of two ATP binding sites, seems necessary for the 
coordinate functioning of the molecule (Sharom, 1997; Ambudkar et al., 1999). Two 
molecules of ATP are hydrolysed during transport of one molecule of substrate. One is 
involved directly in a conformational change in the transmembrane domains that results in 
Table 2. Nomenclature and classification of mammalian multidrug resistance genes. 
Species Class I 
a
 Class II 
a
 Class III 
a
 
Human MDR1/ABCB1  MDR3/ABCB4 
b
 
Mouse mdr1a/Abcb1a 
c
 mdr1b/Abcb1b 
d
 mdr2/Abcb4 
Rat mdr1a/Abcb1a 
e
 mdr1b/Abcb1b 
e
 mdr2/Abcb4 
e
 
Hamster Pgp1/Abcb1a Pgp2/Abcb1b Pgp3/Abcb4 
Nomenclature used in this thesis is the one introduced by Hsu et al. (1989). The official 
nomenclature based on the new system of nomenclature for ATP-binding cassette (ABC) 
transporter genes is also given. Mdr genes belong to subfamily B of ABC transporters. 
a. Class I and II genes convey the multidrug resistance phenotype; class III genes encode a P-
glycoprotein functioning as a phosphatidylcholine translocase. 
b. MDR3 is also known as MDR2 
c. mdr1a is also known as mdr3 
d. mdr1b is also known as mdr1 
e. Rat mdr genes are designated pgp1, pgp2 and pgp3 in some studies, like the nomenclature of 
hamster mdr genes. 
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translocation of drugs out of the cell, while the second seems to be necessary to restore the 
transporter to its original high affinity state for substrates (Sauna and Ambudkar, 2000; Sauna 
et al., 2001). Interaction between ATP sites and the drug binding domains is essential for drug 
transport. Mutational analysis has shown that the two major drug-binding domains reside in or 
near transmembrane domains 5, 6 and 11, 12 (Ambudkar et al., 1999). Substrates interact with 
different overlapping regions of a single drug binding site that is large enough to 
accommodate more than one compound (Sharom, 1997). Drug binding may occur through a 
substrate-induced fit mechanism; the packing of the transmembrane segments is changed upon 
binding of a particular substrate to Pgp (Loo et al., 2003). 
 
Pgp can actively extrude an overwhelmingly wide range of drugs from the cell generating a 
drug concentration gradient. Many of its substrates are cytotoxic compounds of natural or 
semisynthetic origin (plants, fungi, bacteria), which are extensively used in the chemotherapy 
of cancer (Vinca alkaloids, taxanes, anthracyclines,) or for a large variety of other medical 
purposes like antibiotics (actinomycin D), antiepileptics (phenytoin), hormones 
(dexamethasone), calcium channel blockers (verapamil), HIV protease inhibitors (indinavir), 
pesticides (ivermectin), antidepressants (amitriptyline) and immunosuppressants (cyclosporin 
A, FK506), to name but a few. 
Table 3. Genbank and protein entries of various mammalian mdr genes and P-glycoproteins. 
Genbank entry Homology 
a
 Gene/protein Protein entry Homology 
b
 
NM_133401 
c
 
AF286167 
100 Rat mdr1a NP_596892 
c
 
AAK83023 
100 
99 
M81855 85 Rat mdr1b P43245 84 / >90 
NM_011076 90 Mouse mdr1a NP_035206 95 / 98 
NM_011075 83 Mouse mdr1b NP_035205 83 / >90 
XM_02059 
NM_000927 
83 Human MDR1 XP_02059 
NP_000918 
87 / >93 
The percentage identity to rat mdr1a gene or protein was calculated using the BLAST-program at 
the web server of the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov).  
a. Percentage homology with rat mdr1a gene entry NM_133401 
b. Percentage homology with rat mdr1a Pgp sequence NP_596892; presented is the percentage 
of identical amino acids and of (chemically) similar amino acids (‘positives’). 
c. Two complete sequences of rat mdr1a are presently available cloned from the Wistar 
respectively Sprague Dawley strain and differing in only a few nucleotides. The amino acid 
sequence NP_596892 is derived from NM_133401, whereas the sequence of AAK83023 is 
derived from Genbank entry AF286167. 
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Transport models 
As these compounds have diverse chemical structures, it is difficult to define common 
properties of a typical substrate. Physicochemical properties seem to mainly determine 
whether a particular compound is transported or not. The only features common to Pgp 
substrates appear to be that they are all hydrophobic and amphipathic, i.e. containing spatially 
separated hydrophilic and hydrophobic moieties, with a molecular mass of 300-2000 Da (Ford 
and Hait, 1990; Sharom et al., 1999). Due to this wide variety of chemical structures many 
different models proposing the mechanism used by Pgp to transport substrates have been 
developed. All models agree that Pgp uses the energy of ATP hydrolysis to translocate 
substrates from the cell (Gottesman and Pastan, 1988; Sharom, 1997; Stein, 1997), but the 
precise mechanism by which Pgp transports its substrates is still some matter of debate. The 
direct-pump models are among the more popular models (Higgins and Gottesman, 1992; 
Gottesman and Pastan, 1993), although alternative indirect-pump models have been proposed 
(Roepe, 1995; Zhu, 1999).  
 
One alternative indirect mechanism suggests that Pgp modifies the intracellular pH and 
membrane potential indirectly altering the transmembrane partitioning or intracellular 
sequestering of the drugs (altered partitioning model) (Roepe, 1995; Roepe, 2000). Another 
model hypothesises that Pgp only pumps certain forms of drug conjugates and not the 
lipophilic parent drugs (Zhu, 1999). According to this model Pgp co-localises with drug 
metabolising enzymes that conjugate a common moiety to the lipophilic drug. Pgp 
subsequently excretes the conjugated metabolite. 
 
The majority of experimental data, however, favours the direct transport models (figure 7) 
(Gottesman and Pastan, 1993; Gottesman et al., 1995; Shapiro and Ling, 1995; Gottesman et 
al., 1996; Sharom, 1997; Ambudkar et al., 1999; Sauna et al., 2001). According to these 
hypotheses, pharmacological agents passively diffuse down a concentration gradient through 
the cell membrane, because they are hydrophobic. Pgp subsequently extrudes drugs directly 
from the lipid bilayer even before they can enter the cytoplasm (Gottesman and Pastan, 1993; 
Sharom, 1997; Shapiro and Ling, 1997; Eytan and Kuchel, 1999). Besides the binding affinity 
for Pgp, also the lipid solubility of the substrate and the rate of partitioning within the bilayer 
determine whether a substrate is efficiently transported.  
It remains to be resolved whether Pgp extracts substrates from the cytoplasmic, extracellular, 
or both leaflets of the plasma membrane (Chen et al., 2001). According to the ‘hydrophobic 
vacuum cleaner’ hypothesis (Raviv et al., 1990; Gottesman and Pastan, 1993) Pgp extracts 
drugs relative nonselectively from both leaflets of the membrane directly to the extracellular 
aqueous phase.  
The alternative ‘flippase model’ suggests that Pgp carries its substrate from the inner leaflet to 
the outer leaflet (Higgins and Gottesman, 1992; Higgins, 1994; van Helvoort et al., 1996; 
Sharom, 1997; Shapiro et al., 1997) whereupon the substrate is extruded to the extracellular 
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aqueous phase. This model is based on the analogy between amphipathic drugs and the normal 
phospholipid constituents of membranes, which do not easily flip between both leaflets. It is 
supported by the finding that the non-MDR class II Pgp, MDR2/mdr2 Pgp, is a 
phosphatidylcholine translocase (flippase) essential for extrusion of phosphatidylcholine from 
the hepatic plasma membrane into the bile (Smit et al., 1993; Ruetz and Gros, 1994). Due to 
the rapid partitioning of most substrates into the extracellular leaflet, it is very difficult to 
determine whether Pgp is able to remove substrates from the outer leaflet (Chen et al., 2001). 
Moreover, as there are many different substrates, it can not be excluded that there will be more 
than one mechanism with which Pgp transports drugs depending on the particular substrate. 
Modulators 
The many different inhibitors of Pgp-mediated resistance also interfere with Pgp function 
through various mechanisms. Pgp-mediated MDR can be reversed by so-called 
chemosensitizers or modulators resulting in decreased drug efflux and increased cellular drug 
accumulation (Van Zuylen et al., 2000). There are probably as many Pgp chemosensitizers as 
there are “true” substrates, in particular because it is not easy to discriminate (Litman et al., 
2001). The complexity of interactions of Pgp with its substrates is such that, for instance, 
substrates can modulate Pgp transport of other substrates, while at the same time they are 
FIGURE 7. Possible mechanisms of action for substrate efflux transport by P-glycoprotein. 
Substrates enter the membrane before they interact with Pgp. (Left) Pgp might recognise substrates
in both leaflets of the membrane and expel them directly to the extracellular medium (‘vacuum
cleaner model’). (Right) Alternatively, a substrate intercalated into the inner leaflet is flipped into
the outer leaflet by Pgp and subsequently released into the extracellular medium (‘flippase
model’). Membrane release from the inner leaflet to the cytosol should be a slow process for
effective functioning of Pgp. Adapted from Johnstone et al. (2000) with permission from Elsevier
Science. 
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transported themselves. Good inhibitors of Pgp usually seem to be substrates as well 
apparently transported at a low rate. They may have such a high affinity for Pgp that their off-
rate is too low to detect. Alternatively, they may enter the membrane faster than Pgp can pump 
them out occupying binding sites (Barecki-Roach et al., 2003). 
Tissue distr ibution 
Besides expression in MDR tumour cells, Pgp is also expressed in various nonmalignant 
human and rodent tissues including the BBB. Northern blot (Fojo et al., 1987; Croop et al., 
1989) and immunohistochemical studies using different antibodies (Thiebaut et al., 1987; 
Sugawara et al., 1988a; Thiebaut et al., 1989; Cordon-Cardo et al., 1990; Bradley et al., 1990) 
have shown that Pgp is differentially expressed among tissues in various species. High 
expression is found in intestine, adrenal, pregnant uterus and placenta. Significant levels of 
Pgp are further found in brain, spinal cord, liver, kidney, heart, testes, lung and spleen.  
 
Interestingly, very high levels of Pgp are found in the adrenal gland of mice (Croop et al., 
1989), hamster (Georges et al., 1990) and human (Thiebaut et al., 1987; Sugawara et al., 
1988a), primarily in the cortical regions (Sugawara et al., 1988b; Cordon-Cardo et al., 1990). 
Pgp was found absent in rat adrenals but this was ascribed to possible preservation problems 
(Thiebaut et al., 1989). Observations in hamsters indicate that high level of adrenal expression 
is limited to males, suggesting that Pgp may be involved in transport of sex-specific adrenal 
hormones (Bradley et al., 1990). 
 
The tissue distribution of murine mdr1a/1b together matches very neatly to that of human 
MDR1. In conjunction with their overlapping but distinct transport properties (Devault and 
Gros, 1990), this suggests that they perform together the same set of functions in mouse as 
MDR1 in man. The distribution of the mdr1a and mdr1b genes is tissue-specific (Croop et al., 
1989). In mice the mdr1a gene is predominantly expressed in the intestine, lung, testis and 
brain. Only in adrenal, kidney and uterus in pregnancy mdr1b is the main isoform in mice. 
Although the first report showed high mdr1b mRNA levels in placenta (Croop et al., 1989), it 
is now clear that mdr1a is the major isoform in this tissue (Schinkel et al., 1997; Borst and 
Elferink, 2002). In other tissues both isoforms are present at similar levels. This distribution 
pattern was generally similar in hamster (Bradley et al., 1990; Georges et al., 1990) and in rat 
(Hooiveld et al., 2000).  
 
Pgp frequently appeared to be confined to distinct specialised cells and to have a specific 
subcellular localisation. With the exception of the homogeneous distribution at adrenal 
cortical cell membranes, Pgp is mainly expressed at the luminal membrane of epithelial or 
endothelial cells forming physiological barriers like at the secretory surface of intestinal 
mucosal and renal proximal tubular cells, at the biliary canalicular surface of hepatocytes, and 
at pancreatic ductule cells in human (Thiebaut et al., 1987; Cordon-Cardo et al., 1990) as well 
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as in rat (Thiebaut et al., 1989) and hamster (Bradley et al., 1990). Pgp expression is also 
observed in hematopoietic stem cells (Chaudhary and Roninson, 1991) and in mature 
lymphoid cells (Drach et al., 1992; Klimecki et al., 1994). 
 
Importantly, Pgp is highly expressed at blood-tissue barriers of the brain and spinal cord 
(Cordon-Cardo et al., 1989; Thiebaut et al., 1989; Sugawara, 1990; Cordon-Cardo et al., 
1990; Jette et al., 1993; Beaulieu et al., 1995; Lechardeur et al., 1996), and also of the testis 
(Cordon-Cardo et al., 1989; Thiebaut et al., 1989). In all studied rodents the mdr1a gene has 
been demonstrated to be the single isoform expressed at the blood-brain barrier (Bradley et al., 
1990; Jette et al., 1995; Demeule et al., 2001). 
Localisation at the BBB 
Most studies support the idea that Pgp is exclusively expressed at the luminal membrane of 
brain endothelial cells of rat and human, although the exact localisation of Pgp at the BBB is 
still a matter of debate. By immunoelectron and confocal microscopy of brain sections the 
presence of Pgp at endothelial cells lining the BBB was detected exclusively at the luminal 
membrane (Sugawara et al., 1990; Tsuji et al., 1992; Stewart et al., 1996; Virgintino et al., 
2002).  The most convincing evidence came from a study employing a novel technique in 
which luminal membranes were isolated and purified from brain microvasculature using a 
coating of colloidal silica particles and polyacrylate (Beaulieu et al., 1997). This procedure 
resulted in a luminal membrane preparation strongly enriched of the brain endothelial 
membrane marker GLUT1 and of Pgp. The strong enrichment of Pgp in the luminal 
membrane fractions can only be explained by assuming that the luminal membrane is the 
major site of Pgp expression.  
Some studies, however, suggest that Pgp is mainly expressed at the astrocyte foot processes 
attached to the BBB. Double immunolabelling and confocal light microscopy of isolated 
human brain capillaries showed that the anti-Pgp antibodies were bound to the microvessels 
with a similar, overlapping staining pattern as an antibody against the astrocyte marker glial 
fibrillary acidic protein (GFAP) (Pardridge et al., 1997; Golden and Pardridge, 1999). The 
punctate pattern contrasted with the continuous staining pattern for the glucose transporter 
GLUT1 showing only minimal overlap. As astrocyte foot processes are tightly associated with 
the basement membrane of brain capillaries and remain so after isolation of the capillaries, 
these results are suggestive for astrocyte specific abluminal expression.  
At present, the exact localisation of Pgp is not clear. Most evidence supports the luminal 
localisation, but this site of expression is inconsistent with some data suggesting presence of 
Pgp at the astrocyte foot processes. To establish conclusively the site of Pgp expression 
employment of in situ hybridisation detecting mdr1a mRNA may be useful.  
Regulation of Pgp expression 
It is currently not fully understood how and when Pgp expression might be regulated. 
Although tumours are known to increase their Pgp expression when treated with 
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chemotherapeutic drugs, it is not known whether this increase is due to increase of mRNA 
translation or due to selection of Pgp-expressing cells (Gottesman and Pastan, 1993). Several 
stressors like oxidative stress (Felix and Barrand, 2002) are known to increase Pgp expression 
in vitro (Sukhai and Piquette, 2000). Furthermore, epileptic insults have been shown to induce 
Pgp expression in the brain (Rizzi et al., 2002; Seegers et al., 2002a), but the exact mechanism 
is not known. It is unclear whether Pgp plays a role in adaptational responses to stress. 
Preliminary results, particularly concerning mdr1b Pgp, suggest that steroids might be able to 
alter Pgp expression (Arceci et al., 1988; Zhao et al., 1993; Piekarz et al., 1993; Sérée et al., 
1998; Demeule et al., 1999). Unlike the mdr1b promoter, the mdr1a and MDR1 promoters do 
not have a glucocorticoid responsive element (Cohen et al., 1991; Labialle et al., 2002), 
although regulation of expression through protein-protein interactions of glucocorticoid 
receptors and other transcription factors might be possible.  
Physiological role 
The specific tissue distribution and subcellular localisation of Pgp in conjunction with its 
properties suggests that it is an important factor in limiting absorption and distribution of 
exogenous toxins and in increasing excretion of these xenobiotics or metabolites. A protective 
role is also indicated by its expression in specific capillary endothelial cells like those of the 
BBB. The generation of mice with disrupted mdr1a, mdr1b or both genes has made it possible 
to investigate the normal physiological role of Pgp in depth (Schinkel et al., 1994; Schinkel et 
al., 1997). All three types of knockout mice appear to be completely normal as long as they 
are not challenged with drugs. Each of the deficient mice appears to have normal growth, 
development, viability, life span and fertility and does not show gross anatomical or 
histological abnormalities. Except for increased hepatic and renal upregulated expression of 
mdr1b in mdr1a knockouts, no compensatory enhanced expression of diverse other ABC 
transporters has been found so far in any other tissue including the brain (Borst and Schinkel, 
1997). This lack of any obvious physiological change indicates that Pgp is not essential for 
normal life. 
 
When treated with drugs that are substrates of Pgp, these knockout mice appear to have severe 
problems in pharmacological handling of these drugs. The most striking results were obtained 
with mice with an inactivated mdr1a gene. These mice have no detectable Pgp in gut 
epithelium and brain capillaries corroborating that this isoform is the single one expressed at 
these barriers (Schinkel et al., 1994). Increased oral uptake, decreased clearance, shifts in 
excretion route and enhanced uptake in foetuses of various potentially harmful or therapeutic 
compounds have been demonstrated in these knockouts (Mayer et al., 1996; Sparreboom et 
al., 1997; Smit et al., 1999).  
Increased accumulation of Pgp substrates in the brain of mdr1a deficient mice has 
demonstrated the importance of Pgp expressed at the BBB. Brain levels of vinblastine and 
many other drugs are much higher in mdr1a knockouts than in normal mice while plasma 
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levels were only slightly increased (Schinkel et al., 1994; Schinkel et al., 1995; Van Asperen 
et al., 1996; Schinkel et al., 1996). Even more strikingly is the effect of treatment with 
neurotoxic drugs that are Pgp substrates. The lethal dose of antihelminthic ivermectin is one 
hundred fold lower in mdr1a knockout mice than in normal mice concomitant with highly 
increased brain penetration (Schinkel et al., 1994). These studies show that Pgp has no vital 
function in normal metabolism, but is essential in protecting the body and crucial organs like 
the brain against exogenous toxic compounds.  
 
In addition to its protective role, various other physiological functions of Pgp have been 
proposed to provide an explanation for the unusual basal ATP hydrolysis in absence of any 
known substrate. Recently, Pgp was suggested to actively translocate cholesterol to the outer 
cell membrane (Garrigues et al., 2002). In addition, Pgp might be involved in transport of 
cytokines or translocation of phospholipids (Chong et al., 1993) and it may participate in 
programmed cell death (Johnstone et al., 2000). A specific function of Pgp at the BBB that 
was recently postulated may be excretion of peripherally acting small peptides, like opioids, 
out of the brain (King et al., 2001). In addition, Pgp may further be involved in elimination of 
ß-amyloid from the brain, which is indicative for a possible role in aetiology of Alzheimer’s 
disease (Lam et al., 2001). The most frequently suggested function is, however, a role in 
steroid transport. 
P-GLYCOPROTE IN  AND  GLUCOCORT ICO IDS  
Interactions of Pgp and steroids 
Relatively little attention has been given to the factors that influence the intracellular 
concentration of steroids. Glucocorticoids are commonly believed to readily diffuse across 
plasma membranes by virtue of their highly lipophilic nature and their small size. As early as 
1968 there has been evidence that steroids may be transported out of different, but not all, 
mammalian cells by an energy-dependent mechanism within the membrane resulting in a 
reduced accumulation (Gross et al., 1968). The extrusion process only affects some steroids 
such as cortisol, dexamethasone and prednisolone, whereas accumulation of other steroids like 
deoxycorticosterone, progesterone and cortexolone was not affected (Gross et al., 1969; Gross 
et al., 1970). The basis for this phenomenon was not understood.  
Fifteen years later, another cell line was isolated that showed resistance to dexamethasone 
unrelated to changes of the GR, and that appeared to have acquired multidrug resistance 
(Johnson et al., 1984). The phenotype of this dexamethasone resistant variant of a normally 
glucocorticoid sensitive murine thymona cell line was eventually shown to be associated with 
expression of mdr1b Pgp (Bourgeois et al., 1993). This cell line turned out to be also resistant 
to apoptosis induced by various other steroids such as cortisol, prednisolone and, to a lesser 
extent, corticosterone and aldosterone (Bourgeois et al., 1993).  
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Data from a substantial number of other studies using different methods have further 
corroborated the ability of Pgp to transport dexamethasone and several other steroids. Pgp 
expressed in MDR1 cDNA transfected pig kidney epithelial cell lines can transport 
dexamethasone, cortisol and aldosterone (Ueda et al., 1992; Schinkel et al., 1995). The Pgp-
mediated transport of cortisol was confirmed for hamster Pgp (Van Kalken et al., 1993). 
Additionally, corticosterone has been reported to be effluxed by mdr1b Pgp expressed at MDR 
murine macrophage-like cells (Wolf and Horwitz, 1992). Mouse adrenal Y1 cells, in which 
one copy of the mdr1b gene has been inactivated by insertional mutagenesis, show reduced 
steroid secretion upon activation with ACTH (Altuvia et al., 1993). 
 
Several other methods have been used to study interactions of various steroids with Pgp, but it 
is important to keep in mind that photoaffinity labelling, accumulation and inhibition studies 
all show that a compound that can bind to Pgp, does not necessarily have to be transported by 
Pgp. Moreover, the more a steroid binds to Pgp, the less effectively it is transported out of the 
cell. 
Several studies have used photoaffinity labelling of Pgp to study interactions of steroids with 
Pgp. This method uses the ability of ultraviolet irradiation to fix compounds to membrane 
constituents. Isolated membranes are incubated with a radiolabelled Pgp-substrate with or 
without unlabelled Pgp-substrates, after which the membranes are immunoprecipitated with a 
Pgp-specific antibody, followed by gel electrophoresis. Photoaffinity labelling is a measure of 
the ability of Pgp to bind the particular substrate, rather than a measure of its ability to 
transport it. Most corticosteroids are able to inhibit 125I-azidopine photoaffinity labelling of 
Pgp to a greater or less extent depending on their hydrophobicity (Yang et al., 1989; Qian and 
Beck, 1990). Photoaffinity studies further show that 3H-corticosterone specifically photolabels 
murine mdr1b Pgp (Wolf and Horwitz, 1992) whereas 3H-cortisol does not label human Pgp 
(Qian and Beck, 1990). Besides a possible species difference, this may only indicate that 
cortisol binds less avidly to Pgp than corticosterone. 
Studies of accumulation in Pgp expressing cells show reduced accumulation of corticosterone 
(Wolf and Horwitz, 1992; Barnes et al., 1996), cortisol (Van Kalken et al., 1993; Barnes et al., 
1996), dexamethasone (Bourgeois et al., 1993; Barnes et al., 1996) and aldosterone (Barnes et 
al., 1996), although not all studies agree on this (Fojo et al., 1985; Van Kalken et al., 1993; 
Gruol et al., 1999). In an extensive study of interactions of Pgp with various steroids using 
resistant human colon carcinoma cells, it was found that the accumulation of dexamethasone, 
cortisol, corticosterone, aldosterone and various other steroids was reduced to an extent that 
correlates well with their respective hydrophilicity (Barnes et al., 1996). An inverse 
correlation was found when studying steroid induced enhancement of vinblastine or 
daunorubicin accumulation; increased antagonism of Pgp mediated transport correlates with 
decreased steroid hydrophilicity (Van Kalken et al., 1993; Barnes et al., 1996). Inhibition of 
accumulation of other substrates is not a direct measure of transport, but rather a measure of 
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binding capacity, whereas accumulation studies are less reliable because of nonspecific 
membrane binding.  
Taken together, these studies show that interaction of steroids with Pgp comprises a spectrum 
with at the one end steroids like dexamethasone and cortisol that are mainly transported and at 
the other end steroids that mainly inhibit Pgp. The clearest example of the latter is 
progesterone.  
While progesterone binds avidly to Pgp in photoaffinity studies (Qian and Beck, 1990), and is 
an efficient inhibitor of azidopine photoaffinity labelling (Yang et al., 1989; Qian and Beck, 
1990) and Pgp-mediated transport of other substrates (Yang et al., 1989; Ueda et al., 1992; 
Van Kalken et al., 1993), the hormone itself is not transported out of the cell by Pgp (Yang et 
al., 1990; Ueda et al., 1992; Bourgeois et al., 1993). This paradoxical phenomenon may be 
explained by its high lipophilicity, resulting in a fast partitioning into the plasma membrane 
leaflets (Eytan et al., 1996). This high rate of back diffusion fully counteracts the Pgp-
mediated outward flipping of progesterone and no drug gradient can be established (Eytan et 
al., 1996; Sharom, 1997). Progesterone is a strong MDR reversal agent, because like some 
other highly lipophilic compounds functioning as MDR modulator, it strongly competes for 
Pgp mediated transport (Eytan et al., 1996). Due to its continuous rapid insertion into the 
plasma membrane progesterone overwhelms the Pgp transport machinery, which leads to the 
inability of Pgp to transport other substrates.  
Possible role in steroid transport 
The above-mentioned in vitro studies in conjunction with the presence of Pgp in adrenal cells 
has lead to suggestions that Pgp has a physiological role in steroid secretion. Steroid efflux by 
drug transporters may be a more generally occurring phenomenon than is currently 
appreciated (Thompson, 1995; Kralli and Yamamoto, 1996), as a yeast homologue of Pgp, 
LEM1, has also been shown to transport several steroids (Kralli et al., 1995).  
The importance of Pgp as a steroid transporter is questioned, however, by the lack of Pgp in 
rat adrenal and the generation of the mdr1b knockout mice and the mdr1a/b double knockout 
mice. These mice show no gross disturbances in corticosteroid handling, although mdr1a/b 
double knockouts have been reported to have consistently lower ACTH and corticosterone 
plasma levels than their wild type littermates under various conditions (Müller et al., 2003) 
suggesting an altered HPA-axis regulation. The lack of gross changes in glucocorticoid targets 
as reported thus far suggests that both mdr1a and mdr1b Pgp have no essential function in the 
normal steroid metabolism of the adrenal (Schinkel et al., 1997). Pgp might be still involved 
in steroid transport in a more subtle way by protecting the plasma membranes of steroid-
secreting cells from the toxic effects of high steroid concentrations (Van Kalken et al., 1993; 
Ambudkar et al., 1999) under conditions of e.g. stress-induced HPA-axis activity. A protective 
role of Pgp would also be more consistent with its property to transport drugs out of the 
plasma membrane. Alternatively, Pgp may play a role in regulation of glucocorticoid exposure 
of glucocorticoid responsive cells like neurons. 
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Possible role in steroid transport at the BBB 
Evidence that Pgp may be able to protect the brain against potentially harmful glucocorticoid 
action was derived from studies with mdr1a knockout mice receiving dexamethasone. Pgp was 
demonstrated to be responsible for the impaired access of low to moderate doses of 
dexamethasone in brain, as it excludes this synthetic glucocorticoid from brain. Uptake of 
dexamethasone to the brain was enhanced in mdr1a (-/-) mice compared to wild type mice 
(Schinkel et al., 1995) increasing the access to the glucocorticoid receptor (Meijer et al., 1998) 
(figure 8). A role of Pgp at the BBB in protecting the brain against steroids has therefore been 
postulated. Its presence at the BBB and ability to transport several glucocorticoids suggests 
that Pgp may play an important role in modulation of glucocorticoid access to the brain 
corticosteroid receptors, thus affecting central glucocorticoid action. This suggestion formed 
the basis of the research described in this thesis.  
 
 
 
FIGURE 8. Representative autoradiograms of 10-µm coronal sections of the brain of wild type
(A) and mdr1a knockout mice (B) at hippocampus level.  
Autoradiograms show radioactive labelling at 1 hour after systemic treatment with a tracer dose of
3H-dexamethasone. The dark spots in (A) represent transverse sectioning of the chorioid plexus
and adjacent cerebroventricular space. Adapted from Meijer et al. (1998) with copyright
permission from The Endocrine Society. 
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SCOPE  OF  THE  THES I S  
Rationale and objectives 
The aim of the studies described in this thesis is to examine the interaction of glucocorticoids 
and the efflux transporter P-glycoprotein expressed at the BBB as a possibly new level at 
which access to the brain and thus central corticosteroid receptor function may be controlled. 
Modulation of access of glucocorticoids to the brain may provide a new way to restore 
aberrant corticosteroid signalling associated with hypercortisolemia, glucocorticoid feedback 
resistance or MR/GR imbalance. In this thesis, I focus on the following objectives.  
 
First, the expression of Pgp in the brain at the level of mRNA was examined to determine 
which particular cell types express Pgp and whether glucocorticoid treatment would affect 
expression levels.  
The second phase of the project was aimed to investigate whether various synthetic as well as 
naturally occurring glucocorticoids are substrates of Pgp. Since previous studies have shown 
that mdr1a Pgp hampers dexamethasone to enter the brain, the question arose whether Pgp 
may also exclude other glucocorticoids from the brain. We hypothesised that endogenous 
glucocorticoids would rather easily reach the central glucocorticoid target areas, whereas Pgp 
would protect the brain against exogenous synthetic glucocorticoids. 
 
Further research was based on the hypothesis that treatment with moderate amounts of 
dexamethasone provides a strategy to correct aberrant corticosteroid levels and receptor 
dysfunction in brain. Dexamethasone is well known as potent suppressor of HPA-activity. It 
acts at the level of the pituitary to suppress ACTH and consequently corticosterone secretion 
(De Kloet et al., 1974). As dexamethasone poorly penetrates into the brain, this implies that 
administration of low to moderate amounts of dexamethasone depletes the brain from 
endogenous glucocorticoids, for which dexamethasone does not appropriately substitute 
(figure 9). Peripherally, glucocorticoid receptors are still activated by dexamethasone. The 
resulting condition is a brain-selective state of adrenalectomy. Neural functions would suffer 
from underexposure to corticosteroids, whereas peripheral functions would still be directly 
influenced by dexamethasone.  
Experimental approach and outline 
To examine the expression of mdr1a mRNA in brain in situ mRNA hybridisation was 
employed, using both radioactive and non-radioactive RNA-probes (chapter 2). To determine 
the exact localisation of cells expressing mdr1a mRNA a digoxigenin-labelled RNA probe 
was applied on brain sections of naive animals. To reveal whether expression might be 
regulated under some conditions, expression levels were measured in adrenalectomised rats 
and in intact rats treated with dexamethasone and kainic acid, a seizures-inducing agent. 
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FIGURE 9. Hypothesised creation of brain-selective low-corticosteroid condition by low-dose
dexamethasone. Low plasma concentrations of dexamethasone primarily act on the anterior
pituitary to suppress pituitary-adrenal secretion. Dexamethasone replaces corticosterone at
peripheral glucocorticoid targets. However, due to the presence of P-glycoprotein at the BBB
dexamethasone can not replace corticosterone in the brain. The ensuing low-corticosteroid state in
the brain is reminiscent of a brain-selective adrenalectomy condition, and will likely affect MR/GR
balance and glucocorticoid actions on brain function.  
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In order to study the uptake of various glucocorticoids in brain we used mice with a disrupted 
mdr1a gene lacking Pgp at the BBB. After adrenalectomy, which removes the endogenous 
source of corticosterone, wild type and mdr1a (-/-) knockout mice were systemically injected 
with radiolabelled corticosteroids. Uptake in brain and retention in central corticosteroid 
receptor expressing areas was measured with autoradiography both in brain homogenates and 
in brain sections apposed to sensitive films. Uptake of corticosterone and cortisol (chapter 3) 
and prednisolone (chapter 4) was determined this way. 
 
The role of Pgp in uptake of glucocorticoids in human brain was examined in two different 
albeit indirect ways. Pig kidney epithelial (LLC-PK1) cells stably transfected with human 
MDR1 cDNA were used to study the Pgp mediated transport of radiolabelled glucocorticoids 
(figure 10). These cells form monolayers when seeded on filters and express Pgp at their 
apical membrane (Florea et al., 2001). These monolayers are a suitable model for Pgp-
mediated transport at the BBB as they express Pgp at high levels, presumably comparable to 
brain endothelial cells and unlike many in vitro models of the BBB (Lechardeur and 
Scherman, 1995; Barrand et al., 1995; Seetharaman et al., 1998; Gaillard et al., 2000). Polar 
transport of glucocorticoids indicates Pgp-mediated transport. The involvement of Pgp was 
confirmed by comparison with monolayers of untransfected cells and by the abolishing effect 
of a potent and selective Pgp blocker (chapter 3 and 4). Further, cortisol and corticosterone 
levels were measured in extracts of human post-mortem brain samples and plasma using LC-
MS to determine the ratio of corticosterone over cortisol (chapter 3).  
  
To test the working hypothesis about the brain-selective depletion of glucocorticoids provided 
by exclusion of low amounts of dexamethasone from the brain, rats were treated with low 
amounts of dexamethasone and different central as well as peripheral markers of 
glucocorticoid action were measured (chapter 5). Dexamethasone was administered 
chronically in two different ways, via subcutaneous injection or through the drinking water. 
The focus was on the stress system as endogenous glucocorticoids play an important role in 
FIGURE 10. Pgp-mediated transepithelial transport in monolayers of pig kidney epithelial
(LLC-PK1) cells stably transfected with human MDR1 cDNA. Pgp is localised at the apical side,
transporting its substrates from the basal compartment to the apical compartment, or from the
apical compartment back into the apical compartment. Monolayers of non-transfected host cells are
used as a control. Pgp-mediated polar transport will be demonstrated as increased transport from
basal to apical and decreased diffusion from apical to basal as compared with host cells.  
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the stress response. Since central effects of glucocorticoids are often only seen after 
stimulation of the stress system the animals were stressed at the end of the treatment. The 
brain was examined for diverse molecular markers of the stress system. Various peripheral 
markers of glucocorticoid action were used to determine the effects of dexamethasone in the 
periphery.  
 
All data are discussed in a broader perspective (chapter 6) and general conclusions are drawn 
(chapter 7). Finally, in an addendum I summarise the latest results regarding brain uptake of 
the antiglucocorticoid C-1073/RU486, a novel fast-acting powerful antidepressant. 
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Abstract  
The multidrug resistance (mdr) P-glycoprotein (Pgp) is an energy dependent efflux transporter 
that protects the brain against a wide variety of neurotoxic compounds including 
glucocorticoids. This transmembrane protein is a well-known functional component of the 
blood-brain barrier and might be present in brain parenchyma cells as well, although there is 
some controversy about the particular cell types expressing Pgp.  
Since in situ mRNA hybridisation might be helpful in determining the exact localisation of 
Pgp expression, we have developed a riboprobe against the murine multidrug resistance 1 
mRNA recognising both subtypes of the rodent mdr1 gene. We have also studied the effects of 
treatment with known inducers of Pgp expression, the chemical convulsant kainic acid and the 
synthetic glucocorticoid dexamethasone. 
The data demonstrate that mdr1 mRNA is present in the endothelial cells of brain capillaries 
throughout the rat brain indicating that Pgp is expressed at the endothelial cells forming the 
blood-brain barrier.  
Surprisingly, specific mdr1 mRNA expression was also found in neuronal layers of 
hippocampal fields, particularly in the granule cells of the dentate gyrus. Three-week high-
dose dexamethasone treatment did not affect mRNA expression in granule cells. However, 
kainic acid treatment surprisingly decreased the expression levels of mdr1a mRNA in the 
dentate gyrus 6 and 24 hours after treatment. Our methodology did not permit to detect 
whether any treatment altered the expression at the BBB. 
Our data indicate that under normal, healthy conditions Pgp is likely only expressed by 
endothelial cells and possibly dentate gyrus neurons, although it can not be excluded that 
certain pathological conditions may induce Pgp expression in astrocytes. 
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Introduction 
The multidrug resistance (mdr) P-glycoprotein (Pgp) is a transmembrane protein that functions 
as an energy dependent efflux transporter of numerous substrates (Gottesman and Pastan, 
1993). Due to its presence at the blood-brain barrier (BBB) (Cordon-Cardo et al., 1989; 
Thiebaut et al., 1989; Jette et al., 1993) Pgp plays a vital role in the defence of the brain 
against a wide variety of excitotoxic compounds, particularly hydrophobic, amphipathic 
agents (Schinkel, 1999). Pgp-mediated exclusion from the brain is of particular importance for 
compounds that act centrally including antiepileptic drugs (Loscher and Potschka, 2002) and 
glucocorticoids (Meijer et al., 1998).  
 
A small highly homologous gene family, the multidrug resistance genes, encodes Pgp. The 
human MDR1 is the only gene conveying multidrug resistance present in human (Van de Vrie 
et al., 1998). In rodents the mdr1a gene is the single isoform expressed at the BBB (Bradley et 
al., 1990; Jette et al., 1995; Demeule et al., 2001). The second isoform mdr1b may be present 
in brain at low levels (Croop et al., 1989; Schinkel et al., 1994), most likely in glial cells (Lee 
et al., 2001a) although the exact localisation is not yet known. 
 
Although a vast amount of studies support the idea that Pgp is exclusively expressed at the 
luminal membrane of brain endothelial cells (Sugawara et al., 1990; Tsuji et al., 1992; Stewart 
et al., 1996; Beaulieu et al., 1997; Virgintino et al., 2002), the exact localisation of Pgp at the 
BBB is still a matter of debate. Some studies have provided data suggesting that Pgp is 
primarily expressed at astrocyte foot processes tightly attached to the capillaries (Pardridge et 
al., 1997; Golden and Pardridge, 1999). Although other studies have never reported Pgp 
expression in healthy brain glial cells, nor in neurons, Pgp was found overexpressed in glial 
cells within the epileptogenic lesion of brains of patients with different pathologies causing 
refractory epilepsy (Tishler et al., 1995; Sisodiya et al., 1999; Sisodiya et al., 2002) and in 
brains of rats treated with the chemical convulsant kainic acid (Zhang et al., 1999; Rizzi et al., 
2002; Seegers et al., 2002b).  
 
To establish whether Pgp is synthesised by astrocytes, endothelial cells or both, in normal and 
epileptogenic brain in situ mRNA hybridisation was applied using a riboprobe against both 
mdr1a and mdr1b. Radioactive and DIG-labelled probes were used in order to visualise mdr1 
mRNA in rat and mouse brain tissue. The effect of kainate treatment was examined in rats, 
because of its potency to induce Pgp expression. In addition, the effect of glucocorticoid 
treatment on expression in rat brain was studied, since glucocorticoids may induce expression 
(Aquilante et al., 2000). 
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Materials and methods 
Animals 
Young adult male Wistar rats (Charles River, Sulzfeld, Germany) were housed under a 12-12 
hour light dark cycle with lights on at 7:00hr in a temperature (21°C) and humidity controlled 
room. Food and drinking water were available ad libitum. Before and during experiments rats 
were handled daily. All experiments were carried out in accordance with the European 
Communities Council Directive 86/609/EEC and with approval from the animal care 
committee of the Faculty of Medicine, Leiden University (The Netherlands).  
Treatments 
Twelve rats weighing around 230g received an injection of the potent non-NMDA glutamate 
receptor agonist kainate (8 mg/kg body weight) in the morning of the experiment. Another 
twelve rats received an injection of vehicle (0.9% saline). After injection animals were 
watched and epileptic behaviour was recorded based on the five stadia described by Sperk 
(Sperk, 1994). At six hours and 24 hours after injection rats were decapitated. Thus, all groups 
consisted of 6 animals. Trunk blood was collected in EDTA-coated tubes and centrifuged for 
determination of corticosterone plasma levels using a 125I-corticosterone radioimmunoassay 
kit (ICN Biomedicals, Costa Mesa, USA). Brains were rapidly removed from the skull and 
quickly frozen in isopentane precooled on dry ice/ethanol. All tissues were stored at –80°C 
until further use. Brains were used for in situ hybridisation of mdr1a mRNA. 
 
To detect changes of mdr1a mRNA expression after glucocorticoid treatment in situ 
hybridisation was employed on brains of rats that have been treated with 10 µg/ml 
dexamethasone 21-phosphate through their drinking water for three weeks (see chapter 5). 
This dose is known to enter the brain at sufficient concentrations to act in glucocorticoid target 
areas. Control animals not treated with dexamethasone were also included.  
Probe  
From the pJ3Ω vector containing the full-length mouse mdr1a cDNA (courtesy of A.H. 
Schinkel and P. Gros) an 890 basepair fragment (1348-2237) was excised using BglII and 
EcoRI and cloned into the BamHI/EcoRI site of pBluescript KS vector. The identity of the 
probe was confirmed by partial DNA sequence analysis. Specificity of the probe was 
confirmed by blasting it to known genes in GenBank. The homology of the probe sequence 
was 100% with mouse mdr1a, 91% with mouse mdr1b, 93% with rat mdr1a, 88% with rat 
mdr1b and less than 80% with any other mdr gene. 
Non-radioactive in situ hybridisation 
To qualitatively determine the cellular localisation of mdr1 mRNA non-radioactive in situ 
hybridisation was applied. The protocol used for in situ hybridisation with digoxigenin (DIG)-
labelled RNA probes has been described previously (Asbreuk et al., 2002). The linearised 
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vector was in vitro transcribed using a DIG RNA labelling mix (Roche Diagnostics, 
Mannheim, Germany) and T3 polymerase (Roche) to obtain a DIG-labelled anti-sense probe.  
Twenty-micrometer coronal sections of brain were cut on a cryostat and thaw-mounted on 
poly-L-lysine (Sigma Chemical, St Louis, USA) coated microscopic slides. The sections were 
postfixed in a freshly prepared 4% paraformaldehyde solution (pH 7.2) for 10 minutes at room 
temperature, rinsed three times in phosphate buffered saline (PBS) for 3 minutes at room 
temperature. Subsequently the sections were acetylated (0.25% acetic anhydride in 
triethanolamine (TEA)) for 10 minutes at room temperature and rinsed three times in PBS. 
Thereafter the sections were prehybridised for 2 hours at room temperature: each slide was 
loaded with 300 µl hybridisation mix containing 50% deionised formamide, 5x SSC 
(SSC=0.15M NaCl and 0.015M sodium citrate), 5x Denhardt’s, 250 µg/ml bakers yeast tRNA, 
500 µg/ml sonificated salmon sperm DNA. After prehybridisation the mix was removed and 
the slides were loaded with 150 µl hybridisation mix containing the digoxigenin-labelled RNA 
probe (890 ng/ml). The slides were covered with NESCO-film and hybridisation was 
performed overnight in a moist chamber at 72°C. The next day, NESCOfilm was removed in 
2xSSC (72°C) and the slides were rinsed in 0.2xSSC for 2 hours at 72°C. The slides were then 
transferred to 0.2xSSC at room temperature.  
For immunohistochemical detection slides were incubated in 100 mM Tris/150 mM NaCl (pH 
7.4) for 5 minutes at room temperature. Subsequently, heat-inactivated fetal calf serum (HI-
FCS) was added to this buffer (0.2%) shortly before preincubation with 1.5 ml 10% HI-
FCS/Tris/NaCl for 1 hour at room temperature. Finally, overnight incubation with an alkaline 
phosphatase-labelled antibody raised against DIG (Roche, 1:5000 in 10% HI-FCS/Tris/NaCl) 
was performed at 4°C. The next day the slides were rinsed three times for 5 minutes in 
Tris/NaCl (pH 7.4) and 5 minutes in 50 mM MgCl2 in Tris/NaCl (pH 9.5) at room 
temperature. The DIG-probe labelled sites were visualised using nitroblue tetrazolium 
chloride/5-bromo-4-chloro-3-indolylphosphate p-toluidine (NT/BCIP, Boehringer Mannheim) 
as a substrate. The enzymatic reaction was terminated in 10 mM Tris/5 mM EDTA (pH 8.0).   
Radioactive in situ hybridisation 
The vector was linearised with NotI respectively EcoRI and in vitro transcribed using 33P-
labelled UTP (ICN Biomedicals, Isoblue stabilised, S.A. 3000 Ci/mmol) and T3 respectively 
T7 polymerase to obtain anti-sense or sense probe, respectively.  
Cryostate sections were postfixed in a freshly prepared 4% paraformaldehyde solution (pH 
7.2) for 60 minutes at room temperature, rinsed twice in PBS for 5 minutes at room 
temperature, and treated with proteinase K (1 µg/ml in 0.1M Tris, pH 8.0) at 37°C for 10 
minutes. After a brief rinse in diethyl pyrocarbonate (DEPC) treated water, they were treated 
with 0.25% acetic anhydride in 0.1M TEA (pH 8.0) for 10 minutes at room temperature and 
finally rinsed in 2xSSC for 10 minutes at room temperature. Subsequently the sections were 
dehydrated trough a graded series of ethanol and air-dried. Each slide, containing six sections, 
was loaded with a 100µl mix containing 70% deionised formamide, 10% dextran sulphate, 
3xSSC, 1xDenhardt’s solution, 0.1 mg/ml yeast tRNA, 0.1 mg/ml sheared herring sperm DNA 
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and 3x106 dpm of the probe, and covered with microscopic coverslips. Overnight 
hybridisation was performed in a moist chamber at 55°C. As a control, a few slides were 
hybridised with sense probe. The next day, coverslips were removed and the slides were 
washed in 2xSSC at room temperature for 10 minutes, treated with RNAse A (2 mg/100 ml in 
0.5M NaCl, pH 7.5) at 37°C for 10 minutes and 3 times washed in 2xSSC/50% formamide at 
60°C for 15 minutes. After a short wash with 2xSSC, sections were dehydrated in an ethanol 
series and air-dried. Finally, the slides were put in an X-ray exposure holder and apposed to 
X-OMAT AR film (Kodak, Rochester, NY) for 12 days.  
Quantification and statistics 
Optical density was quantified with an Olympus image analysis system with the appropriate 
software (Paes Nederland B.V., the Netherlands) equipped with a Cue CCD camera or using 
the public domain NIH Image program (developed at the U.S. National Institutes of Health 
and available on the Internet at http://rsb.info.nih.gov/nih-image/). After shading correction, 
the hippocampal images were corrected for film background. Densities were determined by 
outlining the granule cell layer of the dentate gyrus, the pyramidal cell layers of CA1 and CA3 
areas and cortex. The optical density of the CA2/CA3 stratum radiatum was used for tissue 
background. Generally, 6-9 sections were measured per animal and averages were used for 
subsequent statistical analysis of treatment groups. Data were analysed using ANOVA and, 
when appropriate, post-hoc comparisons were performed using Tukey’s Honestly Significant 
Difference test. Statistical difference was accepted at p < 0.05. 
Immunohistochemistry 
Pgp expression was detected with the primary monoclonal mouse antibody C219 
(Calbiochem; Bad Soden, Germany). The antibody C219 reacts against the cytoplasmic 
VVQEALD epitope of human, mouse and rat Pgp (Vore et al., 1996) and has been used to 
detect Pgp in rat brain (Zhang et al., 1999; Seegers et al., 2002b). It does not discriminate 
between the mdr1a and mdr1b isoforms of Pgp.  
Cryostate sections thaw-mounted on poly-L-lysine slides were fixated for 30 minutes in 4% 
paraformaldehyde on ice, washed two times with PBS, dehydrated, and delipidated for 1 
minute in chloroform. After each incubation sections were washed several times in 0.1M Tris 
buffered saline (TBS). The sections were treated with 1% hydrogen peroxide (H2O2) in TBS 
for 15 min to eliminate endogenous peroxidase activity. To minimise nonspecific binding, 
sections were immersed in 10% normal goat serum in TBS containing 2% NS and 0.2% Triton 
X-100 (TBS-T) for 30 minutes. The slides were incubated overnight at 4ºC with the primary 
antibody in a 1:40 dilution in TBS-T/NS. The antibody was detected using a biotinylated goat 
anti-mouse secondary antibody (Vector Laboratories, USA) in a 1:200 dilution in TBS-T/NS 
at 37ºC for 1 hour. Sections were then incubated with an avidin-biotine horseradish peroxidase 
complex (ABC) in 0.1 M TBS-T at room temperature for 45 minutes followed by two washes 
in 0.01M Tris buffer (pH 7.5-7.6) for 10 min each. The staining was visualised by incubation 
with 0.5 mg/ml 3,3’-diaminobenzidine tetrahydrochloride (DAB) in 0.01M Tris containing 
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0.033% H2O2 for ten minutes. After dehydration, the slides were air-dried and lightly 
counterstained with haematoxylin before coverslipping with Permount. Control sections 
incubated with preimmune NS instead of primary antibody showed absence of staining. 
Results 
Expression mdr1 Pgp at BBB 
Using a DIG-labelled RNA probe against mouse mdr1a/mdr1b, which has high homology 
with rat mdr1a/mdr1b, we demonstrated that mdr1a/mdr1b mRNA is present in the endothelial 
cells of brain capillaries throughout the rat brain (figures 1A and B). Grains were found 
FIGURE 1. Expression of mdr1 mRNA at brain capillaries.  
DIG-labelled in situ hybridisation showing grains overlaying larger brain capillaries reveals
expression of mdr1 mRNA in endothelial cells (A,B). Grains are located at the luminal side of
endothelial cells (B). Bars indicate 10 µm. 
C219 immunohistochemical staining shows presence of P-glycoprotein throughout the brain at
both small and larger brain capillary. Bar indicates 50 µm. 
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mainly in larger vessels close to nuclei. Immunohistochemistry using the C219 antibody 
demonstrated a more widespread presence of Pgp at both small and larger brain capillaries 
(figure 1C). A high density of C219 labelled vessels was found in the hypothalamic 
paraventricular nucleus (Figure 2).  
Expression mdr1 mRNA in hippocampus 
Surprisingly, we also found mdr1a/mdr1b mRNA in neuronal layers of hippocampal subfields 
in both rat and mouse brain, either using radioactive labelling (figure 3A) or DIG-labelling 
(figure 4B). Highest expression levels were found in dentate gyrus (DG) with lower levels in 
CA3. Expression in CA1 was as low as in cortex. Hybridisation with a sense probe did not 
result in labelling of hippocampal cells (figure 3C). The staining overlaying granule cells is 
suggestive of neuronal localisation of the mdr1 mRNA (figure 4B). Within the hippocampus, 
C219 labelling was relatively weak and mainly localised in the stratum lacunosum moleculare 
(Figure 4A). The C219 antibody did not visualise Pgp in the dentate gyrus granule cell layer.  
Regulation expression mdr1a/b by kainate or dexamethasone  
Kainate treatment resulted in a significant effect on mdr1 mRNA expression levels in rat 
hippocampus as determined by in situ hybridisation (ANOVA, F(3,19)=11.326, p<0.001). At 
both time points examined, 6 hours and 24 hours after s.c. injection of kainate, mdr1 mRNA 
expression was strongly reduced in DG, but not in other areas (figures 3A, 3B and 5A), 
although the reduction in CA3 tended to be significant (p<0.07). We did not find apoptotic 
cells or any other indication for massive cell loss at both time points. There was a significant 
correlation between severity of the epileptic convulsions and the magnitude of the reduction of 
expression (t-value= -5.08, p<0.0005) (figure 5B). Corticosterone plasma levels were not 
significantly elevated at both time points. 
Treatment with dexamethasone 21-phosphate administered through drinking water at a dose of 
10 µg/ml for three weeks did not significantly affect mdr1 mRNA expression levels in any 
hippocampal subfield (data not shown).  
 
Discussion 
The present study demonstrates the localisation of mdr1a/mdr1b mRNA encoding Pgp around 
brain capillaries, suggesting that Pgp is expressed at the endothelial cells forming the blood-
brain barrier. This finding is consistent with previous studies demonstrating expression of Pgp 
in endothelial cells at the protein level (Thiebaut et al., 1989; Sugawara, 1990; Cordon-Cardo 
et al., 1990; Beaulieu et al., 1995; Lechardeur et al., 1996). By immunoelectron and confocal 
microscopy of brain sections the presence of Pgp at endothelial cells lining the BBB appeared 
to be exclusively present at the luminal membrane (Sugawara et al., 1990; Tsuji et al., 1992; 
Stewart et al., 1996; Virgintino et al., 2002). Convincing evidence also came from a study 
using luminal membrane preparations from rat brain microvasculature isolated by density 
modification (Beaulieu et al., 1997). These preparations were strongly enriched of the brain 
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endothelial membrane marker, the glucose transporter GLUT1, and of Pgp, whereas the 
presence of the abluminal membrane marker integrin αv was reduced. The strong enrichment 
of Pgp in the luminal membrane fractions can only be explained by assuming that the luminal 
membrane of brain capillaries is the major site of Pgp expression.  
Contradictory results from studies of Pardridge et al., however, suggest that Pgp is mainly 
expressed at the astrocyte foot processes (Pardridge et al., 1997; Golden and Pardridge, 1999). 
They observed that the anti-Pgp antibody MRK16 bound to isolated human brain microvessels 
with a similar and overlapping punctuated staining pattern as an antibody against the astrocyte 
marker glial fibrillary acidic protein (GFAP). In contrast, staining for GLUT1 was continuous 
and showed only minimal overlap. As astrocyte foot processes are tightly associated with the 
basement membrane of brain capillaries and remain so after isolation of the capillaries, these 
results are suggestive for astrocyte specific expression (Golden and Pardridge, 2000). 
Although Pgp present at astrocytes may affect total brain uptake of Pgp substrates, astrocyte 
localisation is not likely to affect uptake into neurons. Hence, it would not explain the 
reduction of neuronal retention of dexamethasone in its neuronal targets like hippocampal and 
paraventricular neurons due to presence of Pgp (Meijer et al., 1998). Another study examining 
colocalisation of GFAP and Pgp did not find both proteins colocalised in brain sections of 
adult rats (Matsuoka et al., 1999). Our data show that mRNA encoding for Pgp is expressed in 
endothelial cells of adult rat brain suggesting that Pgp is localised at brain endothelial cells. 
This finding is consistent with a previous study performing in situ hybridisation 
histochemistry on brain sections of mice at embryonic stages (Qin and Sato, 1995), during 
which expression of Pgp is very low (Matsuoka et al., 1999; Tsai et al., 2002). 
Although it might be possible, though unlikely, that mRNA is expressed in astrocyte foot 
processes closely attached to the endothelial cells, the discontinuous staining pattern of 
antibodies against Pgp may satisfactorily be explained by local induction of Pgp due to 
unknown astrocyte-derived factors. It is known that in in vitro cultures astrocytes induce 
various BBB properties including expression of Pgp (Tatsuta et al., 1994; Gaillard et al., 
2000). Thus, it appears from this and other studies that under normal, healthy conditions Pgp 
is only expressed by endothelial cells, although it can not be excluded that under certain 
pathological conditions astrocytes may express Pgp as well.  
 
A remarkable finding of the present study is the mRNA expression found in hippocampal 
neurons, particularly in the granule cells of the dentate gyrus. No other studies have reported 
neuronal expression of Pgp. The differential expression of various hippocampal neuronal cell 
layers and the fact that the sense probe did not give any signal indicate that labelling was 
specific and not due to the high cell density in the granule cell layer. It is at present unknown 
whether mdr1a, mdr1b or both are expressed in these neurons. Recently, using reverse 
transcriptase PCR mdr1a and mdr1b were both found to be expressed in hippocampus, 
whereas only mdr1a was found in other brain regions (Kwan et al., 2003).  
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FIGURE 3. Reduced expression of mdr1
mRNA in dentate gyrus after kainic acid.
Representative autoradiographs of coronal brain
sections showing mdr1 mRNA expression in
hippocampus of a rat treated with saline (A) or a
rat treated with kainic acid 6 hours before
decapitation (B). Sense probe did not result in
signal confirming specificity of the mdr1 probe
(C). In situ hybridisation was performed with a
radioactive-labelled probe. 
FIGURE 2. Anti-Pgp (C219) immuno-
histochemical staining of hypothalamic
paraventricular nucleus illustrating the
high vascularisation of this brain area.  
Bar indicates 100 µm. 
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FIGURE  4. Presence of P-glycoprotein and
mdr mRNA encoding Pgp in rat hippocampus. (A)
Immunohistochemical staining shows highest
staining in stratum granulosum moleculare
(arrowheads), while staining is relatively weak in
CA1 (arrows). (B) DIG-labelled in situ
hybridisation of mdr1 mRNA in hippocampus
demonstrates that mdr1 mRNA is mainly present in
the dentate gyrus (arrows). (C) Detail of medial
dentate gyrus shows granule cells expressing mdr1
mRNA. Bar in A/B indicates 500 µm, while bar in
C indicates 50 µm. 
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Unfortunately, C219 immunohistochemistry did not reveal protein expression nor in the DG 
itself nor in its projection area CA3, even though the C219 epitope is encoded by the part of 
the gene covered by the probe sequence. Protein expression may be low and/or diluted and, 
thus, below threshold of detection of C219 immunohistochemistry. With respect to this, it is 
interesting that a recent report using RT-PCR showed presence of mdr1a/1b mRNA in 
LMCAT fibroblast cells (Webster et al., 2002). These cells are known to express a functional 
Pgp-like transporter (Kralli and Yamamoto, 1996; Medh et al., 1998; Pariante et al., 2001), 
that can not be detected at Western blot with the C219 antibody (Kralli and Yamamoto, 1996). 
Alternatively, our mRNA probe may detect mRNA that encodes a hippocampal protein 
closely related to Pgp, although blasting the sequence against known sequences in Genbank 
did not result in any significant hits of other than mdr proteins. Whether granule cells express 
functional protein, remains therefore unresolved for now. 
 
Dexamethasone did not affect mRNA expression in granule cells, while our methodology did 
not permit to detect whether dexamethasone has altered the expression at the BBB. The 
resolution of radioactive in situ hybridisation is not high enough to detect the widespread and 
scattered distribution throughout the brain of mdr mRNA expression at the BBB. Non-
radioactive in situ hybridisation is not suitable to detect group differences due to nonlinearity 
of the visualisation technique. Several studies have evaluated the effects of dexamethasone on 
Pgp expression at protein as well as mRNA expression level in various settings (Zhao et al., 
1993; Chieli et al., 1994; Sérée et al., 1998; Salphati and Benet, 1998; Demeule et al., 1999; 
Aquilante et al., 2000). However, contradictory results were obtained which suggests that 
Kainate-induced reduction of mdr1 mRNA in brain
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FIGURE 5. Optical density measurements showing reduced expression of mdr1 mRNA in
dentate gyrus after kainic acid. Kainate treatment resulted in a reduction of mdr1 mRNA
expression specifically in the dentate gyrus (A). The decrease in DG was 35% or 30% at 6 hours
respectively 24 hours after injection. Expression tended to be reduced in CA3 6 hours after
injection (p<0.07). Half of the saline treated animals was killed after 6 hours, the other half was
killed after 24 hours.  
There was a correlation (r2= 0.72; p<0.05) between the average epileptic scores and mdr1 mRNA
expression in DG, as illustrated by the data of the 24 hour group (B).  
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modulation of mdr expression is both gene-specific and cell-type-dependent. With regard to 
the brain, dexamethasone may possibly induce Pgp (Aquilante et al., 2000), perhaps by 
induction of mdr1b mRNA expression (Sérée et al., 1998), but these studies are far from 
conclusive.  
 
Kainate treatment surprisingly decreased the expression levels of mdr1a mRNA in the dentate 
gyrus. As cell density was not decreased, this downregulation was not due to cell death. 
Kainate is known to cause apoptosis or necrosis, but this is confined to CA3 respectively CA1 
(Pollard et al., 1994; Nishiyama et al., 1996), areas that are not affected in this study. 
Furthermore, both processes take generally more than 24 hours before their effects can be 
detected (Sperk et al., 1983). 
Using Western blots and immunohistochemistry, two studies described induction of 
hippocampal Pgp expression at the protein level 24 hour after intracerebroventricular (Zhang 
et al., 1999) respectively intraperitoneal (Seegers et al., 2002b) injection of kainate. The 
former study reported that induction of Pgp primarily occurred in cell bodies and processes of 
astrocytes in the CA1 field, whereas the latter study observed induction of Pgp primarily in 
microvascular endothelial cells of dentate gyrus. Both studies used the C219 and the mdr1 
(Ab-1) antibodies, which both recognise a similar epitope, without proper controls of 
specificity. As the high incidence of cross-reactivity of various Pgp antibodies including C219 
(Thiebaut et al., 1989; Beaulieu et al., 1995; Liu et al., 1997) is a serious caveat of Pgp 
immunostaining studies, the necessity of the use of more than two distinct antibodies in a 
single study is highly recommended (Beck et al., 1996). On the other hand, a study using RT-
PCR showed induction of mdr mRNA in mouse hippocampus after kainate-induced limbic 
seizures (Rizzi et al., 2002). Kainate-induced regulation of mdr1 mRNA expression might be 
cell-type specific, explaining the discrepancy between our study and others. At least, it is clear 
that regulation of Pgp expression is complex. 
 
In conclusion, using in situ hybridisation we demonstrated the presence of mdr1 mRNA 
encoding Pgp in endothelial cells forming the BBB and surprisingly in the neuronal layer of 
the dentate gyrus. Although Pgp in the granule cells at the protein level was below the 
detection limit, the mRNA signal appears to be specific. Kainate treatment of rats resulted in a 
reduction of mdr1 mRNA expression levels.  
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Abstract 
In the present study, we investigated the role of the multidrug resistance P-glycoprotein (Pgp) 
at the blood-brain barrier in the control of access of cortisol and corticosterone to the mouse 
and human brain. 
3H-cortisol poorly penetrated the brain of adrenalectomised wild type mice, but its uptake was 
3.5 fold enhanced after disruption of Pgp expression in mdr1a (-/-) mice. In sharp contrast, 
treatment with 3H-corticosterone revealed high labelling of brain tissue without difference 
between both genotypes. 
Interestingly, human MDR1 P-glycoprotein also differentially transported cortisol and 
corticosterone. LLC-PK1 monolayers stably transfected with MDR1 cDNA showed polar 
transport of 3H-cortisol that was blocked by a specific Pgp blocker, whereas 3H-corticosterone 
transport did not differ between transfected and host cells.  
Determination of the concentration of both steroids in extracts of human post mortem brain 
tissue using liquid chromatography mass spectrometry revealed that the ratio of corticosterone 
over cortisol in brain was significantly increased relative to plasma. 
In conclusion, the data demonstrate that in both mouse and human brain the penetration of 
cortisol is less than that of corticosterone, because of the differential Pgp-mediated efflux 
transport of both hormones. This finding suggests a more prominent role for corticosterone in 
control of human brain function than hitherto recognised.  
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Introduction 
The naturally occurring glucocorticoid in rodents, corticosterone, readily gains access to the 
brain and accumulates particularly in cell nuclei of limbic brain areas such as hippocampus, 
septum and amygdala (McEwen et al., 1968; McMurry and Hastings, 1972; De Kloet et al., 
1975; Coutard et al., 1987). In these brain areas corticosterone is retained by 
mineralocorticoid receptors (MR) that bind corticosterone with a ten fold higher affinity than 
glucocorticoid receptors (GR) (Reul and De Kloet, 1985). In contrast, the synthetic 
glucocorticoid dexamethasone, when administered in tracer doses to adrenalectomised rats or 
mice, is poorly retained in glucocorticoid target areas in brain (De Kloet et al., 1974; De Kloet 
et al., 1975; Rees et al., 1975; McEwen et al., 1976; Coutard et al., 1978). Uptake and 
retention in the anterior pituitary is very high, although both brain and pituitary express similar 
amounts of GR.  
 
These observations raised the possibility that the blood brain barrier (BBB) limits the access 
of dexamethasone to the brain (De Kloet et al., 1975; Rees et al., 1975; Coutard et al., 1978). 
Recently, it was indeed demonstrated that the penetration of dexamethasone into brain is 
hampered because the multidrug resistance 1a (mdr1a) P-glycoprotein (Pgp) excludes this 
exogenous compound from mouse brain (Schinkel et al., 1995; Meijer et al., 1998). The drug-
transporting Pgp is expressed at the luminal membranes of endothelial cells of the blood brain 
barrier (Cordon-Cardo et al., 1989; Thiebaut et al., 1989). This transmembrane protein is 
encoded by the mdr1a gene in rodents and by the highly homologous MDR1 gene in humans 
(Jette et al., 1995; Van de Vrie et al., 1998).  
 
Thus, Pgp may explain why moderate amounts of dexamethasone primarily act at the anterior 
pituitary level to suppress ACTH release (De Kloet et al., 1975). In contrast, in rodents the 
endogenous glucocorticoid corticosterone primarily acts in the brain on functions underlying 
the activity of the hypothalamic-pituitary-adrenal (HPA) axis and behavioural adaptation (De 
Kloet, 1991; Dallman et al., 1992; De Kloet et al., 1998). In many other species cortisol is the 
principal endogenous glucocorticoid; e.g., in human blood cortisol circulates in 10- to 20-fold 
higher levels than corticosterone (Underwood and Williams, 1972; West et al., 1973; Nishida 
et al., 1977; Kage et al., 1982). As a naturally occurring glucocorticoid, cortisol is commonly 
accepted to exert similar actions in human brain as corticosterone does in rat and mouse brain. 
However, although it has a high affinity for MR, a tracer dose of cortisol has been reported to 
be poorly retained in cell nuclei of rat hippocampi (McEwen et al., 1976). This may not be 
surprising, because rat and mouse lack adrenal 17α-hydroxylase needed for synthesis of 
cortisol, which therefore makes this steroid exogenous in these species and hence, given that 
Pgp substrates are predominantly exogenous compounds (Van de Vrie et al., 1998), a potential 
target for Pgp-mediated export from the brain,  
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In the present study, we have first tested the hypothesis that mdr1a Pgp at the mouse BBB 
limits in vivo brain penetration of cortisol. For this purpose we have used adrenalectomised 
mdr1a null and wild type mice injected with a tracer dose of 3H-cortisol or 3H-corticosterone. 
The latter glucocorticoid freely crosses the BBB (Meijer et al., 1998). In addition, we have 
investigated whether a species difference exists between the multidrug resistance P-
glycoproteins of mouse and man, which would allow free entrance of cortisol into the human 
brain. To explore this possibility, we have examined the corticosteroid transport capabilities of 
monolayers of human MDR1 transfected porcine LLC-PK1 cells compared to nontransfected 
LLC-PK1 cells. In order to examine the in vivo effect of MDR1 Pgp we have extracted both 
corticosteroids from human plasma as well as from post mortem human brain material to 
simultaneously determine cortisol and corticosterone concentrations using liquid 
chromatography-mass spectrometry.  
 
Materials and methods  
In vivo distribution and autoradiography 
The in vivo distribution experiments were carried out as described previously (Meijer et al., 
1998) with some modifications. Male mdr1a (-/-) and wild-type FVB (for Friend’s virus B-
type susceptible) mice were bred under SPF conditions at TNO (Leiden, The Netherlands). 
Male mice at the age of 15-20 weeks were used for this study. All experiments were carried 
out in accordance with the European Communities Council Directive 86/609/EEC and with 
approval from the animal care committee of the Faculty of Medicine, Leiden University 
(Leiden, The Netherlands).  
After transport, the mice were housed individually at our laboratory, at ambient temperature 
and at a 12/12 hour lighting schedule (lights on at 7, lights out at 19 hr) with free access to 
food and water. To remove the source of endogenous corticosterone, mice were bilaterally 
adrenalectomised under gas anaesthesia (isoflurane) by a dorsal approach. After 
adrenalectomy (ADX) the animals had free access to 0.9% saline. At the time of the 
experiment the animals weighted 27 ± 2.7 gr. (mean ±SD).  
Two days after ADX, the animals were subcutaneously injected with tritiated steroids 
(dissolved in 2% ethanol/0.9% saline) for in vivo autoradiography. Wild type (n=4) and 
mutant mice (n=6) were injected with 13 µCi/10 gr (1,2,6,7)-3H-cortisol (Amersham 
Pharmacia Biotech, Little Chalfont, UK; specific activity 63 Ci/mmol). As a control for non-
specific retention, one mouse of each genotype was pretreated with a 100-fold excess of 
unlabelled cortisol 30 minutes before treatment. In a separate but similar experiment, mice 
(n=7-8) were treated with 2.5 µCi/10 gr (2,4,6,7)-3H-corticosterone (Amersham Pharmacia 
Biotech; specific activity 70 Ci/mmol). One hour after injection the animals were decapitated. 
Trunk blood was collected in EDTA-coated tubes and centrifuged for determination of 
radioactivity and of remaining corticosterone in the plasma using a 125I-corticosterone 
radioimmunoassay kit (ICN Biomedicals, Costa Mesa, USA). Liver, testis, intestine and 
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cerebellum were dissected and frozen on dry ice. The pituitary was dissected and mounted on 
top of the brain (without cerebellum), which were then frozen together in isopentane 
precooled on dry ice/ethanol. All tissues were stored at –80°C until further use.  
All organ tissues studied, except for the brain, were homogenised using Soluene-350 (Packard 
Bioscience, Groningen, The Netherlands). Hionic-Fluor (Packard Bioscience) was added to 
tissue homogenates and plasma and radioactivity was determined in a Tricarb ß-counter 
(Packard Instruments, Meriden, USA). Twelve-micrometer coronal sections of brain were cut 
on a cryostat and thaw-mounted on poly-L-lysine (Sigma Chemical, St Louis, USA) coated 
microscopic slides. The slides were put in an X-ray exposure holder (Kodak) and apposed to 
Ultrofilm (Leica, Heerbrugg, Switzerland) for 8 weeks. Optical density of radiolabelled 
steroid retained in pituitary and different brain areas was quantified after subtraction of film 
background using an computerised Olympus image analysis system (Paes, The Netherlands) 
equipped with a Cue CCD camera. From each brain, 3-5 sections were measured by outlining 
the different brain regions. The means were used for further analysis of group differences. 
Transepithelial transport and inhibition studies 
In order to examine the interactions of cortisol and corticosterone with the human P-
glycoprotein we used monolayers of the porcine kidney epithelial cell-line LLC-PK1, and 
LLC-PK1 cells stably transfected with cDNA of the human MDR1 gene (LLC-PK1:MDR1). 
Cells originally obtained from the American Type Culture Collection (Manassas, USA) were 
kindly provided by the Netherlands Cancer Institute (Amsterdam, The Netherlands) (Schinkel 
et al., 1995). Human P-glycoprotein has been shown before to be specifically expressed on the 
apical surface of LLC:PK1:MDR1 cells in these monolayers (Ueda et al., 1992; Florea et al., 
2001). Therefore, Pgp substrates entering these cells from the basal side will be translocated to 
the apical compartment, while those entering the apical membrane will be pumped back into 
the medium, thus resulting in polarised transport of substrates. This system models the way 
Pgp is likely to function at the BBB in excluding drugs from the brain.  
Cells were cultured at 37°C in the presence of 5% CO2 in complete medium, which consisted 
of DMEM (BioWhittaker, Verviers, Belgium) supplied with HEPES (25 mM) and glucose 
(4.5 g/l) and supplemented with penicillin (100.000 U/l), streptomycin (100 mg/l), L-
glutamine (2 mM) and 10% (v/v) foetal calf serum. The LLC-PK1 and LLC-PK1:MDR1 cell 
lines were subcultured by trypsinisation every 3 to 4 days and medium was replaced twice a 
week. 
During the experiments complete medium was used. The LLC-PK1 and LLC-PK1:MDR1 
cells were seeded on microporous polycarbonate membrane filters (0.4 µM pore size, 12 mm 
diameter, TranswellTM; Costar, Cambridge, USA) at a density of 120*103 cells/cm2. The cells 
were grown for 5-6 days in complete medium with one medium replacement at day 3. Two 
hours before the start of the experiment, the medium was replaced with 800 µl fresh medium 
at both the apical and basal side of the monolayer. In the inhibition experiments, one hour later 
the potent and selective P-glycoprotein blocker LY 335979 (1 µM; kindly provided by Eli 
Lilly, USA) or water was added at the basal side. To measure the transepithelial transport from 
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the apical to the basal side or from basal to the apical side 8 µl of a 100x stock of tritiated 
steroid (3H-cortisol, 3H-corticosterone or (1,2(n))-3H-cortisone (Amersham Pharmacia 
Biotech; specific activity 50 Ci/mmol)) in ethanol was added in triplicate at the apical or basal 
side respectively, at the start of the experiment (t=0). The starting concentrations for each 
experiment are mentioned in the legends of the appropriate figures. In the dose-response 
experiment, different concentrations of unlabelled cortisol were used, supplemented with 3H-
cortisol. Over the four hours of study 75 µl aliquots were taken once every hour from both 
compartments. Eight µl samples of the 100x stock, and samples from the compartment 
opposite that to which activity was added, were counted in a Tricarb ß-counter after adding 3 
ml Emulsifier Safe (Packard Bioscience). Basal to apical and apical to basal transport is 
presented as percentage of total activity added at the beginning of the experiment. 
Transepithelial electrical resistance was measured before and after the experiments to check 
the integrity of the monolayers (Gaillard and De Boer, 2000).  
Corticosteroid determination in post mortem human brain 
Human brain material was collected through the rapid autopsy program of the Netherlands 
Brain Bank (NBB) (Amsterdam, The Netherlands; Coordinator: Dr. R. Ravid). The NBB 
abides to all local ethical legislation. All tissue has been obtained with informed consent of the 
donor or next of kin to perform brain autopsy and the subsequent use of brain tissue for 
scientific purposes, that is requested in advance together with the permission to use the 
medical records. Patient tissue was carefully selected; none of the subjects was reported to 
suffer at the moment of death or to have suffered before from a known neurological or 
psychiatric disease, or from conditions that might have affected BBB integrity, like transient 
ischaemic attacks (TIA), (suspected) prolonged arterial blood pressure changes, prolonged 
fever or the presence of multiple brain infarcts. Moreover, none of the subjects had been 
treated with synthetic steroids or antidepressants at time of death or at any time during life. 
From every subject, a standard set of brain areas has been carefully investigated (Ravid et al., 
1995) by neuropathologists Prof. Dr. D. Troost (Academic Medical Centre, Amsterdam), Prof. 
Dr. F.C. Stamand and Dr. W. Kamphorst, (Free University, Amsterdam). The final diagnosis 
was established by relating this neuropathological examination to the outcome of the clinical 
diagnosis. Following this careful examination, all present subjects were confirmed to be true 
controls as the tissue was free of any such changes. Post mortem delay was kept as short as 
possible and was on average 6:45 hr. Further clinicopathological details are presented in Table 
1. All 11 brain tissue samples used in this study were dissected from superior parietal cortex of 
male control subjects (mean age 65 ± 5.1) and rapidly frozen in liquid nitrogen and then stored 
at –80 °C until use. 
Plasma samples were obtained from 11 male volunteers (mean age 57 ± 6.3). 
 
Samples were prepared for assay by dichloromethane/ethanol extraction. The brain samples 
(weighing about 350 mg) were homogenised in 2 ml 0.1 M perchloric acid with a Potter-
Elvehjem tissue homogeniser (10 times up and down, 1000 rpm). To check for differences in 
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recovery 100 ng of dexamethasone was added to each sample. The homogenates were 
transferred with a 4 ml wash of dichloromethane (DCM) to screw-capped glass tubes. After 
adding an extra 4 ml DCM the tubes were shaken on a horizontal reciprocating shaker for 30 
minutes and subsequently centrifuged at 1000x g at 4°C for 10 minutes. The DCM layer was 
transferred to a clean coned tube and rinsed with 1 ml water, centrifuged at 700x g for 10 
minutes. Then, the DCM-layer was transferred to a long tube and evaporated to dryness in a 
SpeedVac. To maximise the amount transferred, the extracts were redissolved in 750 µl 
ethanol and after transferring to an eppendorf, evaporated again. The final extracts were 
resuspended in 100 µl 25% methanol and centrifuged at 13000 rpm for 5 minutes. To avoid 
potential dissimilarities between different extraction methods, the 250 µl plasma samples were 
extracted in the same way.  
 
Liquid chromatography-mass spectrometry (LC-MS) was the method of choice to measure the 
levels of cortisol and corticosterone in the supernatants of the extracts as it allowed the 
simultaneous measurements of both hormones in small samples with dexamethasone as 
TABLE 1. Clinicopathological data of the male subjects. 
case NBB # Autopsy # age PMD pH BW  cause of death 
1 90-090 90/234.3 59 4:25 7.23 1409 Myocardial infarction and cardial 
decompensation 
2 94-125 S94/340 51 6:00 6.50 1518 Progressive liposarcoma and ileus 
3 95-007 S95/019 54 9:10 6.89 1335 Bleeding from right A.carotis communicans 
4 97-162 S97/387 38 10:45 6.71 1618 Wegener’s disease, aluminium intoxication 
5 98-006 S98/014 50 8:30 6.65 1436 Cardiac arrest 
6 98-127 S98/235 56 5:25 6.55 1522 Cardiac infarction 
7 96-085 S96/251 84 9:00 6.20 1367 Heartfailure, uremia 
8 97-157 S97/368 69 5:55 6.41 1475 Serious prostate cancer with metastasis 
9 98-062 S98/142 85 4:35 6.95 1332 Respiratory insufficiency secondary to a 
metastasised adenocarcinoma 
10 98-157 S98/280 85 5:13 6.23 1394 Cardiac tamponade 
11 98-189 S98/326 81 5:20 6.64 1276 Respiratory insufficiency 
 All tissue was taken from the superior parietal gyrus. 
Abbreviations used: NBB#: Netherlands Brain Bank identification number; PMD: post mortem 
delay (hrs); pH: pH of the cerebrospinal fluid; BW: brain weight (g) 
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internal standard. The assays were performed on a Triple Stage Quadrupole mass spectrometer 
(Finnigan MAT TSQ-700, San Jose, USA) with a custom-made atmospheric pressure 
chemical ionisation interface. A modification of the method of Van der Hoeven et al. (1997) 
was used. The analysis was performed in negative ionisation mode using selective ion 
monitoring of [M+CH3COO]
- of cortisol, corticosterone and dexamethasone, alternately 
scanning m/z 421, 406 and 452. The ion-source temperature and the nebulisation heater were 
kept at 200°C and 400°C, respectively. The voltages on the corona needle and on the electron-
multiplier were set at -3200 and –1800 V, respectively. Each experiment, a new calibration 
series was made in 25% methanol with eight concentrations ranging from 5-500 ng/ml of both 
cortisol and corticosterone. Dexamethasone (1µg/ml) was used as an internal standard. An 
ADS C18 column was used to separate the steroids. After injection of 20 µl of the calibration 
or extraction samples, the column was washed with acetonitrile-water (40/60%, v/v) 
containing 1 g/l acetic acid, at a flow rate of 0.5 ml/min. The detection limit of this assay was 
5 ng/ml. Corticosteroid concentrations were calculated from a standard plot of area under the 
curve versus concentration. Presented data are corrected for recovery of dexamethasone, 
which was in the order of 20-40%. 
Statistical analysis  
Human and mouse data were evaluated by Student’s t-test. The results of the monolayer 
experiments were analysed by Repeated Measures ANOVA. Significance was taken at p < 
0.05. 
Results 
Differences in brain uptake and retention of 3H-corticosterone and -cortisol 
At 1 hour after administration of 3H-cortisol to ADX mice, the uptake of radioactivity in brain 
showed a clear difference between mdr1a (-/-) mutant mice and wild type mice (table 2). The  
 
FIGURE 1.  Radioactivity of 3H-corticosterone (A) and 3H-cortisol (B) in cerebellum and liver
homogenates and plasma of wild type and mdr1a (-/-) mice (n=3-7). Data are presented relative to
wild type set at 1.0. * p< 0.01, t-test on untransformed data. 
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FIGURE 2. Representative autoradiograms of 12-µm coronal sections of the brain of wild type
(A,C) and mdr1a (-/-) mice (B,D) at hippocampus level. Autoradiograms show labelling with 3H-
cortisol (A,B) or 3H-corticosterone (C,D). Note the pituitary mounted on top of the brain. The dark
spots in (A) represent transverse sectioning of choroid plexus and adjacent cerebroventricular
space.  
TABLE 2. Uptake of radioactivity in tissue homogenates and blood 1 hr after administration of 3H-
cortisol without or with pretreatment with 100-fold excess unlabelled cortisol. 
 wild type mdr1a (-/-) 
3
H-Cortisol   dose 8 µg/kg    
N 3 5    
cerebellum [nCi/mg] 0.093 ± 0.001 0.335 ± 0.034 * 
plasma [nCi/µl] 0.441 ± 0.038 0.422 ± 0.056  
liver [nCi/mg] 8.390 ± 0.380 8.479 ± 0.657  
testis [nCi/mg] 0.224 ± 0.005 0.217 ± 0.027  
intestine [nCi/mg] 2.245 ± 1.232 2.399 ± 0.938  
brain/blood ratio 0.215 ± 0.020 0.809 ± 0.034 * 
     
Pretreatment with 0.8 mg/kg unlabelled cortisol   
N 1   1   
cerebellum [nCi/mg] 0.088   0.321   
plasma [nCi/µl] 0.590   0.563   
liver [nCi/mg] 6.852   7.200   
brain/blood ratio 0.148   0.571   
* p < 0.01 compared to wild type 
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amount of cortisol in cerebellum homogenates was 3.5-fold higher in mdr1a knockouts than in 
wild type mice (figure 1). In contrast, the amount of 3H-corticosterone in cerebellum did not 
differ between the two genotypes (figure 1 and table 3). For both corticosteroids the presence 
or absence of the mdr1a gene did not affect their concentration in plasma, liver, testis and 
intestine (figure 1; tables 2 and 3).  
 
The autoradiograms (figures 2 and 3) extend these results to the regional distribution of the 
3H-steroids in the brain. The mdr1a (+/+) animals showed hardly any labelling of brain tissue 
after administration of 3H-cortisol (figure 2A). Labelling in brain sections was restricted to the 
cerebral ventricles. The mdr1a (-/-) mutants, however, showed increased labelling of whole 
brain (figure 2B). In particular, radioactivity was retained in hippocampal cell fields and, to a 
lesser extent, the amygdala. In contrast, after treatment with 3H-corticosterone the mutant and 
wild type ADX mice did not differ in their strong labelling of hippocampal neurons or of any 
other part of the brain (figures 2C and D). In both mutants and wild types, 3H-cortisol labelling 
of the pituitary, which lies outside the BBB, was not affected by the absence of mdr1a Pgp.  
 
 
 
 
 
TABLE 3. Uptake of radioactivity in tissue homogenates and blood 1 hr after administration of 3H-
corticosterone without or with pretreatment with 100-fold excess unlabelled corticosterone. 
 wild type mdr1a (-/-) 
3
H-Corticosterone  dose 1.5 µg/kg   
N 5   7   
cerebellum [nCi/mg] 0.111 ± 0.016 0.102 ± 0.015  
plasma [nCi/µl] 0.264 ± 0.026 0.194 ± 0.027  
liver [nCi/mg] 1.801 ± 0.050 1.718 ± 0.085  
testis [nCi/mg] 0.110 ± 0.021 0.130 ± 0.009  
intestine [nCi/mg] 1.227 ± 0.411 1.968 ± 1.000  
brain/blood ratio 0.415 ± 0.023 0.546 ± 0.048  
     
Pretreatment with 0.15 mg/kg unlabelled corticosterone  
N 1   1   
cerebellum [nCi/mg] 0.075   0.086   
plasma [nCi/µl] 0.260   0.242   
liver [nCi/mg] 1.641   1.612   
brain/blood ratio 0.290   0.355   
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Pretreatment with excess unlabelled cognate steroid to block specific labelling to receptors 
resulted in loss of labelling of hippocampal neuronal fields and amygdala, but not of the rest 
of the brain (data not shown). Moreover, hippocampal optical density showed an inverse 
correlation with residual levels of endogenous corticosterone, illustrating that the signal 
represents specific mineralocorticoid receptor bound steroid (data not shown). The cortex and 
the pituitary lack this correlation, but cortex labelling showed a clear effect of disruption of 
the mdr1a gene (figure 3). In accordance, uptake of radioactivity in cerebellum was hardly 
affected by pretreatment (tables 2 and 3). These data evidently demonstrate that the presence 
of mdr1a Pgp in the BBB hampers the access of cortisol to the mouse brain, but does not have 
any effect on the access of the endogenous glucocorticoid corticosterone.  
Transepithelial transport of steroids in LLC-PK1- and MDR1-monolayers 
Corticosterone transport in the monolayers of LLC-PK1 cells stably transfected with the 
human MDR1 gene was not different from transport in monolayers of its control cell line 
(figure 4B), although some polar transport was observed in both cell lines in all our 
experiments (figures 4B and 5B). Nonetheless, this demonstrates the absence of human MDR1 
Pgp mediated transport of corticosterone. In contrast, cortisol was transported in a polarised 
fashion in the MDR1 transfected monolayers, but not in the host cells (figure 4A). Polarised 
transport in MDR1 monolayers of cortisol was abolished in presence of LY335979, a potent 
and selective Pgp blocker (Starling et al., 1997; Dantzig et al., 1999), resulting in similar 
fractions transported as in monolayers of untransfected cells (figure 5A). This confirms that 
cortisol transport is mediated by human P-glycoprotein. LY335979 did not change the fraction 
of corticosterone translocated through the membrane (figure 5B).  
FIGURE 3. Quantification of the autoradiograms of 3H-cortisol in wild type (n=3) and mdr1a
(-/-) (n=5) mice. Presented is the mean ± SEM of both genotypes for pituitary, cortex and
hippocampal areas. There are no differences between wild type and mutants for pituitary.
Differences in cortex and hippocampal areas CA1 and DG are significant at p < 0.05. The values
for CA3 are not significantly different (p = 0.07). Three sections per animal were measured.  
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FIGURE 4. Activity of 3H-cortisol (A) and 3H-corticosterone (B) present in medium at
different time points after adding 3H-steroid to the opposite compartment at t=0. Transepithelial
transport from basal to apical (∆,▲) and from apical to basal (○,●) compartment was measured in
wild type LLC-PK1 (broken line) or MDR1 transfected LLC-PK1 (solid line) monolayers.
Presented is the fraction of the dose of radioactivity, which is 9 nM for both steroids, added to the
respective compartment. Each point represents the mean of three monolayers ± SEM. Repeated
measures ANOVA showed a significant interaction of time*celltype*transport for cortisol (p<
0.0005), but not for corticosterone. 
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FIGURE 5. Activity of 3H-cortisol (A) and 3H-corticosterone (B) present in medium at
different time points after adding 3H-steroid to the opposite compartment at t=0 and 1 µM
LY335979 (broken line) or water (solid line) one hour before. Transepithelial transport from basal
to apical (∆,▲) and from apical to basal (○,●) compartment was measured in MDR1 transfected
LLC-PK1 monolayers. Presented is the fraction of the dose of radioactivity, which is 8 nM for
cortisol and 28 nM for corticosterone, added to the respective compartment. Each point represents
the mean of three monolayers ± SEM. Repeated measures ANOVA showed a significant interaction
of time*cell type*transport for cortisol (p< 0.0005), but not for corticosterone. 
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We also examined transepithelial transport of different concentrations of cortisol, ranging 
from 5 to 625 nM, but did not demonstrate any saturation at higher dose. At all concentrations 
tested, about 3.5 times more 3H-cortisol had been transported from basal to apical sides than 
from apical to basal sides after four hours (data not shown). Interestingly, our data show that 
human MDR1 Pgp is also able to transport cortisol, while corticosterone passage remains 
unchanged.  
 
A potential limitation of our assay is the use of radiolabelled glucocorticoids and, 
consequently, the possibility that the transport of metabolites has been measured rather than 
the unmetabolised compounds. Because of the presence of 11ß-HSD type 2 in LLC-PK1 cells 
(Leckie et al., 1995), the main probable metabolites are the inactive forms of the 
glucocorticoids, i.e. cortisone in case of cortisol and 11-dehydrocorticosterone in case of 
corticosterone. Therefore, we first tested cortisone transport in our monolayers. Cortisone 
showed polarised transport in LLC-PK1:MDR1 monolayers, which could be blocked by 
LY335979 (figure 6). Thus, transport of metabolites may potentially have interfered. 
However, cotreatment with the 11ß-HSD inhibitor carbenoxolone (10-6 and 10-5 M) did not 
FIGURE 6A. Activity of 3H-cortisone present in medium at different time points after adding 3H-
cortisone to the opposite compartment at t=0. Transepithelial transport from basal to apical (∆,▲)
and from apical to basal (○,●) was measured in wild type LLC-PK1 (broken line) or MDR1
transfected LLC-PK1 (solid line) monolayers.  
B. Transepithelial transport of 3H-cortisone was measured in MDR1 transfected LLC-PK1
monolayers after adding 1 µM LY335979 (broken line) or water (solid line) one hour before start
of the experiment.  
Presented is the fraction of the dose of radioactivity, which is 9 nM, added to the respective
compartment. Each point represents the mean of three monolayers ± SEM. Repeated measures
ANOVA showed a significant interaction of time*celltype*transport for cortisone in both (A) and
(B) (p < 0.0005). 
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change the transport capabilities of LLC-PK1 or LLC-PK1:MDR cells in any way (data not 
shown) excluding the possibility that we have measured the metabolites. 
These monolayer data suggest that P-glycoprotein in human BBB like in mice limits the 
access of cortisol to the brain, but does not affect the penetration of corticosterone. 
Accordingly, we expected more corticosterone relative to cortisol in human brain than in 
human plasma.  
 
TABLE 4. Corticosterone and cortisol levels and the corticosterone/cortisol ratio in extracts of human 
brain tissue and plasma 
Brain NBB # corticosterone [ng/mg] cortisol [ng/mg] ratio 
case 1 90-090 81.28 291.48 0.28 
case 2 94-125 32.20 201.62 0.16 
case 3 95-007 35.07 121.88 0.29 
case 4 97-162 11.23 33.08 0.34 
case 5 98-006 14.18 46.49 0.31 
case 6 98-127 55.83 176.90 0.32 
case 7 96-085 83.41 507.46 0.16 
case 8 97-157 122.76 442.02 0.28 
case 9 98-062 84.17 265.42 0.32 
case 10 98-157 280.57 443.14 0.63 
case 11 98-189 24.10 70.25 0.34 
 AVG 74.98 236.34 0.31 
 SEM 23.14 50.92 0.04 
Plasma age [ng/ml] [ng/ml]  
case 1 27 5.77 306.49 0.02 
case 2 20 8.14 286.48 0.03 
case 3 32 4.87 224.65 0.02 
case 4 62 12.57 78.50 0.16 
case 5 83 3.89 57.70 0.07 
case 6 70 11.42 126.29 0.09 
case 7 76 4.18 66.68 0.06 
case 8 69 4.38 84.18 0.05 
case 9 63 2.21 71.03 0.03 
case 10 68 4.11 54.22 0.08 
case 11 56 0.95 39.22 0.02 
 AVG 5.68 126.86 0.06 
 SEM 1.09 29.53 0.01 
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Corticosteroid levels in human brain 
In order to test whether MDR1 Pgp in human BBB increases the ratio of corticosterone over 
cortisol in brain, we measured the concentrations of both glucocorticoids in human brain 
samples (table 4). Thus, we were able to determine the brain corticosterone/cortisol ratio of 11 
subjects, which was 0.31 ± 0.04 (mean ± SEM) (figure 7). In contrast, we measured a 
corticosterone/cortisol ratio in plasma samples of age-matched males of 0.06 ± 0.01 (figure 7). 
Statistical analysis showed that the difference between the brain and plasma ratios was 
significant (t (1,20) = 6.444, p < 0.01). Thus, corticosterone appears to penetrate more easily 
than cortisol in the human brain, resulting in a higher ratio of corticosterone over cortisol 
present in brain as compared to plasma. 
 
 
Discussion 
The present study indicates that Pgp at the level of the BBB is of importance with respect to 
the degree of brain exposure to the naturally occurring glucocorticoids cortisol and 
corticosterone. Our data show that the mdr1a Pgp present at the murine BBB hampers the 
penetration of cortisol into the mouse brain, whereas corticosterone uptake is not affected. 
Interestingly, our results with monolayers of human MDR1 transfected LLC-PK1 cells 
suggest that Pgp exports cortisol and not corticosterone from human brain as well. This is, at 
least, consistent with the accumulation of corticosterone over cortisol in the samples of human 
post mortem brain relative to plasma, as determined in our LC-MS experiments.  
 
FIGURE 7. Ratio of corticosterone over cortisol in extracts of human brain and plasma.  
The ratio is significantly higher in brain compared to plasma indicating preferential uptake into
brain of corticosterone compared to cortisol. Data are presented as mean ± SEM. * p < 0.01.  
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Previous studies had already established in vivo the low cell nuclear retention of cortisol in rat 
brain (McEwen et al., 1976). In rats, the first-pass uptake in brain after a carotid injection of 
3H-cortisol appeared to be negligible in contrast to uptake of 3H-corticosterone, while uptake 
of the labelled steroids in liver after portal injection was not different (Pardridge and Mietus, 
1979). A tracer dose of corticosterone is known to label only the high affinity hippocampal 
MR leaving the lower affinity GR undetectable. The uptake of this steroid is not affected by 
disruption of the mdr1a gene (Meijer et al., 1998, this study). Cortisol also binds with a rather 
high affinity to MR (De Kloet, 1991). In fact, our autoradiography study revealed a pattern of 
cortisol labelling in the mdr1a (-/-) mouse hippocampus reminiscent of that of corticosterone. 
In the present study, the effect of mdr1a ablation on specific binding of cortisol to the low 
capacity MR in the hippocampus is less pronounced than its effect on whole brain uptake in 
e.g. the cortex. This is probably due to the lower affinity of cortisol for MR in rodent brain 
(De Kloet et al., 1984a; Myles and Funder, 1994). Anyhow, our data convincingly 
demonstrate that the mouse mdr1a Pgp hampers the brain uptake of cortisol but not of 
corticosterone. 
 
As a model for Pgp function in human BBB, we have used monolayers of pig kidney epithelial 
LLC-PK1 cells stably transfected with the MDR1 gene to measure transport of steroids by 
human Pgp. Such monolayers of epithelial cells are a suitable model for Pgp-mediated 
transport at the BBB, given the apical localisation of Pgp forming a barrier between the two 
compartments. A confounding factor is that LLC-PK1 host cells contain low levels of porcine 
Pgp (Horio et al., 1990; Ueda et al., 1992; Decorti et al., 1998). Thus, in theory, porcine Pgp 
might be responsible for polar transport of corticosterone seen in both cell lines, although any 
effect after application of the potent and selective Pgp-blocker was absent. LLC-PK1 cells 
also have endogenous 11ß-hydroxysteroid dehydrogenase type 2 activity, able to inactivate 
cortisol and corticosterone (Leckie et al., 1995). Because we used radiolabelled 
glucocorticoids it is possible that we have actually measured transport of labelled metabolites 
rather than the parent hormone. However, the transport of 3H-cortisol and 3H-corticosterone 
did not change in the presence of the 11ß-HSD inhibitor carbenoxolone, indicating that 11ß-
HSD activity did not interfere. We conclude therefore that our monolayers are a suitable 
model of Pgp function at human BBB.  
 
Our data corroborate several studies on transport of cortisol and corticosterone by Pgp (Yang 
et al., 1989; Wolf and Horwitz, 1992; Ueda et al., 1992; Van Kalken et al., 1993; Gruol and 
Bourgeois, 1994; Orlowski et al., 1996; Barnes et al., 1996). Differential transport of these 
two steroids by murine Pgp has been observed in several drug-resistant cell lines, using steroid 
induced apoptosis (Bourgeois et al., 1993; Gruol and Bourgeois, 1994) or steroid 
accumulation (Wolf and Horwitz, 1992; Barnes et al., 1996) as read-outs. The murine mdr1b 
Pgp has some capacity to transport corticosterone (Wolf and Horwitz, 1992), but this second 
murine multidrug resistance Pgp is not expressed at the BBB. In view of the lack of 
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corticosterone transport that we have observed in cells stably transfected with the human 
MDR1 gene, the corticosteroid transport capabilities of the human MDR1 Pgp apparently 
correspond to that of murine mdr1a rather than to that of mdr1b Pgp. Using comparable 
monolayers to those in this study, Ueda et al. (1992) have already demonstrated that cortisol is 
transported by the human MDR1 Pgp, but corticosterone was not included in their assay. In 
human colon carcinoma cells the amount of accumulated 3H-cortisol is lower than of 
corticosterone (Barnes et al., 1996), while both steroids equally increase accumulation of the 
Pgp substrate 3H-vinblastine – exemplifying a difference between actual transport by and 
binding of steroids to the pump.  
 
The difference in interaction of Pgp with cortisol and corticosterone is remarkable considering 
their large similarity in molecular structure. Pgp is an efflux transporter with a surprisingly 
broad substrate spectrum (Schinkel et al., 1994), but corticosterone only differs from cortisol 
in the lack of the 17-hydroxyl group. However, a detailed study of Bourgeois et al. (1993) 
provided indications that both the 17-hydroxyl and the 11-hydroxyl group determine the 
ability of steroids to be transported by Pgp. Pgp transports steroids having both these 
hydroxyl-groups while steroids lacking one of these groups are probably minimally if at all 
transported. A caveat is that these indications are based on the extent of glucocorticoid 
resistance, which also depends on GR affinity. It is difficult to assess the influence of the 11-
hydroxyl group because steroids lacking this group do also have a low affinity for GR. 
Therefore, cortisone could not be identified as a substrate of Pgp in the previous study; using 
LLC-PK1:MDR1 monolayers, however, we demonstrated that cortisone is also transported by 
Pgp.  
 
Our study with the mdr1a null mice is the first to directly show the involvement of Pgp in 
excluding a naturally occurring glucocorticoid from the brain. Previous studies have 
demonstrated that access of the synthetic glucocorticoid dexamethasone to the brain was also 
enhanced in the mdr1a (-/-) mouse (Schinkel et al., 1995; Meijer et al., 1998). In vitro studies 
have confirmed that dexamethasone is a Pgp substrate (Ueda et al., 1992; Bourgeois et al., 
1993; Gruol et al., 1999). In fact, in our stably MDR1 transfected LLC-PK1 monolayers 
dexamethasone behaved very similar to cortisol (Karssen et al., 2003). Thus, human MDR1 
Pgp, like mouse mdr1a Pgp, transports both cortisol and dexamethasone, but not 
corticosterone. 
 
Our in vitro results using monolayers of stably MDR1 transfected LLC-PK1 cells show that 
the endogenous presence in a species of a naturally occurring glucocorticoid is not a 
prerequisite to exclude transport by Pgp. We have clearly demonstrated that human MDR1 
Pgp is able to discriminate between cortisol and corticosterone. Both glucocorticoids are 
present in human plasma, although cortisol circulates in about 10 to 20 times higher levels 
than corticosterone (Underwood and Williams, 1972; West et al., 1973; Nishida et al., 1977; 
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Kage et al., 1982; Seckl et al., 1990). The data strongly suggest that corticosterone rather than 
cortisol can freely gain access to the human brain.  
 
An in vivo cell nuclear retention study in ADX rhesus monkeys, which have cortisol as their 
main glucocorticoid, showed a similar regional pattern for both corticosteroids, but the amount 
of cortisol radioactivity was lower than that of corticosterone (Gerlach et al., 1976). This 
observation substantiates that even in an animal that normally produces cortisol, this 
glucocorticoid penetrates less efficiently into the brain than corticosterone.  
Alternatively, BBB passage of cortisone and subsequent conversion of cortisone to cortisol by 
11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) present in brain (Seckl, 1997), might 
regenerate cortisol in brain. The fact that MDR1 Pgp also transports cortisone, argues against 
the possibility that cortisol would be able to circumvent Pgp in the BBB through this route, as 
less cortisone would be available for 11ß-HSD1 conversion in brain as well. Therefore, the 
limited access of cortisol and cortisone is likely to result in overall lower brain levels of 
glucocorticoids.  
 
Since corticosterone is not transported by Pgp, reduction of cortisol brain levels would lead to 
an increase of corticosterone levels relative to cortisol levels in human brain when compared 
to plasma. Indeed, we demonstrated a shift in the corticosterone/cortisol ratio in favour of 
corticosterone in human autopsy brain samples as compared to plasma samples. These results 
support data reported by Brooksbank et al. (1973), who also demonstrated that corticosterone 
is accumulated in brain to a substantially greater extent than cortisol. They found a ratio of 
corticosterone to cortisol of about 0.4. Earlier, Fazekas & Fazekas (1967) also determined 
corticosteroid levels in human brain using paper chromatography and similarly reported high 
levels of corticosterone relative to cortisol.  
 
The privileged uptake of corticosterone in brain is also expected to promote its receptor 
occupancy relative to cortisol. There are indications that corticosterone might have a higher 
affinity for the MR than cortisol. At least this is the case for the rat MR (De Kloet et al., 
1984a; Myles and Funder, 1994), but data presented by Arriza et al. (1987) also suggests that 
corticosterone is the more potent competitor at human MR. Furthermore, transactivation of 
human MR in response to cortisol and corticosterone indicates that corticosterone is more 
effective than cortisol (Lombes et al., 1994). Thus, besides the hampered uptake in human 
brain, cortisol might also less effectively mediate the human brain MR response. Should it 
indeed be confirmed that levels of GR are relatively low in the human hippocampus, as was 
recently claimed for the rhesus monkey (Sanchez et al., 2000), glucocorticoid mediated effects 
on hippocampal functioning might then mainly reflect corticosterone acting through MR 
rather than cortisol. At least, our data suggest that the human glucocorticoid feedback system 
might be more complex than the rodent system in view of the potentially different roles for 
cortisol and corticosterone.  
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The influence of cortisol on brain functioning and its role as main corticosteroid in 
glucocorticoid feedback to the human brain is commonly accepted. However, in contrast to 
rodents where corticosterone readily enters the brain, the main glucocorticoid in human 
appears to be partially excluded from the brain. It would be interesting to know how much 
either corticosterone and cortisol contributes to stabilisation of neuronal excitability (Joëls and 
De Kloet, 1994), maintenance of neuronal integrity (McEwen et al., 1993), suppression of 
HPA activity (Dallman et al., 1992) and facilitation of behavioural adaptation (Oitzl et al., 
1997). The preferential uptake of corticosterone in human brain may further be used as a lead 
towards the development of novel selective steroids for treatment of stress-related brain 
disorders. 
 
In conclusion, we have demonstrated the involvement of Pgp in hampering the access of the 
naturally occurring glucocorticoid cortisol rather than corticosterone to both mouse and human 
brain. The data, therefore, suggest that corticosterone may play a more prominent role in the 
modulation of human brain function than hitherto recognised.  
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Abstract 
The multidrug resistance (mdr) P-glycoprotein (Pgp) functions as a glucocorticoid efflux 
transporter at the blood-brain barrier. In the present study, we have investigated the role of 
Pgp in hampering the access of the synthetic glucocorticoid prednisolone to the brain.  
In vivo, a tracer dose of 3H-prednisolone poorly penetrated the brain of adrenalectomised wild 
type mice. In contrast, the uptake was more than three fold enhanced in absence of Pgp 
expression in mdr1a (-/-) mice. In vitro, in stably transfected LLC-PK1 monolayers the human 
MDR1 P-glycoprotein was able to transport prednisolone present at a micromolar 
concentration. This polar transport of 3H- prednisolone was blocked by a specific Pgp blocker. 
Human Pgp does not transport all steroids, as cortexolone was not at all transported and 
aldosterone was only weakly transported.  
The ability of Pgp to export the synthetic glucocorticoid prednisolone suggests that uptake of 
prednisolone in human brain is impaired, leading to a discrepancy between central and 
peripheral actions. Furthermore, the ensuing imbalance in activation of the two types of brain 
corticosteroid receptors may have consequences for cognitive performance and mood. 
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Introduction 
The synthetic glucocorticoids prednisolone and dexamethasone are widely used as anti-
inflammatory and immunosuppressive drugs, because of their potent glucocorticoid actions in 
combination with their low mineralocorticoid (salt-retaining) actions. These actions are 
mediated by glucocorticoid receptors (GR) and mineralocorticoid receptors (MR), respectively 
(De Kloet et al., 1998). Both types of corticosteroid receptors are present in the brain, where 
they play important roles in mediating glucocorticoid actions on brain function. Treatment 
with synthetic glucocorticoids, therefore, has major effects on cognitive function (Belanoff et 
al., 2001), whereas blockade of GR action seems to be a promising anti-depression strategy 
(Belanoff et al., 2002). Glucocorticoids are commonly believed to cross endothelial barriers 
with relative ease because of their highly lipophilic nature and their small size. However, we 
recently demonstrated that the penetration of dexamethasone into mouse brain is hampered 
because the multidrug resistance 1a (mdr1a) P-glycoprotein (Pgp) excludes this high affinity 
GR ligand from brain (Schinkel et al., 1995; Meijer et al., 1998). The drug-transporting Pgp is 
expressed at the luminal membranes of endothelial cells of the blood brain barrier (BBB) 
(Cordon-Cardo et al., 1989; Thiebaut et al., 1989). This transmembrane protein is encoded by 
the mdr1a gene in rodents and by the highly homologous MDR1 gene in humans (Jette et al., 
1995; Van de Vrie et al., 1998). We hypothesised that the synthetic GR ligand prednisolone is 
a substrate of this efflux transporter as well and is thus hampered in its ability to enter the 
glucocorticoid target areas in the brain. A poor penetration of the BBB by this synthetic 
glucocorticoid may have important implications for its actions on brain function.  
 
Pgp mediated transport is not a common feature of each steroid. We have examined Pgp 
mediated transport of several naturally occurring corticosteroids. Recently, we have shown 
that there is a large difference in transport between the mixed MR/GR agonists cortisol and 
corticosterone (Karssen et al., 2001). Cortisol is transported by human MDR1 Pgp and, in line 
with the presence of MDR1 Pgp at the BBB, the levels of cortisol in human brain are 
decreased towards those of corticosterone. In contrast, the latter compound freely crosses the 
BBB in rodents as well as man (Karssen et al., 2001). We now demonstrate the lack of robust 
Pgp mediated transport for two other corticosteroids, which are circulating in human plasma, 
i.e. the high affinity MR ligand aldosterone and the precursor of cortisol, 11-deoxycortisol 
(cortexolone). 
 
We have tested our main hypothesis about the role of Pgp at the BBB in reducing the 
penetration of prednisolone into brain in two ways. First, we tested whether mdr1a Pgp at the 
mouse BBB limits in vivo brain penetration and retention of prednisolone. For this purpose we 
have injected adrenalectomised mdr1a (-/-) and wild type mice with 3H-prednisolone with or 
without pretreatment with excess of unlabelled prednisolone. Secondly, we investigated in 
vitro whether the human homologue, MDR1 Pgp, is also able to transport prednisolone. 
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Therefore, we have measured polar transport of prednisolone in monolayers of pig kidney 
epithelial cells stably transfected with human MDR1 cDNA in comparison with 
nontransfected host cells.  
Materials and methods  
In vivo distribution and autoradiography 
The in vivo distribution experiments were carried out as described previously (Meijer et al., 
1998; Karssen et al., 2001) with some modifications. Male mdr1a (-/-) and wild-type Friends 
virus B (FVB) mice were bred under SPF conditions at TNO (Leiden, The Netherlands). Male 
mice at the age of 18-23 weeks were used for this study. All experiments were carried out in 
accordance with the European Communities Council Directive 86/609/EEC and with approval 
from the animal care committee of the Faculty of Medicine, Leiden University (Leiden, The 
Netherlands).  
After transport, the mice were housed individually at our laboratory, at ambient temperature 
and at a 12/12 hour lighting schedule (lights on at 0700 h, lights off at 1900 h) with free access 
to food and water.  
To remove the source of endogenous corticosterone, mice were bilaterally adrenalectomised 
under gas anaesthesia (isoflurane) by a dorsal approach. After adrenalectomy (ADX) the 
animals had free access to 0.9% saline. At the time of the experiment the animals weighed 28 
± 2.0 gr. (mean ±SD). Two days after ADX, the animals were subcutaneously injected with 
tritiated prednisolone (dissolved in 2% ethanol/0.9% saline) for in vivo distribution. Wild type 
(n=9) and mutant mice (n=6) were injected with 3.5 µCi/10 gr (2,4,6,7)-3H-prednisolone 
(Amersham Pharmacia Biotech, UK, specific activity (S.A.) 48 Ci/mmol). For in vivo 
autoradiography mice (n=2) were treated with 13.5 µCi/10 gr 3H-prednisolone in a separate 
but similar experiment. As a control for non-specific retention, one mouse of each genotype 
was pretreated with a 100-fold excess of unlabelled prednisolone (Sigma-Aldrich, Germany). 
One hour after injection the animals were decapitated. Trunk blood was collected in EDTA-
coated tubes and centrifuged for determination of radioactivity and of remaining 
corticosterone in the plasma using a 125I-corticosterone radioimmunoassay kit (ICN 
Biomedicals, Costa Mesa, USA.). The brain was dissected and quickly frozen in isopentane 
precooled on dry ice/ethanol. Liver, testis, intestine and cerebellum were dissected and frozen 
on dry ice. All tissues were stored at –80 °C until further use.  
All organ tissues studied, except for the brain, were homogenised using Soluene-350 (Packard 
Bioscience, Groningen, The Netherlands). Hionic-Fluor (Packard Bioscience) was added to 
tissue homogenates and plasma and radioactivity was determined in a Tricarb ß-counter 
(Packard Instruments, Meriden, U.S.A.). Twelve-micrometer coronal sections of brain were 
cut on a cryostat and thaw-mounted on poly-L-lysine (Sigma Chemical Co., St Louis, USA) 
coated microscopic slides. The slides were put in an X-ray exposure holder (Amersham 
Pharmacia Biotech) and apposed to Ultrofilm (Leica Corp., Heerbrugg, Switzerland) for 18 
months.  
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Transepithelial transport and inhibition studies 
In order to examine the interactions of the glucocorticoid prednisolone, the mineralocorticoid 
aldosterone and partial antiglucocorticoid cortexolone with the human P-glycoprotein we used 
monolayers of the porcine kidney epithelial cell-line LLC-PK1 and LLC-PK1 cells stably 
transfected with cDNA of the human MDR1 gene (LLC-PK1:MDR1). Cells originally 
obtained from the American Type Culture Collection (Manassas, USA) were kindly provided 
by the Dutch Cancer Institute (Amsterdam, The Netherlands) (Schinkel et al., 1995). Human 
P-glycoprotein has been shown before to be specifically expressed on the apical surface of 
LLC:PK1:MDR1 cells in these monolayers (Ueda et al., 1992; Florea et al., 2001). Therefore, 
Pgp substrates entering these cells from the basal side will be translocated to the apical 
compartment, while those entering the apical membrane will be pumped back into the 
medium, thus resulting in polarised transport of substrates. This system models the way Pgp is 
likely to function at the BBB in excluding drugs from the brain (Yamazaki et al., 2001).  
Cells were cultured at 37 °C in the presence of 5% CO2 in complete medium, which consisted 
of DMEM (BioWhittaker, Verviers, Belgium) supplied with 25 mM HEPES and 4.5 g/l 
glucose and supplemented with 100.000 U/l penicillin, 100 mg/l streptomycin, 2 mM L-
glutamine and 10% (vol/vol) foetal calf serum. The LLC-PK1 and LLC-PK1:MDR1 cell lines 
were subcultured by trypsinisation every 3 to 4 days and medium was replaced twice a week. 
During the experiments complete medium was used. The LLC-PK1 and LLC-PK1:MDR1 
cells were seeded on microporous polycarbonate membrane filters (0.4 µM pore size, 12 mm 
diameter, TranswellTM; Costar, Cambridge, USA) at a density of 120*103 cells/cm2. The cells 
were grown for 5-6 days in complete medium with a medium replacement at day 3. Two hours 
before the start of the experiment, the medium was replaced with 800 µl fresh medium at both 
the apical and basal side of the monolayer. In the inhibition experiments, one hour later the 
potent and selective P-glycoprotein blocker LY 335979 (1 µM in water; kindly provided by 
Eli Lilly, USA) or water was added at the basal side. To measure the transepithelial transport 
from the apical to the basal side or from the basal to the apical side 8 µl of a 100x stock of 
tritiated steroid in ethanol was added in triplicate at the apical or basal side respectively, at the 
start of the experiment (t=0). We have tested 3H-prednisolone, and (1,2,6,7)-3H-aldosterone 
(Amersham Pharmacia Biotech, S.A. 64 Ci/mmol), (1,2(n))-3H-deoxycortisol (=cortexolone; 
NEN Life Science Products, Boston, USA, S.A. 57 Ci/mmol) and, as a positive control, 
(1,2,4,6,7)-3H-dexamethasone (Amersham Pharmacia Biotech, S.A. 91 Ci/mmol). As we were 
interested whether MDR1 Pgp was able to transport prednisolone even at high concentrations 
we supplemented 3H-prednisolone with 1 µM unlabelled prednisolone. The starting 
concentrations for each experiment are mentioned in the legends of the corresponding figures. 
Over the four hours of study 75 µl aliquots were taken once every hour from both 
compartments. Eight µl samples of the 100x stock, and samples from the compartment 
opposite the one to which activity was added, were counted in a Tricarb ß-counter after adding 
3 ml Emulsifier Safe (Packard). Basal to apical and apical to basal transport is presented as 
percentage of total radioactivity added at the beginning of the experiment. Transepithelial 
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electrical resistance was measured before and after the experiments to check the integrity of 
the monolayers (Gaillard and De Boer, 2000).  
Statistical analysis  
Mouse data were evaluated by Student’s t-test. The results of the monolayer experiments were 
analysed by repeated measures ANOVA. Significance was taken at p < 0.05. 
 
FIGURE. 1. Representative auto-
radiograms of 12-µm coronal sections
of the brain demonstrate the large
difference in uptake of 3H-
prednisolone in wild type (A) and
mdr1a (-/-) mouse (B) brains one
hour after administration of 13.5
µCi/10 gr. body weight. The dark
spots in (A) represent transverse
sectioning of the cerebroventricular
space and adjacent ventricular walls.
Pretreatment with unlabelled
prednisolone abolishes specific
hippocampal labelling in mdr1a (-/-)
mouse brain but does not affect the
labelling of the rest of the brain (C). 
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Results 
Difference in 3H-prednisolone brain uptake in mdr1a(-/-) and wild type mice 
One hour after administration of 3H-prednisolone to ADX mice, the uptake of radioactivity in 
brain showed a clear difference between mdr1a (-/-) mice and wild type mice. After injection 
with 2.5 µg/kg radiolabelled prednisolone the amount of radioactivity in cerebellum 
homogenates was 3.2-fold higher in mutants than in wild types (table 1). The plasma levels of 
radioactivity were similar and the concentrations in the liver or any other peripheral tissue 
examined were not significantly different between both genotypes (table 1). Comparable 
results were obtained after administration of 10 µg/kg 3H-prednisolone (table 2). Although 
absolute levels in all tissues and blood were obviously higher after this higher dose, the brain-
to-blood ratios were not significantly different from the ratios obtained after administration of 
the lower dose. Remarkably, pretreatment with unlabelled prednisolone does not lead to any 
change in uptake of radioactivity in cerebellum (tables 1 and 2).  
The autoradiograms also clearly demonstrate the difference between knockouts and controls. 
The mdr1a (+/+) animals showed negligible labelling of brain tissue after administration of 
3H-prednisolone (figure 1A). Labelling in brain sections was restricted to the cerebral 
ventricles. Some radioactive label seemed to have penetrated into the brain tissue around the 
ventricles, but the amount was considerably lower compared to the amount taken up by the 
TABLE 1. Uptake of radioactivity in tissue homogenates and blood 1 hr after administration of 2.5 
µg/kg 3H-prednisolone without or with pretreatment with 100-fold excess unlabelled prednisolone 
 wild type mdr1a (-/-) 
Prednisolone  dose 2.5 µg/kg   
N 7  5  
cerebellum [nCi/mg] 0.010 ± 0.001 0.030 ± 0.001 * 
plasma [nCi/µl] 0.046 ± 0.004 0.044 ± 0.001  
liver [nCi/mg] 1.500 ± 0.086 1.631 ± 0.160  
testis [nCi/mg] 0.031 ± 0.001 0.034 ± 0.004  
intestine [nCi/mg] 0.779 ± 0.198 0.937 ± 0.305  
brain/blood ratio 0.226 ± 0.027 0.708 ± 0.023 * 
     
Pretreatment with 0.25 mg/kg unlabelled prednisolone  
N 2  1   
cerebellum [nCi/mg] 0.009 ± 0.001 0.031   
plasma [nCi/µl] 0.040 ± 0.003 0.038   
liver [nCi/mg] 1.951 ± 0.533 2.191   
brain/blood ratio 0.222 ± 0.002 0.796   
* p < 0.01 compared to wild type 
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brain of mdr1a (-/-) mice. These mutant mice showed increased labelling of whole brain 
(figure 1B). In particular, radioactivity was retained in the paraventricular nucleus (PVN) and 
hippocampal cell fields. These brain areas abundantly express GRs. Pretreatment with a 100-
fold excess of unlabelled prednisolone prevents this specific labelling (figure 1C). 
Remarkably, this pretreatment does not affect the labelling of the rest of the brain as was also 
shown in the cerebellum homogenates. Thus, disruption of the mdr1a gene leads to enhanced 
uptake of prednisolone into the brain. High-dose pretreatment did not abolish this effect. 
Accordingly, these data clearly demonstrate that the presence of mdr1a Pgp in the BBB 
hampers the access of prednisolone to the mouse brain, particularly to the target areas within 
the brain that abundantly express GR.  
Transepithelial transport of prednisolone in LLC-PK1 and MDR1 monolayers 
To test whether the human homologue of the mdr1a Pgp, MDR1 Pgp, is also able to transport 
prednisolone, we studied the transport capabilities of monolayers of pig kidney cells stably 
transfected with human MDR1 cDNA. For comparison, we also examined prednisolone 
transport in monolayers of untransfected cells. Unlabelled prednisolone (1µM) supplemented 
with a tracer dose of 3H-prednisolone was added to the basal or apical compartment. 
Prednisolone was transported in a clear polarised fashion in the MDR1 transfected 
monolayers, but not in monolayers of the parental cells (figure 2A), indicating that the human 
Pgp is able to transport prednisolone, even at the high concentration tested. Polarised transport 
in MDR1 monolayers of prednisolone was abolished in presence of LY335979, a potent and 
selective Pgp blocker (Starling et al., 1997; Dantzig et al., 1999), resulting in similar fractions 
transported as in monolayers of untransfected cells (figure 2B). This confirms that 
prednisolone transport is largely mediated by human P-glycoprotein.  
 
TABLE 2. Uptake of radioactivity in tissue homogenates and blood 1 hr after administration of 10 
µg/kg 3H-prednisolone without (-) or with (+) pretreatment with 100-fold excess unlabelled 
prednisolone 
 wild type mdr1a (-/-)  
Pretreatment 1mg/kg - / + - / +  
Prednisolone dose 10 µg/kg   
N 1 / 1 1 / 1  
cerebellum [nCi/mg] 0.040 / 0.061 0.246 / 0.204  
plasma [nCi/µl] 0.212 / 0.282 0.371 / 0.303  
liver [nCi/mg] 6.277 / 8.647 11.22 / 7.657  
brain/blood ratio 0.189 / 0.216 0.664 / 0.673  
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As a positive control, we also assessed transepithelial transport of dexamethasone in our 
monolayers and demonstrated that MDR1 Pgp also efficiently transports this synthetic 
glucocorticoid (data not shown), as has been shown previously (Ueda et al., 1992; Schinkel et 
al., 1995).  
Transepithelial transport of naturally occurring steroids 
We further examined Pgp-mediated transport of corticosteroids that are naturally occurring in 
humans. Previously we published the marked difference between Pgp-mediated cortisol and 
corticosterone transport (Karssen et al., 2001). Now we focused on two additional 
corticosteroids, cortexolone and aldosterone. Cortexolone transport in the MDR1 transfected 
monolayers was not different from transport in monolayers of control cells (figure 3A), 
indicating the absence of human MDR1 Pgp mediated transport of cortexolone. Although 
polarised transport was observed in both cell lines, this is likely caused by other renal 
transporters. Administration of LY335979 did not change the fraction of cortexolone 
translocated through the membrane (figure 3B), confirming the lack of Pgp contribution to the 
transport of cortexolone.  
FIGURE 2. (A) Activity of 3H-prednisolone present in medium at different time points after
adding 1 µM prednisolone supplemented with 3H-prednisolone to the opposite compartment at t=0.
Transepithelial transport from basal to apical (∆,▲) and from apical to basal (○,●) was measured
in wild type LLC-PK1 (broken line) or MDR1 transfected LLC-PK1 (solid line) monolayers. (B)
Transepithelial transport of prednisolone was measured in MDR1 transfected LLC-PK1
monolayers after adding 1 µM LY335979 (broken line) or vehicle (water, solid line) one hour
before start of the experiment.  
Presented is the fraction of the dose of radioactivity, which is 7 nM, added to the respective
compartment. Each point represents the mean of three monolayers ± SEM. Repeated measures
ANOVA showed a significant interaction of time*cell type*transport for prednisolone in both (A)
and (B) (p < 0.0001). 
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Examination of the transport of aldosterone shows that, although aldosterone displayed 
polarised transport in both transfected and parental monolayers, there was a small but 
significant MDR1 Pgp contribution (figure 3C). This Pgp mediated transport could be partly 
blocked by LY335979 (figure 3D). These results demonstrate that aldosterone is only weakly 
transported by MDR1 Pgp. 
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FIGURE 3. Activity of 3H-cortexolone (A,B) and 3H-aldosterone (C,D) present in medium at
different time points after adding 3H-steroid to the opposite compartment at t=0. (A,C)
Transepithelial transport from basal to apical (∆,) and from apical to basal (○,●) compartment
was measured in wild type LLC-PK1 (dotted line) or MDR1 transfected LLC-PK1 (solid line)
monolayers. (B,D) Transepithelial transport from basal to apical (∆,▲) and from apical to basal
(○,●) compartment was measured in MDR1 transfected LLC-PK1 monolayers after adding 1 µM
LY335979 (broken line) or water (solid line) one hour before start. 
Presented is the fraction of the dose of radioactivity, which is 4 to 5 nM for both steroids, added to
the respective compartment. Each point represents the mean of three monolayers ± SEM. In case of
aldosterone the experiment was repeated three times with similar results. Repeated measures
ANOVA did not show a significant interaction of time*cell type*transport for either corticosteroid. 
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Discussion 
The present study indicates that the efflux transporter Pgp at the level of the BBB decreases 
the degree of brain exposure to the synthetic glucocorticoid prednisolone. Our in vivo 
autoradiography data show that the mdr1a Pgp present at the BBB hampers the penetration of 
3H-prednisolone into the mouse brain, whereas our results with monolayers of human MDR1 
cDNA transfected LLC-PK1 cells suggest that Pgp may export prednisolone from human 
brain as well. We further demonstrated that aldosterone is transported by Pgp to a much 
smaller extent, while cortexolone is not at all transported. 
  
Cells expressing P-glycoproteins are able to exclude a wide variety of structurally and 
functionally unrelated drugs, a phenomenon called multidrug resistance (Van de Vrie et al., 
1998). It is now well established that Pgp is expressed in many normal tissues including the 
intestinal epithelium, the adrenals and brain capillary endothelial cells (Schinkel, 1999). 
Several steroids such as dexamethasone and cortisol but not corticosterone are among its 
substrates (Ueda et al., 1992; Bourgeois et al., 1993; Ueda et al., 1996; Karssen et al., 2001). 
In the last decade, several studies have established the Pgp mediated transport of the widely 
used synthetic glucocorticoid, dexamethasone. Pgp overexpressing cells accumulate reduced 
amounts of dexamethasone (Barnes et al., 1996), while the steroid is transported in a polarised 
fashion in monolayers of LLC-PK1 cells transfected with MDR1 cDNA (Ueda et al., 1992; 
Schinkel et al., 1995,this study; Karssen et al., 2003). Furthermore, penetration of 
dexamethasone into mdr1a (-/-) mouse brain is enhanced compared to wild type brain 
(Schinkel et al., 1995) increasing its access to the glucocorticoid receptor (Meijer et al., 1998). 
While dexamethasone transport by Pgp has thus been convincingly demonstrated, information 
about Pgp mediated transport of prednisolone is sparse. Bourgeois et al. (1993) have shown 
that murine thymoma cells expressing mdr1b Pgp are resistant to prednisolone (and 
dexamethasone) induced apoptosis, but this second murine multidrug resistance Pgp is not 
expressed at the BBB. Our study clearly shows that both mouse mdr1a and human MDR1 Pgp 
transport prednisolone, as has been shown previously for dexamethasone and cortisol. This 
implicates that any GR expressing cell type that also express the efflux transporter Pgp is 
resistant to these glucocorticoids, which is in line with recent results of Pariante et al. (2001).  
 
In contrast to these glucocorticoids, Pgp does not transport corticosterone (Karssen et al., 
2001), a glucocorticoid that also circulates in human plasma but at 10 fold lower levels than 
cortisol, and some other naturally occurring steroids. In line with the presence of MDR1 Pgp 
at the BBB the levels of cortisol in human brain are decreased towards the brain levels of 
corticosterone as measured in post mortem specimens with liquid chromatography-mass 
spectrometry (LC-MS) (Karssen et al., 2001). We now demonstrate that Pgp is also unable to 
transport cortexolone, which is a weak partial agonist/antagonist at the GR in vitro (Kaiser and 
Mayer, 1980; Schmidt and Davidson, 1987) and in vivo (Acs and Stark, 1975; Duncan and 
Duncan, 1979; Kaiser and Mayer, 1980). In addition, the high affinity MR ligand aldosterone 
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is only weakly transported by Pgp in our MDR1-monolayers. These results agree with several 
in vitro studies on Pgp mediated transport of aldosterone. Using comparable monolayers to 
those in this study, Ueda et al. (1992) have demonstrated that aldosterone is moderately 
transported by the human MDR1 Pgp, while Bourgeois et al. (1993) showed that cortexolone 
was not and aldosterone was only weakly transported by mdr1b Pgp.  
 
Although prednisolone is among the most common clinically used glucocorticoids, this study 
is one of the first that has examined the fate of prednisolone in brain, whereas other major 
glucocorticoids have been extensively studied before (for review see (McEwen et al., 1986a)). 
In contrast to uptake into the brain of both corticosterone and aldosterone (McEwen et al., 
1968; De Kloet et al., 1975; McEwen et al., 1976; De Nicola et al., 1981; Coutard et al., 
1987), access of dexamethasone and cortisol to brain is impaired (De Kloet et al., 1974; De 
Kloet et al., 1975; Rees et al., 1975; McEwen et al., 1976), because of the presence of Pgp at 
the BBB (Meijer et al., 1998; Karssen et al., 2001). We now demonstrate that prednisolone is 
also hampered to reach the brain due to the presence of Pgp at this barrier. The active 
exclusion from the brain provides an explanation for the long-established puzzling 
phenomenon that GR in the brain is not labelled after in vivo administration of tracer doses of 
synthetic GR ligands. 
 
In mdr1a null mice the high affinity GR-ligand prednisolone is retained by hippocampal and 
paraventricular neurons as expected based on localisation of GR expressing cells (Van 
Eekelen et al., 1987). Among the hippocampal subfields, the CA3 pyramidal layer retained the 
lowest amount of label, in accordance with the neuro-anatomical distribution of hippocampal 
GR as measured with immunohistochemistry and in situ hybridisation (Van Eekelen et al., 
1987; Van Eekelen et al., 1988). Pretreatment of mice with 100-fold excess of unlabeled 
prednisolone abolishes this selective retention in hippocampal cells and PVN, but does not 
affect the overall uptake elsewhere in the brain. This indicates that the uniform labelling of the 
rest of the brain may be due mainly to non-receptor bound, freely moving prednisolone 
masking specific nuclear retention of low abundantly expressed GR in many parts of the brain.    
 
Prednisolone, like dexamethasone, can bind to MR in vitro, but the affinity to this receptor is 
much lower than to GR to which these steroids bind with very high affinity (< 1 nM) (Lan et 
al., 1981; Lan et al., 1982; De Kloet et al., 1984a).  In contrast corticosterone and cortisol bind 
with high affinity to MR (< 1 nM) and with tenfold lower affinity to GR. In line with this low 
affinity to the MR prednisolone has only minor effects on salt retention in the kidney (Karssen 
and De Kloet, 2000). Using in vivo autoradiography only very high affinity receptors can be 
visualised due to the low doses used (De Kloet, 1991); e.g. in mdr1a (-/-) mice only MR can 
be made visible with 3H-cortisol autoradiography as is the case with 3H-corticosterone in both 
wild type and mutant mice (Karssen et al., 2001). In this study, prednisolone is only able to 
visualise GR while the MR has a too low affinity for this steroid to be detectable.  
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The lack of effect of pretreatment of unlabeled prednisolone on uptake of 3H-prednisolone in 
wild type brain indicates that the capacity of Pgp to expel prednisolone from brain is rather 
high. Furthermore, the monolayer results using 1 µM prednisolone also suggest that even at 
high concentrations Pgp is able to reduce prednisolone concentrations in the brain. 
Interestingly, a recent study was not able to detect prednisolone in guinea pig brain, in contrast 
to liver and plasma, at various time points after administration of a high dose of 100 mg/kg 
(Tobita et al., 2002). Therapeutically prednisolone is used in high doses in the treatment of 
diverse medical conditions, including pulmonary, rheumatologic, neurological and 
autoimmune diseases and immune suppression following organ transplantation. Our results 
suggest that in humans treated with prednisolone, the resultant glucocorticoid levels in brain 
would be considerably lower than plasma levels. As most peripheral tissues are not protected 
by a Pgp expressing barrier, peripheral effects would therefore be relatively more potent than 
central effects, although this does not preclude central effects of prednisolone.  
 
Hippocampal-dependent memory impairment after long-term high dose treatment with 
prednisone (which is quickly converted to prednisolone in vivo) has been described (Keenan et 
al., 1996). As hippocampal GR is involved in memory performance (Oitzl and De Kloet, 
1992), these effects could be attributed to activation of this receptor. On the other hand, an 
imbalance in central MR and GR activation as a result of prednisolone treatment could 
provide an alternative explanation. Differential effects mediated by MR and GR activation on 
cognitive function have been proposed (De Kloet et al., 1999; Lupien and Lepage, 2001). 
Although mainly based on animal studies, De Kloet et al. (1991; 1999) have postulated that a 
balance between MR and GR mediated effects critically determines human cognitive 
functioning. Whether prednisolone reaches the brain or not, due to the prednisolone induced 
suppression of pituitary-adrenal activity and thus of adrenocortical secretion, the brain 
becomes deprived of the endogenous glucocorticoids, corticosterone and cortisol. As a 
consequence, the ratio of MR/GR occupation will shift towards GR occupation with 
consequences for cognitive performance, mood and regulation of the behavioural stress 
response.  
 
As many different drugs used in the clinic are Pgp substrates as well, one has to be aware of 
undesired side effects when prednisolone (or dexamethasone) is used in conjunction with 
these drugs. Cotreatment may be able to enhance the brain uptake of the synthetic 
glucocorticoid. The potent immunosuppressants FK506 and cyclosporine A have been shown 
to potentiate dexamethasone but not corticosterone mediated transcriptional activity 
apparently due to inhibition of a MDR pump similar to Pgp (Medh et al., 1998). The 
facilitation of prednisolone’s poor penetration into the brain by anti-cancer drugs may also 
give a rationale to the reported success of combination therapy in treatment of different types 
of brain tumours (Wu et al., 1999; Shibamoto et al., 1999; Maipang and Janjindamai, 2000). 
Many anti-cancer drugs (e.g. Vinca alkaloids, anthracyclines, and taxanes) are known to be 
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Pgp substrates. In fact, the first reports of Pgp expression dealt with tumour cells developing 
multidrug resistance after treatment with a single cytotoxic drug. Further treatment of these 
tumours is difficult. Provided that the tumour does not disrupt the BBB, brain tumours are 
even intrinsically resistant to these drugs, as they are behind the BBB (Regina et al., 2001). A 
combination of prednisolone and other drugs, that are all Pgp substrates, may mutually 
increase their active brain levels by saturating Pgp.  
 
In conclusion, we have demonstrated the involvement of Pgp in hampering the access of the 
synthetic glucocorticoid prednisolone to mouse brain. The ability of the human MDR1 Pgp to 
transport prednisolone suggests that prednisolone access to human brain is also impeded. The 
poor penetration of prednisolone into human brain would presumably lead to a discrepancy in 
the extent of central and peripheral actions of prednisolone. The subsequent imbalance in MR 
and GR activation may explain the reported changes in cognitive performance and mood in 
response to prednisone/prednisolone therapy.  
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Abstract 
At the blood-brain barrier the efflux transporter P-glycoprotein hampers the access into the 
brain of the potent glucocorticoid receptor agonist dexamethasone, but does not affect the 
penetration of the endogenous glucocorticoid corticosterone. We hypothesised that the poor 
access of dexamethasone to the brain provides a subtle way to deplete glucocorticoids 
selectively from the brain. At low levels, dexamethasone will strongly block secretion of 
ACTH/corticosterone at the pituitary level and replace corticosterone at peripheral 
glucocorticoid targets, while in the brain dexamethasone would poorly substitute 
corticosterone. The ensuing central adrenalectomy-like condition would result in a relative 
lack of central glucocorticoid actions.  
To test our hypothesis, rats were treated with various amounts of dexamethasone-21-
phosphate either for five days by subcutaneous injection or for three weeks through their 
drinking water. At the last day animals were restrained for 30 minutes and then immediately 
decapitated. Our results show that basal and stress-induced corticosterone secretion, body 
weight gain and thymus weight were reduced even at low concentrations of dexamethasone 
demonstrating the potent peripheral glucocorticoid action of dexamethasone. In contrast, 
central markers like stress-induced responses of c-fos mRNA and CRH hnRNA in the 
paraventricular nucleus were not altered, while paraventricular CRH mRNA expression was 
increased after treatment with low concentrations of dexamethasone particularly after a longer 
period of treatment. Adrenalectomy affected these markers in a similar way.  
It is concluded that the poor central access of low circulating dexamethasone concentrations 
has functional consequences and that treatment with small amounts of dexamethasone may 
provide a subtle model to selectively study central effects of corticosterone. 
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Introduction 
The synthetic glucocorticoid dexamethasone is a potent and rather selective glucocorticoid 
receptor (GR) ligand in vivo (Reul et al., 2000b). It has profound effects on energy 
metabolism, the immune system and Hypothalamus-Pituitary-Adrenal (HPA)-axis activity. In 
the clinic, it is commonly used for diagnostic purposes to test HPA-axis function in affective 
disorders. Several studies have demonstrated a pituitary rather than a brain site of action of 
moderate amounts of dexamethasone in suppression of HPA-axis activity (De Kloet et al., 
1974; De Kloet et al., 1975; Rees et al., 1975; Miller et al., 1992; Cole et al., 2000). In 
support of these findings, we have demonstrated that the efflux transporter P-glycoprotein, 
expressed at the luminal side of the blood-brain barrier (BBB) (Cordon-Cardo et al., 1989), 
hampers the penetration of dexamethasone into the brain (Schinkel et al., 1995; Meijer et al., 
1998). Therefore, we hypothesised that dexamethasone exclusion from the rat brain by P-
glycoprotein provides a subtle way to create a brain-selective adrenalectomy-like state without 
affecting the exposure of peripheral corticosteroid targets to glucocorticoids. This state may 
arise because treatment with small amounts of dexamethasone results in suppression of 
endogenous corticosterone secretion and, at the same time, dexamethasone may poorly 
substitute corticosterone in the brain. As a consequence, a reduced feedback of glucocorticoids 
to the central glucocorticoid targets will ensue, which is reminiscent of the adrenalectomised 
state.  
 
To test our hypothesis we treated rats with different doses of dexamethasone for either five 
days or three weeks. We compared rats treated with small amounts of dexamethasone with 
various control groups. Adrenalectomised (ADX) rats were used as a control for central and 
peripheral hypocorticoid state, and rats treated with a high dose of dexamethasone were used 
to demonstrate central and peripheral hypercorticoid effects, whereas untreated control rats 
formed the ‘normo-corticoid’ control group. As effects of central glucocorticoid negative 
feedback are most obvious under stress circumstances, the animals were exposed to a restraint 
stressor for 30 minutes at the last day and decapitated immediately thereafter. We used the 
psychological stressor of acute restraint stress to activate the central stress responsive 
pathways to minimise possible confounding peripheral effects of systemic stressors.  
 
We chose a number of well-described glucocorticoid responsive markers in both brain and 
periphery to determine the effects of dexamethasone. Its action at the pituitary level results in 
suppression of markers of HPA-axis activity like proopiomelanocortin (POMC) mRNA 
expression in the anterior pituitary (Lundblad and Roberts, 1988) and corticosterone plasma 
levels (De Kloet et al., 1974). Adrenal weight is decreased as the dexamethasone-induced 
reduction of adrenocorticotropin (ACTH) levels results in atrophy of adrenal cortical cells 
(Lesniewska et al., 1992). Thymus weight is dramatically reduced after treatment with 
dexamethasone due to glucocorticoid induced apoptosis of thymocytes (Wyllie, 1980; Cohen, 
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1992), while body weight gain is suppressed or reversed due to GR mediated catabolic actions 
of dexamethasone (Simpson et al., 1974; Konagaya et al., 1986). Central effects were 
measured in the parvocellular part of the hypothalamic paraventricular nucleus (PVN), as this 
area is highly responsive to both stress and glucocorticoids (Dallman et al., 1992). 
Glucocorticoids are known to reduce the expression of various genes in the PVN including c-
fos and corticotropin-releasing hormone (CRH) hnRNA and mRNA levels (Swanson and 
Simmons, 1989; Herman et al., 1992; Imaki et al., 1995). Whereas we expected to observe 
clear effects in the periphery, we expected to see an escape from glucocorticoid suppression in 
the response of central (stress) markers. 
Materials and methods 
Animals 
Young adult male Wistar rats (Charles River, Sulzfeld, Germany), weighing around 185-265 g 
at the time of arrival, were used. Animals were group-housed except for the drinking water 
experiment during which they were solitary housed, under a 12/12 hour light-dark cycle with 
lights off at 20hr in a temperature (21°C) and humidity controlled room. They had free access 
to food and drinking water. The experiments took place two weeks after arrival at the lab. 
During this period rats were handled daily. All experiments were carried out in accordance 
with the European Communities Council Directive 86/609/EEC and with approval from the 
animal care committee of the Faculty of Medicine, Leiden University (The Netherlands).  
Experiment 1: Five day treatment with dexamethasone subcutaneously 
At the start of experiment the rats weighed 303±15 gr (mean±SD). They were divided into 
four groups each consisting of 6-10 animals (table 1). One group (ADX) was 
adrenalectomised under gas anaesthesia (isoflurane) by dorsal approach at the start of the 
experiment. After ADX animals had free access to 0.9 % saline and normal drinking water. 
All other animals were sham-operated. For 5 days one group (DEXlow) was subcutaneously 
injected with a low dose of 50 µg/kg dexamethasone-21-phosphate (Sigma Aldrich; dissolved 
in 0.9% saline) twice daily at 9:00 and 21:00 hour. A second group (DEXhigh) was treated 
with a high dose of dexamethasone (500 µg/kg twice daily). Sham-operated (VEH) and ADX 
groups were treated with vehicle. During the whole experimental period body weight was 
monitored. At day 4 blood was sampled one hour after lights off to determine corticosterone 
plasma levels at the circadian peak. At day six animals received one last injection in the 
morning. Six hours later at 15:00 hour half of each group (3-5 rats per group) was exposed to 
restraint stress in a wire mesh/plastic cylinder for 30 minutes. At the start and after 15 minutes 
blood samples were taken using the tail incision method (Fluttert et al., 2000). After 30 
minutes animals were removed from the restrainers and immediately decapitated. Nonstressed 
animals (the second half of each group) were decapitated directly after removal out of their 
home cage. Trunk blood was collected in EDTA coated tubes and centrifuged. Plasma was 
kept at –20°C until determination of corticosterone plasma levels. Brains were rapidly 
DEX-induced brain-selective ADX-like state 
 99
removed from the skull and quickly frozen in isopentane precooled on dry ice/ethanol. 
Thymus, pituitary and adrenal glands were dissected and frozen on dry ice. All tissues were 
stored at –80°C until further use. Thymus and adrenals were weighed. 
Experiment 2: three weeks treatment with dexamethasone in drinking water 
At the start of the drinking water experiment rats weighed 225 ± 9 gr (mean±SD). They were 
divided into six treatment groups consisting of 5-8 animals (table 1). Three groups were 
treated with different concentrations (0.5, 1.0, 10 µg/ml) of dexamethasone 21-phosphate in 
their drinking water for three weeks (DEX0.5, DEX1.0 and DEX10 groups). One group was 
adrenalectomised (ADX) at the start of the experiment. After adrenalectomy animals had free 
access to 0.9 % saline and normal drinking water. All other animals were SHAM operated 
including control animals (CTRL) that received normal drinking water during the whole 
experiment. Each day animals and bottles were weighed to determine the body weight gain 
and volume of drinking solution that each animal had drunk over 24 hours. One animal of the 
highest concentration group died before the end of the experiment. 
After three weeks rats were stressed by restraint in a wire mesh/plastic cylinder and 
decapitated after 30 minutes as described for experiment 1. A control nonstress, nontreated 
group (CTRL nonstress) was decapitated immediately after removal from the home cage.  
TABLE 1. Treatments of experimental groups of experiment 1 and 2 
Groups  Label Operation  Drug Stress 
Experiment 1    
1A  VEH nonstress SHAM VEH nonstress 
1B  VEH stress SHAM VEH stress 
2A  DEXlow nonstress SHAM DEX 100 µg/kg day
-1 
nonstress 
2B  DEXlow stress SHAM DEX 100 µg/kg day
-1 
stress 
3A  DEXhigh nonstress SHAM DEX 1 mg/kg day
-1 
nonstress 
3B  DEXhigh stress SHAM DEX 1 mg/kg day
-1 
stress 
4A  ADX nonstress ADX VEH nonstress 
4B  ADX stress ADX VEH stress 
Experiment 2    
1  CTRL nonstress SHAM none nonstress 
2  CTRL stress SHAM none stress 
3  DEX0.5 SHAM DEX 0.5 µg/ml stress 
4  DEX1.0 SHAM DEX 1.0 µg/ml stress 
5  DEX10 SHAM DEX 10 µg/ml stress 
6  ADX ADX none stress 
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In situ hybridisation 
Coronal sections of 14 µm through the paraventricular nucleus of the hypothalamus and 
hippocampus were cut in a cryostat. Pituitaries were sectioned at 12 µm. Sections were thaw-
mounted on poly-L-lysine coated microscopic slides. These slides were stored at –80 °C until 
hybridisation. The sections were postfixed in a freshly prepared 4% paraformaldehyde 
solution (pH 7.2) for 60 minutes at room temperature, rinsed twice in phosphate buffered 
saline (PBS) for 5 minutes at room temperature. In case of in situ mRNA hybridisations, 
sections were permeabilised with proteinase K (1 µg/ml in 0.1M Tris, pH 8.0) at 37°C for 10 
minutes. After a brief rinse in diethyl pyrocarbonate (DEPC) treated water, they were treated 
with 0.25% acetic anhydride in 0.1M triethanolamine (pH 8.0) for 10 minutes at room 
temperature and finally rinsed in 2xSSC (SSC=0.15M NaCl and 0.015M sodium citrate) for 
10 minutes at room temperature. Subsequently the sections were dehydrated through a graded 
series of ethanol and air-dried. 
Preparation of probes  
To visualize mRNAs, in situ mRNA and oligonucleotide hybridisations were performed. 
Different 33P- and 35S-labelled cRNA antisense probes were employed to hybridise with 
complementary brain tissue c-fos and CRH mRNA, and CRH heteronuclear (hn)RNA. The c-
fos mRNA probe was transcribed from a pBluescript (pBS) KS plasmid containing a 2.1 kB 
full-length rat c-fos cDNA sequence (courtesy of T. Curran, USA) in presence of 33P-UTP 
(ICN Biomedicals, Costa Mesa, CA; Isoblue stabilized, S.A. 3000 Ci/mmol). This probe was 
hydrolysed by incubation in 90 mM 0.2 M Na2CO3 and 60 mM 0.2 M NaHCO3 at 60°C for 
10 minutes to facilitate the tissue penetration. The CRH hnRNA 33P-UTP labelled probe was 
transcribed from a 687 bp fragment (courtesy of P. Sawchenko, USA) covering the single 
intron of the rat CRH gene subcloned into a pBS vector. A full length probe for CRH mRNA 
(1.2 kB subcloned into pBS; courtesy of Dr. K. Mayo, USA) was synthesised in presence of 
35S-UTP. Incorporation of labelled UTP was at least 75%.  
A 42-nucleotides mouse POMC oligonucleotide (GGT-TTT-CAG-TCA-GGG-GCT-GTT-
CAT-CTC-CGT-TGC-CAG-GAA-ACA; 90% homology with rat POMC; Eurogentec, 
Belgium) was end-labelled with 33P-dATP (NEN Life Science Products, Hoofddorp, The 
Netherlands, 2000 Ci/mmol, 10 mCi/ml) using terminal transferase with the manufacturer’s 
protocol (Roche Molecular Biochemicals, Almere, The Netherlands). A 0.33 pmol 
oligonucleotide was labelled at molar ratio of 1:20 (oligo:label). Incorporation was typically 
between 50 and 75%, resulting in a tail of 5 to 7.5 A-residues per oligonucleotide.  
Hybridisation procedure 
When using 33P-labelled probes, each slide, containing four sections, was loaded with a 100µl 
mix containing 70% deionised formamide, 10% dextran sulphate, 3xSSC, 50 mM 
dithiothreitol, 1xDenhardt’s solution, 0.1 mg/ml yeast tRNA, 0.1 mg/ml sheared herring sperm 
DNA (ssDNA) and 1-3x106 dpm of the probe, and covered with microscopic coverslips. 
Overnight hybridisation was performed in a moist chamber at 55°C. As a control, a few slides 
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were hybridised with sense probe. The next day, coverslips were removed and the slides were 
washed in 2xSSC at room temperature for 10 minutes, treated with RNAse A (2 mg/100 ml in 
0.5M NaCl, pH 7.5) at 37°C for 10 minutes and 3 times washed in 2xSSC/50% formamide at 
60°C for 15 minutes. After a short wash with 2xSSC, sections were dehydrated in an ethanol 
series and air dried. Finally, the slides were put in an X-ray exposure holder and apposed to 
Biomax MR film (Kodak) for 3-12 days. 
When using 35S-labelled probes, hybridisation procedures were used as previously described 
(Sibug et al., 1998).  
Oligonucleotide in situ hybridisation 
In situ hybridisation using oligonucleotides was performed essentially as described (Meijer et 
al., 2000). 0.5-0.8x106 dpm of labelled oligonucleotide per 100 µl hybridisation mix was 
applied to each slide. Hybridisation mix consisted of 50% formamide, 10% dextran sulfate, 
4xSSC, 25mM sodium phosphate (pH 7.0), 1 mM sodium pyrophosphate, 20 mM DTT, 5x 
Denhardt’s, 100 µg/ml poly-A, 100 µg/ml ssDNA. Sections were coverslipped and hybridised 
overnight in a moist chamber at 42°C . The next morning, coverslips were removed, rinsed in 
1xSSC at room temperature, washed twice for 30 min in 1xSSC at 50°C, washed for 5 min in 
1xSSC at room temperature, dehydrated in an ethanol series, air dried. Then, sections were 
apposed to Kodak (Rochester, NY) Biomax MR film and films were developed after 17-20 
hours. 
Densitometric quantification 
Optical density was quantified with analysis performed on a Macintosh computer using the 
public domain NIH Image program (developed at the U.S. National Institutes of Health and 
available on the Internet at http://rsb.info.nih.gov/nih-image) 
Densities were determined by outlining the parvocellular part of the paraventricular nucleus 
(PVN). Nissl-staining and light microscopy was used to confirm presence of PVN. The optical 
density of the area dorsolateral from the PVN was used to correct for tissue background. 
Optical density measurements of 3-5 sections were averaged per animal with the mean value 
from each animal used in subsequent statistical analysis.  
Corticosterone plasma levels 
Total plasma corticosterone was determined using a standard in-house radioimmunoassay 
procedure. The antiserum raised in sheep against corticosterone-21-hemisuccinate bovine 
serum albumin was a gift from dr F. Sweep, University of Nijmegen, The Netherlands. The 
detection limit is 0.2 µg/dl.  
Determination of apoptosis 
Number of apoptotic cells in the dentate gyrus was qualitatively scored in Nissl-stained 
sections of the hippocampus at a magnification of 400x. 
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Statistics 
Completeness of adrenalectomy was determined based on corticosterone plasma levels and on 
relative saline intake (Richter, 1941); one animal was excluded from the analysis because of 
incomplete ADX. Plasma corticosterone data were analysed using one-way analysis of 
variance (ANOVA) or repeated measurements ANOVA, where appropriate. All other data 
were analysed using two-way ANOVA with treatment and stress as factors (experiment 1), or 
one-way ANOVA with treatment as factor and stress as covariate (experiment 2). When a 
significant stress effect or treatment*stress interaction was absent, data of stress and nonstress 
groups were combined for further analysis on treatment effects. In case stress or interaction 
effects were significant, stress and nonstress groups were separately analysed applying one-
way ANOVA. When appropriate, post-hoc comparisons were performed using Tukey’s 
Honestly Significant Difference test. Statistical difference was accepted at p < 0.05. All data 
are expressed in mean ±SEM. 
Results 
Experiment 1: Five day treatment with dexamethasone subcutaneously 
Two daily subcutaneous injections of dexamethasone for 5 days suppressed basal 
corticosterone plasma levels both at the onset of the stress response and at the circadian peak 
(p<0.05, table 2). Repeated measurements ANOVA on the stress induced corticosterone 
response revealed a significant interaction effect of stress and treatment (F(6,24)=46.7; 
p<0.05). Although low-dose dexamethasone was not able to completely block the stress-
induced rise of corticosterone plasma levels, the levels at 30 minutes after the initiation of 
stress were still considerably lower in the DEXlow group (p<0.05) compared with those in 
VEH group (figure 1). Further, adrenal weight was significantly reduced in both DEXlow and 
DEXhigh groups (table 2).  
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FIGURE 1. Time course of 
corticosterone secretion in response 
to a 30 minutes restraint stress after 
five days of treatment with various 
doses of dexamethasone or ADX. 
Repeated measures ANOVA revealed 
a significant interaction of time and 
treatment (F(6,24)=46,7; p<0.0005). 
Post-hoc analysis revealed that the 
DEXlow group (twice daily 50 
µg/kg) differed significantly from all 
other groups (p<0.02).  
Values are expressed as mean±SEM 
[µg/dl] of 3-5 rats.  
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TABLE 2. Peripheral glucocorticoid markers affected by five-day dexamethasone treatment or ADX 
(experiment 1). Nonstress and stress groups are pooled. 
Treatment  body weight  adrenal weight  thymus weight  
  [% of start weight]   [mg]   [mg]  
VEH  104% ± 2%  41.0 ± 2.2  522 ± 25.9   
DEXlow  93% ± 1% * 25.5 ± 1.7 * 140 ± 7.1 *  
DEXhigh  84% ± 2% *,# 19.9 ± 2.0 * 73 ± 5.3 *  
ADX  101% ± 2%     608 ± 28.5 *  
 * p < 0.05 compared to SHAM VEH # p < 0.05 compared to SHAM DEXlow 
 
Treatment  corticosterone plasma levels [µg/dl] 
  peak  onset stress  
VEH  16.07 ± 1.47  6.45 ± 0.79  
DEXlow  4.96 ± 0.97 *  0.39 ± 0.03 * 
DEXhigh  0.65 ± 0.11 *,#  0.35 ± 0.04 * 
ADX  n.d.     0.46 ± 0.09 * 
  n.d. not determined
 
FIGURE  2. The effect of five-day dexamethasone treatment on POMC mRNA expression in
the anterior pituitary. As two-way ANOVA revealed no stress effect (F(1,21)=0.319; p>0.05),
stressed and nonstressed rats of the same treatment groups were pooled for further analysis on
treatment. Dexamethasone dose-dependently decreased POMC mRNA levels. In contrast, ADX
significantly increased POMC mRNA levels. Post-hoc analysis showed that the DEXlow group
differed significantly from all other groups (p<0.03). Bars represent mean ± SEM of 5-8 rats/group
in arbitrary units of optical density as measured by in situ hybridisation. * significantly different
from VEH (p<0.01). # significantly different from DEXlow (p<0.03). 
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Two-way ANOVA revealed no stress effect (F(1,21)=0.319; p>0.05) on POMC mRNA 
expression in the anterior pituitary consistent with previous studies (Harbuz and Lightman, 
1989), but there was a significant treatment effect. In both DEXlow and DEXhigh groups 
POMC mRNA expression in the anterior pituitary was significantly reduced in a dose-
dependent manner (p<0.05, figure 2). Intermediate lobe POMC mRNA expression was not 
affected by treatment nor by stress (data not shown). Stress induced a response of c-fos 
mRNA expression in the anterior pituitary (F(1,21)=17.5; p<0.05), but there was no effect of 
low-dose dexamethasone treatment or ADX (table 3). Only the DEXhigh group showed a 
reduced stress-induced response of anterior pituitary c-fos mRNA as the stress-induced 
increase was not significant (Student’s t-test). 
Other peripheral markers not directly related to the HPA-axis were also strongly affected in 
the DEXlow group. The thymus wet weight was dramatically reduced (table 2) (p<0.05). Final 
body weight was slightly decreased compared with start of the treatment in contrast to vehicle 
treated animals which gained weight at a normal rate, which resulted in a significant 
difference between both groups at the end of the treatment (table 2). In the DEXhigh group 
body weight was strongly reduced to 84% of starting weight. 
The effects of low-dose dexamethasone in the DEXlow group on peripheral markers are all 
consistent with well-known effects of glucocorticoid action and thus comparable to the effects 
of high-dose treatment in the DEXhigh group. Likewise, ADX animals showed the typical 
effects seen after removal of the source of circulating corticosterone, i.e. undetectable 
corticosterone plasma levels, increased POMC mRNA expression and increased thymus 
weight (p<0.05, table 2 and figure 2).  
TABLE 3. Effect of stress and five-day 
dexamethasone treatment on expression of 
c-fos mRNA in anterior pituitary (exp. 1) 
Treatment  
c-fos mRNA 
anterior pituitary 
nonstress      
VEH  97.5 ± 27.6  
DEXlow  91.4 ± 24.4  
DEXhigh  84.3 ± 33.8  
ADX  121.0 ± 36.6  
stress      
VEH  187.7 ± 9.1 
$ 
DEXlow  196.4 ± 7.6 
$ 
DEXhigh  138.1 ± 32.1  
ADX  173.6 ± 8.8  
$ p<0.05 t-tests respective nonstress group
 
TABLE 4. Effect of dexamethasone 
treatment on CRH hnRNA expression in the 
PVN in absence of stress (experiment 1) 
Treatment  
CRH hnRNA 
[arb. units] 
nonstress      
VEH  18.5 ± 0.8  
DEXlow  14.2 ± 1.4 
 
DEXhigh  12.2 ± 4.0 
 
ADX  19.5 ± 1.5  
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In contrast to the peripheral effects, the central effects of low-dose treatment are different from 
those of high-dose treatment. The expected reduction of stress-induced responses of c-fos 
mRNA and CRH heteronuclear RNA (hnRNA) expression in the parvocellular part of the 
PVN was indeed evident in the DEXhigh group (p<0.05, figure 3). However, in the DEXlow 
animals the rapid increases of c-fos mRNA and CRH hnRNA after stress were not changed 
compared to VEH animals or five-day ADX animals (figure 3). Dexamethasone treatment had 
no effect on the level of c-fos mRNA expression in the PVN in absence of stress, whereas the 
basal CRH hnRNA expression tended to be affected (F(3,13)=3.236, p=0.057; table 4). 
 
 
Due to high variability within groups CRH mRNA levels are not significantly different (figure 
4), but it is clear that in the DEXhigh group the CRH mRNA expression was differently 
affected than in both ADX and DEXlow groups. Further, another well-known ADX effect, 
apoptosis of dentate gyrus cells, was not found in the brains of DEXlow animals (nor in 
DEXhigh animals). In about two-third of the ADX animals pyknotic cells, which are 
indicative of apoptosis, were abundantly present in the granule cell layer of the dentate gyrus, 
mainly located in the tip of the inner blade. 
 
 
FIGURE 3. The effect of five-day treatment with dexamethasone or ADX on the stress-
induced increase of CRH hnRNA (A) and c-fos mRNA (B) levels in the hypothalamic
paraventricular nucleus. For reasons of clarity nonstress groups (except VEH) are not shown. Basal
CRH hnRNA levels are published in table 3. Two-way ANOVA revealed significant stress and
treatment effects (p<0.02). In the DEXlow as well as in the ADX group the stress response was not
altered, but in the DEXhigh group the response of CRH hnRNA was abolished, whereas only a
minor stress response of c-fos mRNA was seen (#, Student’s t-test, p<0.05). Bars represent mean ±
SEM of 3-5 rats/group in arbitrary units of optical density reflecting the amount of 33P-labelled
hnRNA respectively mRNA. * p<0.05 compared to respective nonstress group and DEXhigh stress
group, Tukey’s HSD. 
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Experiment 2: three weeks treatment with dexamethasone in drinking water 
As five-day treatment with low doses of dexamethasone was not enough to fully suppress 
stress-induced corticosterone response and to augment the stress-induced central markers we 
extended the treatment to three weeks. We switched to administration of dexamethasone 
through drinking water to minimise possible stress effects induced by daily injections. 
Dexamethasone treatment did not affect the volume of drinking solution drunk by the animals 
(table 5). The amounts of dexamethasone ingested by the animals were calculated based on the 
volume drunk and the concentration of dexamethasone. Animals treated with 0.5 µg, 1.0 µg or 
FIGURE 4. Expression of CRH mRNA in hypothalamic paraventricular nucleus of nonstress
animals after five-day dexamethasone treatment or ADX. Neither low-dose dexamethasone
treatment nor ADX significantly affected CRH mRNA levels. Due to high variability and low
number of animals, ANOVA did not reveal significant treatment effects.
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FIGURE 5. Time course of 
corticosterone secretion in response 
to a 30 minutes restraint stress after 
three weeks of treatment with various 
doses of dexamethasone through the 
drinking water.  
Repeated measures ANOVA revealed 
a significant interaction of time and 
treatment (p<0.005). Post-hoc 
analysis revealed that the DEX0.5 
group differed significantly from all 
other groups (p<0.05).  
Values are expressed as mean±SEM
[µg/dl] of 2-7 rats. 
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10 µg dexamethasone per ml in their drinking water ingested per day 42±1, 91±4 respectively 
1447±145 µg dexamethasone per kg average body weight. 
 
Like in the injection study, ADX and treatment with the highest concentration of 10 µg/ml 
dexamethasone in the drinking water have both the expected effects on peripheral 
glucocorticoid markers. ADX abolished the corticosterone plasma levels, increased the POMC 
mRNA levels in the anterior pituitary and increased the thymus weight (table 5, figs. 5 and 6). 
In the DEX10 animals dexamethasone treatment resulted in a complete suppression of 
corticosterone plasma levels, a strong reduction of POMC mRNA levels, a severe loss of body 
weight, and decreased thymus and adrenal weights (p<0.05; table 5, figs. 5 and 6).   
Peripherally, treatment with low concentrations of dexamethasone in both DEX0.5 and 
DEX1.0 groups resulted in effects consistent with glucocorticoid actions. Basal levels of 
plasma corticosterone were completely suppressed and not different from ADX levels and 
adrenal wet weight was dose dependently decreased, as was the case with thymus wet weight 
(p<0.05, table 5). However, only in the DEX1.0 group the stress-induced increase of 
corticosterone was completely blocked. In the DEX0.5 group dexamethasone treatment 
reduced corticosterone plasma levels at 30 minutes after onset of stress to only 35% of control 
TABLE 5. Peripheral glucocorticoid markers after three-week treatment with dexamethasone 
through drinking water (experiment 2). Nonstress and stress CTRL groups are pooled. 
Treatment body weight adrenal weight thymus weight Volume drunk  
 [% of start weight]  [mg]  [mg] [ml/day] 
CTRL  130% ± 2%  22.2 ± 1.7 558 ± 18  22 ± 0.4  
DEX 0.5 106% ± 1% * 13.6 ± 1.3 * 264 ± 58 * 19 ± 0.4  
DEX 1.0 94% ± 1% *,# 9.5 ± 0.8 * 145 ± 10 * 19 ± 0.6  
DEX 10 52% ± 4% *,# 6.9 ± 0.4 *,# 96 ± 20 *,# 22 ± 1.6  
ADX 122% ± 7% 
# 
  
 
837 ± 70 *,# 7 ± 0.7 *,# 
Saline             31 ± 1.4 *,# 
 * p < 0.05 compared to CTRL stress # p < 0.05 compared to DEX 0.5 
 
Treatment  corticosterone plasma levels [µg/dl] 
  peak   onset stress  
CTRL   11.6 ± 2.5  3.3 ± 0.72  
DEX 0.5  4.6 ± 1.6 * <0.02   * 
DEX 1.0  0.6 ± 0.5 *,# <0.02   * 
DEX 10  <0.02   *,# <0.02   * 
ADX  0.5 ± 0.4 *,# 0.5 ± 0.24 * 
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levels (figure 5). Whereas untreated CTRL animals gained 27-33% body weight during the 
experimental period, both DEX0.5 and DEX1.0 animals had not gained substantial weight at 
the end of the experimental period (table 5). The body weight of these animals decreased 
during the first 5 days of the experiment and stabilised or slightly increased from that day on.  
POMC mRNA levels in the anterior pituitary were not altered in both DEX0.5 and DEX1.0 
(figure 6A). The c-fos mRNA expression in the anterior pituitary clearly responded to stress in 
untreated CTRL animals (p<0.05, figure 6B), in agreement with a previous report (Senba et 
al., 1994). Treatment also significantly affected expression levels (F(4,27)=3.676, p<0.05). 
ADX levels were lower compared to those of DEX1.0 animals. Dexamethasone treatment 
seemed to induce a higher c-fos mRNA response than stressed control animals (figure 6B), but 
this effect was only found to be statistically significant after combining both low-
concentration dexamethasone treatment groups. 
 
Similar to the injection study, central markers were differentially affected by treatment with 
small amounts of dexamethasone compared to treatment with large amounts of 
dexamethasone. Both DEX0.5 and ADX animals showed increased levels of CRH mRNA in 
the PVN compared with the CTRL group (p<0.05), whereas the DEX10 animals showed a 
clear reduction in CRH mRNA levels (figure 7). The CRH mRNA expression in the DEX1.0 
animals was not changed compared with untreated CTRL animals. Compared to the stressed 
CTRL group both the c-fos mRNA and the CRH hnRNA response was reduced only in the 
FIGURE 6. The effect of three-week dexamethasone treatment on POMC mRNA expression
(A) and stress-induced c-fos mRNA levels (B) in the anterior pituitary. Bars represent mean ± SEM
of 2-8 rats/group in arbitrary units of optical density as measured by in situ hybridisation. 
A) Only in DEX10 animals POMC mRNA levels were decreased, whereas in ADX rats POMC
mRNA expression was strongly increased (*, p<0.04, Tukey’s HSD). 
B) Both stress (p<0.001) and treatment (p<0.02) significantly affected pituitary c-fos mRNA
expression. After combining the DEX0.5 and DEX1.0 groups, the stress-induced increase was
significantly augmented after treatment with low concentrations of dexamethasone compared
to CTRL stress (#, p<0.03, Student’s t-test). 
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DEX10 animals (figure 8). The two lower concentration groups and the ADX group had c-fos 
mRNA and CRH hnRNA levels not significantly different from the stressed CTRL group. No 
signs of apoptosis within the granule cell layer of the dentate gyrus could be found in any of 
the treatment groups. 
FIGURE 8. Effect of three-week dexamethasone treatment or ADX on the stress-induced
increase of CRH hnRNA (A) and c-fos mRNA (B) levels in the hypothalamic paraventricular
nucleus. Only the high concentration of dexamethasone reduced the response to stress of both CRH
hnRNA and c-fos mRNA ($, p<0.05). In ADX, DEX0.5 and DEX1.0 groups expression levels
were not significantly altered as compared with CTRL stress levels. Data are expressed as mean ±
SEM of 4-8 rats/group. #, p<0.05, Student’s t-tests. 
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FIGURE 7. Expression of CRH mRNA in hypothalamic paraventricular nucleus after three-
week dexamethasone treatment or ADX. In ADX as well as in DEX0.5 animals CRH mRNA
levels were significantly enhanced, whereas in DEX10 animals levels were strongly suppressed.
Bars represent mean ± SEM of 3-10 rats/group in arbitrary units of optical density reflecting the
amount of 35S-labelled mRNA. * p<0.05 Tukey’s HSD. 
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Discussion 
The present study demonstrates the lack of central action of low-dose dexamethasone in a 
functional way. The findings clearly show the divergence of central and peripheral effects of 
treatment with small amounts of dexamethasone. Classic markers of peripheral glucocorticoid 
actions like body weight gain, thymus and adrenal weight and pituitary-adrenal activity were 
all strongly affected by dexamethasone even after administration of small amounts. Small 
amounts of dexamethasone administered either by injection for five days or through drinking 
water for three weeks completely suppressed basal corticosterone plasma levels, whereas 
circadian peak and stress-induced increases were strongly reduced. In the anterior pituitary 
POMC mRNA expression is reduced after treatment with small amounts of dexamethasone for 
five days, although not after treatment for three weeks. On the other hand, strong negative 
feedback effects of dexamethasone at central glucocorticoid responsive markers were absent 
after treatment with small amounts. Both stress-induced increases of c-fos mRNA and CRH 
hnRNA and expression of CRH mRNA in the PVN were comparable to those in untreated 
control or ADX rats. After three weeks of treatment the CRH mRNA levels were even 
augmented instead of reduced compared with untreated animals which resembled the effect of 
ADX. The responsiveness of these central markers to glucocorticoids was confirmed by the 
strong action of large amounts of dexamethasone. Besides, the affinity of the brain GR for 
dexamethasone has been shown to be similar to the affinity of pituitary GR (Miller et al., 
1992). Thus, the lack of effect on these central markers compared with peripheral markers is 
not due to lack of responsiveness of these central glucocorticoid targets. Yet, it is probably 
related to the hampered penetration of dexamethasone into the brain.  
 
In vitro, brain glucocorticoid target areas can easily retain both 3H-dexamethasone and 3H-
corticosterone (De Kloet et al., 1975; McEwen et al., 1976). However, whereas 3H-
corticosterone can easily enter the brain in vivo (De Kloet et al., 1975; Stumpf et al., 1989; 
Karssen et al., 2001), 3H-dexamethasone can not, although both brain and pituitary express 
high amounts of GR (De Kloet et al., 1975; Rees et al., 1975; Stumpf et al., 1989). The 
existence of a blood-brain barrier limiting the uptake of dexamethasone was postulated (De 
Kloet et al., 1975; Rees et al., 1975; Coutard et al., 1978), but could not be proved until 
recently. We have demonstrated that these low doses poorly reach the brain glucocorticoid 
target areas due to the presence of the efflux transporter P-glycoprotein at the blood-brain 
barrier (Meijer et al., 1998).  
 
As a result of its poor central access to the brain dexamethasone primarily acts on the anterior 
pituitary to suppress pituitary-adrenal secretion (De Kloet et al., 1974). In contrast, as 
corticosterone can easily reach the brain, the feedback sites of corticosterone modulating the 
HPA-axis are likely predominantly localised at multiple sites in the brain (Dallman et al., 
1987a; Levin et al., 1988; De Kloet, 1991; Diorio et al., 1993; Dallman et al., 1994). Our data 
corroborate the concept of a pituitary site of dexamethasone action and are consistent with 
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reports studying receptor occupancy in pituitary and brain tissue after either short-term or 
acute dexamethasone treatment (Miller et al., 1990; Miller et al., 1992; Cole et al., 2000). 
These latter studies have demonstrated that low doses of dexamethasone selectively occupy 
GR in the pituitary and thymus, whereas GR levels in different parts of the brain were 
unaffected.  
 
Treatment with large amounts of dexamethasone is effective in suppressing central 
glucocorticoid markers in addition to its potent peripheral effects. In the current study, the 
stress-induced responses were clearly reduced and CRH mRNA expression was abolished 
after administration of large amounts of dexamethasone. This indicates that the barrier formed 
by P-glycoprotein is not complete. Indeed, after administration in large amounts 
dexamethasone reaches the brain (Schinkel et al., 1995). Regardless of whether 
dexamethasone is still hampered to enter the brain at high plasma levels, it will likely reach 
the brain in sufficient amounts to activate the GR. Large amounts of dexamethasone have been 
demonstrated to be able to occupy the GR in the hippocampus and hypothalamus (Reul et al., 
1987b; Spencer et al., 1990; Miller et al., 1992). All studies reporting effects of 
dexamethasone on glucocorticoid targets in the brain used high systemic doses or brain 
implants of dexamethasone (Kovács and Mezey, 1987; Sawchenko, 1987; Imaki et al., 1995; 
Roozendaal and McGaugh, 1996; Feldman and Weidenfeld, 2002). These and our studies 
show that systemically administered dexamethasone is able to act on the brain only when 
administered in large amounts overcoming its P-glycoprotein mediated exclusion from the 
brain.  
 
In contrast to the well-known inhibitory central effects of large amounts of dexamethasone, 
we expected to observe augmented central stress responses after treatment with small amounts 
similar to ADX. Due to depletion of central glucocorticoid receptors from their ligands, both 
conditions were expected to show lack of glucocorticoid negative feedback in brain and 
consequently hyperactive CRH neurons. Indeed, CRH mRNA levels were increased after three 
weeks of either treatment with small amounts of dexamethasone or ADX, although this effect 
was not seen after five-day treatment. However, the stress responses of c-fos mRNA and CRH 
hnRNA in the ADX groups as well as in the small amount dexamethasone groups were not 
augmented compared with those of the control groups in the present study, in contrast to the 
previously reported amplified central stress response 5 days to one week after ADX (Imaki et 
al., 1995; Kovacs et al., 2000) or after acute glucocorticoid withdrawal (Herman et al., 1992). 
However, in concordance with our finding are several other studies reporting no effect of 5 
day ADX on induction of c-fos mRNA in hypothalamus after stress (Melia et al., 1994; 
Helmreich et al., 1996; Brown and Sawchenko, 1997). Lack of an ADX-effect on these 
parameters in the present study neither confirms nor rejects the complete removal of central 
glucocorticoid feedback after treatment with small amounts of dexamethasone. On the other 
hand, ADX and small amount dexamethasone groups never differ significantly from control 
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groups with regard to the various central glucocorticoid markers, whereas peripheral effects 
are often opposite to each other. In contrast, groups treated with large amounts of 
dexamethasone always differ significantly from all groups. Thus, the present study indicates 
that treatments with amounts less than 1 µg/ml in the drinking water or daily injections of less 
than 100 µg/kg may result in a brain-selective depletion of glucocorticoids whereas 
dexamethasone can still act through the peripheral glucocorticoid receptors.  
 
The integrity of peripheral GR mediated actions might be one of the advantageous differences 
of this paradigm to ADX when studying central effects of corticosterone, even though the 
peripheral GR system is hyperactivated. Exclusion of small amounts of dexamethasone from 
the brain may provide a subtle model to study central glucocorticoid action. This model might 
make it possible to distinguish between direct central effects and indirect peripheral effects 
subsequently affecting central responses. The need for such a distinction has been exemplified 
by two recent studies showing that in adrenalectomised rats ingesting sucrose expression of 
corticotropin-releasing hormone in brain is normalised (Laugero et al., 2001) and centrally 
infused corticosterone may stimulate HPA-axis activity under some conditions (Laugero et al., 
2002). In addition, corticosterone effects can be examined without the potential confounding 
effects of removal of aldosterone and adrenal catecholamines as after ADX.  
 
This model would be particularly useful in studying GR mediated actions, as this model is 
hyporesponsive to stress-induced activation of the pituitary-adrenal axis. GR is the main 
receptor type involved in mediating glucocorticoid negative feedback effects in the brain (De 
Kloet, 1991). It has been demonstrated that for proper memory functioning the increase in 
corticosterone and consequently occupation of GR directly after the task is necessary (Oitzl 
and De Kloet, 1992; Sandi, 1998). Furthermore, in many central processes affected by 
glucocorticoids the MR/GR balance is critically important in modulating glucocorticoid 
actions (De Kloet, 1991; De Kloet et al., 1999). It might be worthwhile to use this model in 
studies concerning the role of GR in learning and memory tasks or in situations of chronic 
stress. 
 
The impaired penetration of dexamethasone into the brain has important implications for the 
interpretation of the dexamethasone suppression test (DST). This test is widely used in the 
clinic often in combination with a CRH challenge, to evaluate the dysregulation of the HPA-
axis in depressive patients (Holsboer and Barden, 1996; Holsboer, 2000). Excessive release of 
CRH and vasopressin (AVP) from PVN neurons into the portal circulation leads to a 
hyperdrive of the HPA-axis in many of these patients. A low dose of dexamethasone 
administered the night before does not suppress the basal and exogenous CRH induced 
ACTH/corticosterone release as is seen in controls. The HPA abnormalities seen in the DST 
are often described to decreased negative feedback through corticosteroid receptors. The DST 
may not necessarily provide any proof for this, at least not at suprapituitary levels. As 
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dexamethasone is administered at a low dose it will mainly act on the pituitary. At this level, 
the hyperdrive of CRH/AVP may be strong enough to override even properly functioning 
negative feedback. Dexamethasone suppression in healthy subjects can indeed be overcome 
by concurrent infusion of CRH and AVP (Von Bardeleben et al., 1985). On the other hand, it 
can not be excluded that the hyperdrive itself is caused by an aberrant central feedback 
mechanism, but the DST does not test this.  
A better way to probe the efficacy of the central corticosteroid receptor feedback system may 
be provided by the application of corticosterone. Corticosterone can easily enter the brain 
(Karssen et al., 2001) and likely acts predominantly on the central feedback target areas 
(Levin et al., 1988). It would therefore be able to directly suppress the CRH/AVP drive in the 
PVN. Besides, as corticosterone also activates MR, it would also probe the function of this 
receptor. Regulation of HPA-axis is partly mediated by MR (De Kloet, 1991; Spencer et al., 
1998; Young et al., 1998; Reul et al., 2000b) and may even be the more relevant receptor type 
involved in dysregulation of HPA-axis seen in stress-related disorders (Reul et al., 2000a; 
Pariante and Miller, 2001; Makino et al., 2002). 
 
In conclusion, our findings suggest that treatment with small amounts of dexamethasone may 
deplete glucocorticoids selectively from the brain without removal of glucocorticoid action in 
the periphery. This condition will specifically affect central glucocorticoid target areas 
modulating HPA-axis, behavioural adaptation and synaptic plasticity, particularly after stress. 
Thus, divergence of peripheral and central glucocorticoid effects due to hampered access of 
small amounts of dexamethasone to the brain may serve as a model for states with disturbed 
glucocorticoid signalling in the brain.  
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The data presented in the preceding chapters of this thesis have clearly demonstrated the 
impact of the efflux transporter Pgp expressed at the endothelial cells forming the BBB in 
modulating access of glucocorticoids to glucocorticoid target areas in the brain. Pgp hampers 
the uptake into the brain of various synthetic and naturally occurring corticosteroids, like 
dexamethasone, prednisolone and cortisol. The concentrations of these glucocorticoids in the 
brain are strongly decreased compared with their plasma concentrations and, when circulating 
at low plasma levels, these glucocorticoids hardly reach their central targets. Moreover, 
administration of the potent GR-ligand dexamethasone in small amounts was counter-
intuitively found to decrease central glucocorticoid feedback creating a low corticosteroid 
condition in the brain. The work presented in this thesis has also revealed a remarkable 
difference between the two main naturally occurring glucocorticoids corticosterone and 
cortisol, as Pgp appeared to have no effect on corticosterone uptake into the brain. This 
difference may have implications for central glucocorticoid actions in humans. 
P-glycoprotein expression in the brain 
In the first chapter data are presented showing the localisation of mdr1 mRNA encoding Pgp 
in brain. In situ hybridisation using DIG-labelled or 33P-labelled riboprobes against mdr1a and 
mdr1b mRNA demonstrated the presence of mdr1a/mdr1b mRNA around brain capillaries 
and, surprisingly, in granule cells of the dentate gyrus. Presence of mRNA around brain 
capillaries suggests that Pgp is expressed at the endothelial cells forming the blood-brain 
barrier. This finding is consistent with previous studies demonstrating expression of Pgp in 
endothelial cells at the protein level (Thiebaut et al., 1989; Cordon-Cardo et al., 1990; 
Sugawara et al., 1990; Lechardeur et al., 1996; Beaulieu et al., 1997). Under normal, healthy 
conditions Pgp is likely only expressed by endothelial cells, although it can not be excluded 
that under certain pathological conditions astrocytes may express Pgp as well.  
At the protein level, Pgp was found at capillaries throughout the brain. The expression was 
particularly high in the PVN, which is likely related to its high vascularisation (Sposito and 
Gross, 1987; Badaut et al., 2000). Within the hippocampus, most Pgp was found at capillaries 
in the stratum lacunosum moleculare.  
 
Remarkably, mdr1a/mdr1b mRNA was also detected in hippocampal neurons, particularly in 
the granule cells of the dentate gyrus. Although at the protein level Pgp in the granule cells 
was below the detection limit, the mRNA signal appears to be specific. Whether Pgp 
expressed at granule cells plays a role in modulating glucocorticoid actions on the dentate 
gyrus remains unresolved for now.  
Glucocorticoid transport at the blood-brain barrier  
The data regarding Pgp-mediated transport of corticosteroids presented in this thesis have 
corroborated and extended previous literature data regarding the ability of Pgp to transport 
corticosteroids. Our data show that Pgp transports dexamethasone, prednisolone, cortisol, 
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cortisone and, to a lesser extent, aldosterone (table 1). It does not transport corticosterone and 
cortexolone. It is remarkable that, in spite of its broad spectrum of substrates (Schinkel et al., 
1994), Pgp distinguishes subtle differences in steroid structure. Comparison of the molecular 
structures of these steroids reveals that the 17-hydroxyl moiety in combination with an 11-
hydroxyl or 11-oxo moiety might determine the ability of MDR1 Pgp to transport steroids 
(table 1), as was previously postulated with regard to mdr1b Pgp by Bourgeois et al. (1993) 
using another method. Pgp transports steroids having both these hydroxyl-groups (as 
prednisolone and dexamethasone). Steroids lacking one of these groups (as aldosterone, 
corticosterone and cortexolone) and steroids without any of these groups are minimally if at 
all transported. The high affinity MR ligand deoxycorticosterone belongs to the latter group 
and therefore it should easily be retained in brain. However, although it readily enters the 
brain (Kraulis et al., 1975), McEwen et al (1976) have shown that deoxycorticosterone is 
poorly retained by MR in different brain areas and pituitary of ADX rats. This suggests that 
there are additional factors, e.g. local metabolism, determining the retention of this 
mineralocorticoid in potential target areas.  
 
TABLE 1. Steroid transport capabilities of P-glycoprotein. Summary of data derived from 
studies described in this thesis and from literature. 
corticosteroid 11-OH 17-OH transport by Pgp 
cortisol/hydrocortisone + + + 
corticosterone + - - 
a
 
dexamethasone + + + 
prednisolone + + + 
cortisone - + + 
aldosterone -/+
 b 
+ +/- 
cortexolone/deoxycortisol - + - 
c
 
deoxycorticosterone - - - 
c
 
dehydrocorticosterone - - n/a 
methylprednisolone + + + 
triamcinolone + + + 
betamethasone + + + 
progesterone - - - / inhibitor 
d
 
RU486/mifepristone - (+) - / inhibitor 
d 
a. Corticosterone might be weakly transported by mdr1b Pgp  n/a not available 
b. Aldosterone mainly circulates in the hemiacetal form (see figure 1 Introduction). 
c. Both deoxycortisol and deoxycorticosterone may inhibit Pgp function. 
d. Both progesterone and RU486 are not transported by Pgp, but inhibit Pgp-mediated transport of other 
substrates including glucocorticoids 
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The findings have extended our view on the in vivo importance of Pgp in modulating synthetic 
glucocorticoid action. As synthetic glucocorticoids are hampered to enter the brain, they 
predominantly act on peripheral glucocorticoid targets when present at low plasma 
concentrations. At higher plasma levels, direct central action might progressively emerge, 
although peripheral action may probably still be more pronounced. Central effects at low 
plasma levels should likely be ascribed to decreased rather than increased central 
glucocorticoid action, as synthetic glucocorticoids (particularly dexamethasone) are excluded 
from the brain and, simultaneously, suppress pituitary-adrenal secretion through negative 
actions at the pituitary level. Furthermore, treatment with synthetic glucocorticoids will lead to 
a shift in MR/GR balance, as their ability to activate MR is relatively low, whereas they are 
able to act potently via GR.  
 
Relevance of Pgp-mediated transport of cortisol for endogenous glucocorticoid exposure of 
the human brain is suggested by the increased corticosterone:cortisol ratio in post mortem 
brain as compared to human plasma. While in human plasma corticosterone concentrations are 
only 5% of cortisol levels, in the brain corticosterone levels are 30% of those of cortisol as 
determined using LC-MS. Although no direct comparison can be made between absolute 
plasma and brain glucocorticoid levels from the same subjects, these findings do suggest that 
cortisol levels in brain are 6 times lower than those in blood, which would result in a decrease 
of total glucocorticoid levels.  
The comparison of brain and plasma ratios relies on the unproven assumption that there is no 
selective transport or clearance of corticosterone by some other factor. Steroid transport may 
be a more common phenomenon than currently acknowledged, as exemplified by the polar 
transport of glucocorticoids including corticosterone in the untransfected LLC-PK1 
monolayers. Although autoradiography data regarding corticosterone uptake into brain do not 
provide any indication of transport by other yet unknown steroid transporters, it cannot be 
excluded that inward transporters may exist at the BBB.  
 
The present data indicate that plasma levels of cortisol, even ‘free’, non-CBG bound cortisol, 
or dexamethasone may not mirror brain levels. Unfortunately, determination of CSF levels of 
glucocorticoids may be of limited value, as Pgp is not expressed at the blood side of the blood-
CSF-barrier (BCB), but rather at the CSF side (Rao et al., 1999). It may thus pump 
glucocorticoids into the CSF. Brain and CSF likely constitute different compartments not 
reflecting linear relationships in glucocorticoid concentrations, in the same way as recently 
was postulated for drugs that are Pgp substrates (De Lange and Danhof, 2002).  
Our autoradiography film data, indeed, showed that in wild type mice radioactive labelling 
was restricted to the choroid plexus indicating free access of glucocorticoids to this structure 
and possibly to the ventricles through the BCB. Cortisol, dexamethasone and other Pgp 
substrates like prednisolone may slowly gain access to the brain through the 
cerebroventricular system (Rees et al., 1975; Stumpf et al., 1989), or circumventricular organs 
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and may diffuse into brain areas in the immediate vicinity of the ventricles. However, since 
the surface of the BBB is approximately 5000 times greater than the surface of the BCB 
(Pardridge et al., 1981), the uptake in brain tissue as a whole will probably remain 
considerably reduced even in presence of high plasma levels. This may apply to the PVN even 
more strongly, as this brain area has a high density of Pgp-expressing capillaries and thus has 
a high capacity of efflux of Pgp substrates including glucocorticoids.  
Cortisol access 
Cortisol is one of the first endogenous Pgp substrates identified so far. Active transport of 
cortisol may be a physiological role of Pgp. In light of the huge number of Pgp substrates 
presently known, surprisingly few endogenous substrates have been identified. This lack of 
endogenous substrates and the strongly increased sensitivity of the mdr1a knockout mice to 
neurotoxic drugs essentially form the basis of the generally accepted view that protection of 
the brain and/or BBB against xenotoxic compounds is the main role of Pgp at the BBB, like 
intestinal Pgp protects the whole body against orally supplied xenobiotics. However, multiple 
additional physiological roles of Pgp have been proposed with regard to transport of 
endogenous substrates (Johnstone et al., 2000; Garrigues et al., 2002), but it is presently 
unknown whether any of these proposed additional roles are in any way related to BBB Pgp 
function. A recently postulated specific function of Pgp at the BBB may be excretion of 
endogenous substrates out of the brain (King et al., 2001; Lam et al., 2001). The hampered 
uptake of cortisol suggests that modulating central glucocorticoid feedback or protection of 
neurons from excess glucocorticoid endangerment may also be among the physiological roles 
of BBB Pgp in humans. As a consequence, peripheral actions of cortisol might be relatively 
more potent than central actions. 
 
As glucocorticoids are potent modulators of neuronal activity and function, hampered uptake 
of cortisol may have strong impact on human brain function. The results presented in chapter 
3 do not prove unequivocally that Pgp actually plays a functional role in modulating the 
actions of cortisol in human brain. Although Pgp is clearly able to transport this glucocorticoid 
and hampers it from entering the mouse brain, rather high levels of cortisol in post-mortem 
human brain samples were found. For obvious reasons we were obligated to measure 
glucocorticoid levels in post-mortem brain samples without accompanying plasma samples 
from the same subjects, and thus direct comparisons could not be made. However, the 
increased ratio of corticosterone over cortisol suggested that cortisol was indeed hampered to 
enter the human brain. Consequently, brain levels of cortisol might be considerably reduced 
compared to plasma levels in contrast to corticosterone levels, with possible consequences for 
occupation of corticosteroid receptors. 
 
The ratio of corticosterone over cortisol under physiological conditions may even have been 
underestimated. Determinations of corticosteroid levels in post-mortem samples may be 
confounded by the uncertainty of stress pathology in the period prior to death. Extremely 
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increased plasma glucocorticoid levels might saturate the Pgp transport mechanism enhancing 
the brain cortisol levels relative to those of corticosterone, although our in vitro studies do not 
provide any indication that Pgp-mediated transport of cortisol is saturated within the 
physiological range of plasma cortisol levels. Our finding suggesting impaired uptake of 
cortisol into the brain at physiological levels may be consolidated using other methods like 
microdialysis in animals in which cortisol is circulating in plasma or in animals receiving 
exogenous cortisol.  
Corticosterone access to rodent brain 
The lack of Pgp-mediated exclusion of corticosterone from the brain of wild type mice 
indicates that Pgp probably does not modulate glucocorticoid action in rodent brain. Several 
studies have reported corticosterone transport by Pgp, but these studies mostly rely on Pgp 
encoded by mdr1b (Wolf and Horwitz, 1992; Bourgeois et al., 1993; Uhr et al., 2002). This 
second rodent Pgp may have some capacity to transport corticosterone, but its capacity to 
transport dexamethasone, prednisolone and cortisol is much larger (Bourgeois et al., 1993).  
 
Since we have used mdr1a single knockout mice to demonstrate the involvement of Pgp in 
hampering the access of glucocorticoids to the brain, some mdr1b-encoded Pgp might still be 
present in these mice, which may affect corticosterone uptake into the brain. However, in 
agreement with the finding that the mdr1b gene is not expressed at the BBB at least under 
normal in vivo conditions (Jette et al., 1995), mdr1b (-/-) mice do not show enhanced brain 
uptake of various confirmed mdr1b Pgp-substrates (Schinkel et al., 1997). Upregulation of 
mdr1b expression has been shown to occur in in vitro models of BBB (Barrand et al., 1995; 
Demeule et al., 2001). However, as mdr1b expression has not been shown to be upregulated in 
brain homogenates of these mice (Schinkel et al., 1994), compensatory upregulation of this 
Pgp at the BBB of mdr1a (-/-) mice is not likely to have influenced corticosterone brain 
uptake. Furthermore, it is clear that disruption of the mdr1a gene severely affects the uptake of 
various other glucocorticoids, despite the efficacy of mdr1b Pgp to transport these 
glucocorticoids (Bourgeois et al., 1993). Thus, potential presence of mdr1b at the BBB in 
mdr1a mutant mice is not likely to affect glucocorticoid uptake into the brain of these mice.  
Mdr1b mRNA has been found in whole brain homogenates (Croop et al., 1989; Schinkel et 
al., 1994), which should likely to be ascribed to brain parenchyma cells such as astrocytes and 
microglia that express this isoform (Lee et al., 2001a) and possibly to granule cells in the 
dentate gyrus. The lack of mdr1b might have masked the actual effect of Pgp at the BBB on 
brain uptake of corticosterone in the radioactive uptake study of Uhr et al (2002). They 
showed that the complete absence of both Pgp isoforms in mdr1a/1b double knockouts 
resulted in a two-fold accumulation of 3H-corticosterone into the brain. Enhanced 
accumulation of corticosterone in brain of these mice may be attributed to an increased 
volume of distribution in brain due to enhanced uptake into glial cells. Such an increase is not 
assumed to affect retention at corticosteroid receptors in neuronal cells.  
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The presence or absence of mdr1b Pgp may affect brain uptake of corticosterone in indirect 
ways through effects on steroid metabolism and/or adrenal secretion. Impaired function of 
hepatic Pgp in both single and double knockout mice might affect glucocorticoid metabolism 
as altered Pgp expression may affect the steroid metabolising enzyme cytochrome P450 3A4 
in the liver (Baron et al., 2001). Although not verified, hepatic metabolism is less likely to be 
affected in mdr1a knockout mice than in mdr1a/1b double knockouts, as compensatory 
increased hepatic mdr1b Pgp in mdr1a knockouts (Schinkel et al., 1994) may compensate for 
loss of mdr1a Pgp. Indeed, in contrast to the mdr1a knockout mice, the mdr1a/1b double 
knockouts showed increased plasma levels of radioactivity after administration of 3H-
corticosterone (Uhr et al., 2002). An altered steroid metabolism might also partly explain the 
decreased activity of the HPA system seen in mdr1a/1b (-/-) mice (Müller et al., 2003).  
In addition, the presence of mdr1b Pgp at the mouse adrenal cortical cells may facilitate 
corticosterone secretion from the adrenal (Altuvia et al., 1993), which might increase 
corticosterone plasma levels. Although its role for adrenocortical secretion is not firmly 
established, the lack of mdr1b could explain the reduced amount of circulating corticosterone 
in mdr1a/1b knockouts (Uhr et al., 2002). It is not known what a life-long reduction in 
corticosterone levels implies for the development of the HPA axis. 
 
Another way corticosterone may affect its own uptake into the brain might be through its 
effects on BBB integrity, which is mediated by GR present in endothelial cells (Gaillard et al., 
2001). It has been shown that ADX increases the permeability of the BBB to macromolecules, 
which was restored by corticosterone replacement (Long and Holaday, 1985). However, a 
specific effect of corticosterone-induced changes in BBB integrity on glucocorticoid passage 
has not been reported, and is not likely to occur, as the passage of lipophilic compounds like 
glucocorticoids is probably not affected by changes in paracellular transport. On the other 
hand, it is unknown whether corticosterone may affect the expression or functionality of Pgp. 
 
No study so far has revealed corticosterone as a major Pgp substrate in contrast to cortisol. 
Even the study of Uhr et al. (2002) corroborated the much larger effect of the presence of Pgp 
on the uptake of cortisol into mouse brain compared to its effect on uptake of corticosterone. 
Transport of corticosterone was not affected by the presence of the single human MDR1 gene 
in our monolayers, suggesting that Pgp does not hamper entry of this glucocorticoid into 
human brain. Thus, Pgp is not likely to profoundly affect corticosterone feedback to rodent 
and human brain.  
Aldosterone access 
The transport studies in our MDR1 monolayers show that Pgp only weakly transports the 
high-affinity MR-ligand aldosterone. These results agree with several in vitro studies on Pgp-
mediated transport of aldosterone. Using comparable monolayers to those in our studies, Ueda 
et al (1992) have demonstrated that aldosterone is moderately transported by the human 
MDR1 Pgp, while Bourgeois et al. (1993) showed that cortexolone was not and aldosterone 
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was only weakly transported by mdr1b Pgp. The weak transport of aldosterone by Pgp cannot 
explain why this mineralocorticoid seems to play a limited role in limbic functioning relative 
to corticosterone, while both steroids bind with similar affinity to MR in vitro (Veldhuis et al., 
1982; De Kloet, 1991). Moreover, upon administration of tracer amounts of 3H-corticosterone 
and 3H-aldosterone to adrenalectomised rodents both steroids are retained very well in limbic 
brain structures that abundantly express MR (Birmingham et al., 1984). However, in adrenally 
intact animals only little aldosterone is extracted from hippocampal cell nuclei relative to 
corticosterone, probably because the latter steroid circulates in a one hundred to one thousand 
higher concentration in the blood (Yongue and Roy, 1987). Cells conferring aldosterone 
selectivity are present in the periventricular brain areas involved in salt appetite, regulation of 
the electrolyte balance and autonomic outflow (Seckl, 1997; Van Acker et al., 2002). This 
aldosterone selectivity is due to an 11ß-steroid dehydrogenase that breaks down corticosterone 
allowing access of aldosterone to MR (Seckl, 1997). In hippocampus this reductase activity is 
absent (Robson et al., 1998). Further studies with mdr1a (-/-) mice are necessary to directly 
examine the involvement of Pgp in aldosterone uptake in brain.  
Glucocorticoid feedback to the brain  
Different roles cortisol and corticosterone? 
Whether cortisol acts directly in brain or not, the preferential uptake of corticosterone in 
human brain suggests that this latter endogenous glucocorticoid may play a more prominent 
role in human brain function than hitherto recognised (figure 1). In contrast to rodents, both 
cortisol and corticosterone are circulating in human plasma, although corticosterone is present 
at tenfold lower levels than cortisol. In human, the presence of Pgp at the BBB might 
differentiate the time-course of uptake into the brain of cortisol and corticosterone during rises 
in the plasma corticosteroid levels by slowing down the uptake of cortisol. Due to the 
differential uptake of cortisol and corticosterone, the human glucocorticoid feedback system 
might be more complex than the rodent system. The resultant species difference complicates 
extrapolation of data regarding central glucocorticoid action from rodent to human.  
The question arises whether cortisol and corticosterone might affect brain function differently. 
The differential interaction of Pgp with both hormones is exceptional in the sense that neither 
pharmacological nor physiological differences between both hormones have been discerned 
thus far. Both hormones are secreted by the human adrenal cortex upon activation by ACTH 
and both have a very high affinity for MR combined with a tenfold lower affinity for GR. 
Therefore, both glucocorticoids are generally considered to act in similar ways on brain 
function.  
However, a more thorough examination of literature data reveals small but consistent 
differences between both corticosteroids in affinity and transactivation properties of MR. 
Results from different research groups consistently show that corticosterone has a slightly 
higher affinity for both rat and human MR (Lan et al., 1981; Krozowski and Funder, 1983; De 
Kloet et al., 1984a; Arriza et al., 1987), which may underlie the reported higher effectiveness 
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of corticosterone in promoting human MR transactivation (Lombes et al., 1994; Hellal-Levy 
et al., 1999). Whether GR properties also differ for both hormones is more difficult to uncover 
due to lack of literature data. Very few investigations have tested both glucocorticoids in a 
single study both showing cortisol as the more potent one in transactivation of human GR 
(Arriza et al., 1988; Hellal-Levy et al., 1999). 
Tentatively, corticosterone may be the more active glucocorticoid at the MR in human brain 
with a potentially different role than cortisol. In this regard, it may be of relevance that the 
distribution of MR in humans seems to be broader than in rodents, with relatively high levels 
found in the prefrontal cortex (Lopez et al., 1999). This structure is essential for mood and 
cognitive processing and may be particularly sensitive to glucocorticoid feedback in humans 
(Lupien and Lepage, 2001). In addition, a recent study reported that GR levels are relatively 
low in hippocampus of rhesus monkey in contrast to MR levels (Sanchez et al., 2000). 
Although this latter finding should be confirmed for human hippocampus, the species-specific 
distribution of MR suggests that this receptor might have a more pronounced role in mediating 
glucocorticoid actions in human brain than in rodent brain. 
 
It is presently unknown whether these differences in affinity and transactivational response are 
actually relevant for the actions of both glucocorticoids on normal human brain functioning. 
Besides these features there are a lot of other factors which also determine the final response 
to glucocorticoids and may have presently unknown differential interactions with both 
hormones. These include co-activators/co-repressors and a variety of transcription factors such 
as NFκB and AP-1 (Meijer, 2002), but also interaction with membrane-bound receptors 
(Borski, 2000). Anyway, the difference in relative brain uptake and possibly other features 
warrants further studies into the potentially different roles of cortisol and corticosterone in 
FIGURE 1.  Proposed model of glucocorticoid feedback to human brain.  
Whereas corticosterone easily enters the brain, the main human adrenal glucocorticoid cortisol is
hampered to reach glucocorticoid target areas due to P-glycoprotein mediated efflux at the blood-
brain barrier. Thus, corticosterone may play a more important role as mediator of glucocorticoid
action in human brain than hitherto recognised. 
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modulating human brain function. The use of cortisol secreting animals would facilitate these 
studies as species differences in brain uptake of glucocorticoids and receptor distribution 
complicate extrapolation of rodent data to the human situation. 
Dexamethasone feedback actions 
To show that impaired uptake of glucocorticoids into brain may actually affect brain function 
rats treated with different doses of the synthetic glucocorticoid dexamethasone were studied. 
During the past four decades an increasing body of literature has provided evidence that 
access of dexamethasone to the brain is impaired, which was demonstrated to be caused by the 
presence of Pgp at the BBB (Meijer et al., 1998). We have now demonstrated its impaired 
access in a functional way showing a divergence of direct actions of low-dose dexamethasone 
on central and peripheral glucocorticoid targets. Dexamethasone circulating at low 
concentrations does not act at several glucocorticoid responsive genes expressed in the brain. 
In contrast, these concentrations of dexamethasone potently acted on various peripheral 
glucocorticoid targets. As both these central and peripheral actions are mediated by a single 
receptor - the GR - this suggests impaired access to the brain of dexamethasone, although 
differential cell- or gene-specific sensitivity may provide an alternative explanation (Meijer et 
al., 2003). This barrier is not complete, as after high-dose treatment dexamethasone turned out 
to have entered the brain in sufficient amounts to suppress expression of central glucocorticoid 
responsive genes.  
 
At low plasma concentrations dexamethasone acts primarily at the pituitary level to suppress 
pituitary-adrenal activity. This is supported by its differential effects on POMC and c-fos 
mRNA expression in the anterior pituitary. The POMC gene plays a key role in mediating 
stress and glucocorticoid effects on ACTH/corticosterone secretion. It is well known that CRH 
and glucocorticoids regulate both basal and stress-induced transcription of the POMC gene in 
opposite and complex ways (Gagner and Drouin, 1985; Lundblad and Roberts, 1988). 
Dexamethasone affects POMC expression levels in different ways, through a DNA-binding 
dependent way and through protein-protein interactions. The dexamethasone-GR complex can 
influence POMC gene transcription by binding to a negative glucocorticoid responsive 
element present in the POMC promoter (Drouin et al., 1993). Activated GR may also bind to 
AP-1 complexes containing c-fos and suppress the CRH-induced transcription of POMC 
(Autelitano, 1994). Five-day treatment with small amounts of dexamethasone decreases the 
expression of POMC mRNA, but does not affect the stress induced c-fos mRNA response in 
the anterior pituitary. As stress-induced pituitary c-fos induces POMC expression, this 
indicates that dexamethasone acts downstream from pituitary c-fos in its inhibition of POMC 
transcription.  
After three-week treatment with small amounts of dexamethasone the suppression of POMC 
mRNA has disappeared, but at that time the c-fos mRNA response is augmented. Maximal c-
fos induction may prevail over the dexamethasone-mediated inhibition of POMC transcription 
(Autelitano and Sheppard, 1993) after this long-term treatment, which may explain the lack of 
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POMC mRNA inhibition, assuming that basal pituitary c-fos mRNA levels were increased 
similar to the augmented stress-induced c-fos mRNA levels.  
Creation of a low central corticoid state 
We hypothesised that treatment with small amounts of dexamethasone would create a central 
ADX-like state without removal of glucocorticoid action in the periphery (see figure 9 
introduction). The issue of whether dexamethasone treatment actually creates a low 
corticosteroid state in the brain is still some matter of debate (Feldman and Weidenfeld, 1995; 
Lupien and McEwen, 1997; De Kloet et al., 1998; Roozendaal, 2000; Reul et al., 2000b; 
Belanoff et al., 2001; Feldman and Weidenfeld, 2002). Although our data corroborated the 
notion that low-dose dexamethasone treatment results in relatively weak central actions, it is 
less certain that low-dose treatment completely depletes glucocorticoids from the central 
glucocorticoid targets resulting in a condition resembling that of ADX.  
The increased paraventricular CRH mRNA expression levels in both low-dose dexamethasone 
treated and ADX groups compared to untreated groups supports this latter notion. However, 
this increase is seen only after extended treatment of three weeks. The stress-induced 
responses of CRH hnRNA and c-fos mRNA expression in low-dose dexamethasone treated 
groups do not differ from both ADX and untreated control groups. Furthermore, unlike ADX 
rats, dexamethasone treated rats do not show apoptosis of granule cells of the dentate gyrus, 
suggesting that some residual glucocorticoid action may still be present in low-dose treated 
rats. Protection of granule cells against apoptosis is a MR mediated process and, thus, an 
increase in the occurrence of apoptosis might be expected if depletion of glucocorticoids from 
brain after dexamethasone treatment would also abolish the occupancy of hippocampal MR 
(Sloviter et al., 1989). As dexamethasone does not activate MR in vivo (Reul et al., 2000b), 
the lack of apoptosis is suggestive of presence of at least some corticosterone in brain, 
although occupation of MR by aldosterone might give an alternative explanation (Woolley et 
al., 1991).  
Clearly, the effects of low-dose dexamethasone treatment on other central corticosteroid 
responsive markers should be examined to confirm or reject the creation of an ADX-like state. 
These markers should not only be looked for in the PVN (in which AVP is of particular 
interest), but also in other glucocorticoid responsive brain areas like hippocampus and 
amygdala.  
Model for central corticosterone action 
Even though the complete removal of glucocorticoids from the brain is not yet confirmed, the 
model clearly shows hyporesponsiveness to activation of pituitary-adrenal secretion. Our 
findings show that rats treated with low-dose dexamethasone have a strongly reduced 
circadian rhythmicity of corticosterone plasma levels. Furthermore, they are hyporesponsive 
to stress-induced activation of pituitary-adrenal secretion. The reduced basal and stress-
induced corticosterone secretion in conjunction with the impaired access of dexamethasone to 
the brain under these conditions may make these rats useful as a model of impaired 
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glucocorticoid signalling in brain. As apoptosis is sensitive to very low residual levels of 
corticosterone (Conrad et al., 1997), the lack of apoptosis indicates that this model may 
provide a way of modulating glucocorticoid signalling in which brain function is less severely 
disturbed than after complete ADX. In conjunction with the activation of peripheral GR in this 
model, this may be especially advantageous when studying subtle GR-mediated actions of 
corticosterone action on brain function. 
For instance, involvement of GR in memory processes (Oitzl and De Kloet, 1992) or in neural 
plasticity, particularly of hippocampal neurons (McEwen, 1999; Duman, 2002) may be 
studied using this model. Other aspects of brain function that can be studied might be the 
effects of circadian rhythmicity of glucocorticoid levels on feeding behaviour (Castonguay, 
1991; Müller et al., 2000), motor activity and sleep (Bradbury et al., 1998; Born and Fehm, 
1998). 
Furthermore, this model may be helpful in studying processes in which the MR/GR balance is 
critically involved, e.g. homeostatic control of stress responsiveness, behavioural adaptation 
and cognition (De Kloet, 1991). Treatment with dexamethasone will, irrespective of the dose 
administered, always result in a reduced occupation of MR through suppression of 
endogenous glucocorticoids, as dexamethasone does not bind to MR in vivo. This may lead to 
shifts in the balance between MR- and GR-mediated effects. As both receptor types mediate 
distinct but co-ordinated actions on neuronal excitability, synaptic plasticity and learning and 
memory, these shifts in MR/GR balance may disturb brain function and may thus further 
impair the ability to maintain brain homeostasis.  
Balance of dexamethasone feedback and central drive 
HPA-axis activity is not only determined by the intensity of glucocorticoid feedback. 
Dexamethasone suppression of pituitary-adrenal activity might be, at least partly, surpassed by 
an increased central drive. This may explain the small stress-induced corticosterone response 
seen in animals treated with the lowest amounts of dexamethasone. It would further explain 
studies showing that removing the inhibitory hippocampal input either by hippocampectomy 
or fornix transection causes dexamethasone resistance (Feldman and Conforti, 1980; Sapolsky 
et al., 1991; Feldman and Weidenfeld, 1995). Furthermore, it is supported by the finding that 
depletion of hypothalamic norepinephrine and serotonin enhances the dexamethasone negative 
feedback effect on adrenocortical secretion (Feldman and Weidenfeld, 1991; 1995). The type 
or intensity of stressors may also influence the extent of dexamethasone suppression (Haracz 
et al., 1988; Lurie et al., 1989).  
 
Rats treated with 1 µg/ml dexamethasone through their drinking water do not show any stress-
induced corticosterone response whereas their central stress response at the level of the PVN 
was not reduced below those of intact animals, suggesting that in these animals 
dexamethasone feedback at the pituitary was strong enough to constrain the pituitary-adrenal 
activity. However, in these animals some dexamethasone may have entered the brain, as 
suggested by the unaltered CRH mRNA expression of the 1 µg/ml group in contrast to the 
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increased expression in the 0.5 µg/ml group. Receptor binding studies have indeed shown that 
doses which are slightly higher than those used in the present study (1-1.5 µg/ml), 
administered overnight through drinking water, very modestly reduces the available numbers 
of hippocampal GR in intact rats, while resulting in strongly reduced pituitary GR numbers 
(Spencer et al., 1990; Miller et al., 1990). Although both studies did not estimate the GR 
occupation in hypothalamus, these amounts may also slightly reduce available receptor 
numbers in this area. Thus, also in animals treated with 1 µg/ml dexamethasone through their 
drinking water the main site of action on the HPA-axis is the pituitary, but for full suppression 
of the stress-induced secretion of corticosterone some dexamethasone may need to act at the 
hypothalamic level.  
 
The low central corticoid state created by dexamethasone may even increase the stress 
responsivity of the paraventricular CRH/AVP-secreting neurons due to removal of 
glucocorticoid negative feedback to the PVN itself and to brain areas involved in activation of 
the PVN. Consequently, the central drive on the pituitary in response to stress might be 
augmented, which may override the dexamethasone-mediated inhibition of ACTH production 
and secretion. This phenomenon may be viewed as glucocorticoid feedback resistance 
although the apparent magnitude rather than the potency of feedback has been changed.   
Thus, the magnitude of the inhibitory effect of DEX on pituitary-adrenal secretion depends on 
the balance between the stimulatory action of hypothalamic secretagogues and the inhibitory 
action of DEX on the anterior pituitary. Differential excitatory influences of 
extrahypothalamic brain areas on the paraventricular neurons in the PVN may influence the 
neurochemical composition of the hypothalamic secretion, which subsequently may affect 
feedback efficacy of dexamethasone. This makes the presented model of central 
adrenalectomy less useful in conditions that will shift the balance towards increased central 
drive and decreased feedback efficacy of dexamethasone.  
Dexamethasone feedback in depression 
The reduced central glucocorticoid feedback after treatment with low-dose dexamethasone 
suggests that administration of small amounts of dexamethasone might be helpful in treatment 
of stress-related disorders. Depressed patients often show a state-dependent hyperactive 
central CRH-system (Raadsheer et al., 1994; Arborelius et al., 1999), which likely underlies 
their increased cortisol secretion during a 24hr period (Mitchell, 1998; Holsboer, 1999; Gold 
and Chrousos, 2002). This hypercortisolemia would conceivably be alleviated by a controlled 
low-dose dexamethasone treatment that leads to a graded lowering of central glucocorticoid 
levels. Dexamethasone has indeed been shown to have antidepressant properties (Arana et al., 
1995; Wolkowitz and Reus, 1999), although rather high doses were used in these studies. A 
recovery of a disturbed balance of the two corticosteroid receptor types after dexamethasone 
treatment may also underlie its therapeutic effect.  
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Pgp-mediated impaired uptake of dexamethasone and the ensuing central low-corticosteroid 
state may also provide a rationale for the dexamethasone suppression test (DST). This test is 
widely used in the clinic often in combination with a CRH challenge, to evaluate the 
dysregulation of the HPA-axis in depressive patients. After administration of a low dose of 
dexamethasone the night before, depressives consistently show escape from suppression of 
baseline or CRH-induced cortisol levels (Holsboer, 2000). An imbalance between the central 
drive and dexamethasone inhibition at the pituitary level may underlie the escape from 
dexamethasone suppression seen in the DST (Holsboer, 1999). The sustained hyperactive 
CRH-system of depressed patients may be accompanied with an increased release of AVP 
(Purba et al., 1996; Holsboer, 2000), which synergises with CRH at the corticotrophic cells to 
stimulate ACTH secretion. The increased AVP may result in an apparent glucocorticoid 
feedback resistance at the pituitary level, as AVP-stimulated ACTH-secretion is refractory to 
glucocorticoid feedback (Aguilera and Rabadan-Diehl, 2000). Consistent with a role of 
vasopressin in dexamethasone nonsuppression, coadministration of CRH and AVP to 
dexamethasone-pretreated healthy subjects results in a similar ACTH/cortisol response as in 
depressed patients (Von Bardeleben et al., 1985), while dexamethasone nonsuppression in 
hyperanxious rats is due to enhanced vasopressin activity (Keck et al., 2002). In depressed 
patients, the dexamethasone-induced reduction of central feedback may further aggravate the 
hyperactive central drive of CRH and particularly AVP leading to an escape from the 
suppressive effect of dexamethasone on cortisol plasma levels. The augmentation of CRH 
mRNA levels in the rat PVN after low-dose dexamethasone treatment as found in our study 
may be supportive to this interpretation.  
Glucocorticoid feedback impairment in depression  
Impaired dexamethasone feedback in major depression is often ascribed to disturbed central 
corticosteroid receptor signalling, particularly with regard to the GR (Holsboer and Barden, 
1996; Holsboer, 2000; Pariante and Miller, 2001). Supportive data of a key role of GR 
signalling in depression has been provided by animal studies. Transgenic mice with defective 
GR function show features that are, although only partially, reminiscent of depression 
(Holsboer and Barden, 1996; Müller et al., 2002), whereas different types of antidepressants 
increase GR mRNA and receptor levels (Peiffer et al., 1991; Przegaliñski and Budziszewska, 
1993). Disturbed glucocorticoid feedback may be the cause as well as the consequence of the 
central hyperdrive. It is difficult in a closed-loop system to ascertain whether the HPA-
disturbances in depression represent increased central drive or decreased sensitivity to 
negative feedback or both. Hypercortisolemia due to increased CRH/AVP drive may 
subsequently lead to corticosteroid receptor downregulation or dysfunction in brain. 
Alternatively, resistance to negative feedback through GR may cause a disinhibition of 
hypothalamic CRH neurons leading to hypercortisolemia. 
However, evidence of impaired central glucocorticoid feedback in depression is at present not 
conclusive. As stated above, the dexamethasone depression test does not assess central 
glucocorticoid feedback. Decreased hypothalamic GR levels in depressed patients have not 
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been described so far, and, if present, may merely reflect secondary downregulation due to 
hypercortisolemia as seen in rodent studies (Sapolsky et al., 1986; Pariante and Miller, 2001). 
In addition, neither GR polymorphism nor deficits in transcription factors or coregulators 
involved in glucocorticoid signalling, nor defects in glucocorticoid-driven promoters have 
been demonstrated to be linked to depressive symptomatology thus far. Furthermore, in 
response to a CRH challenge, depressives show a blunted ACTH response (Holsboer, 1999; 
Arborelius et al., 1999), which implies increased feedback due to increased cortisol levels. In 
support of this interpretation, CRH-stimulated ACTH output is normalised after treatment of 
depressed patients with cortisol synthesis inhibitors like metyrapone (Von Bardeleben et al., 
1988). 
On the other hand, healthy subjects at a genetic risk for depression more frequently show mild 
hypercortisolemia and abnormal DEX/CRH test responses than controls, suggesting that 
altered feedback inhibition may represent a genetic vulnerability factor to depression 
(Holsboer, 2000). It has to be verified however whether these high-risk probands will actually 
develop depression.  
The notion of impaired GR function in depression is furthermore questionable because of the 
effectiveness of the GR antagonist RU486 in raising cortisol plasma levels of patients with 
psychotic major depression (Belanoff et al., 2002), similar to its effects in healthy subjects 
(Bertagna et al., 1984; Gaillard et al., 1984). At least, it does not support impaired GR 
function in the PVN.  
Moreover, the effectiveness of RU486 in relieving psychotic and depressive symptoms in 
these patients may suggest that raised levels of cortisol perpetuate the depressive state through 
GR-mediated positive feedback actions in extrahypothalamic areas like e.g. amygdala (Gold 
and Chrousos, 2002). These facilitatory actions on afferent inputs to the PVN, may be 
outbalanced in these patients and may disproportionately activate or disinhibit the 
paraventricular CRH/AVP neurons overriding the normal glucocorticoid negative feedback 
(Makino et al., 2002). In concert with other imbalances of the stress system such as 
hyperactivation of CRH and noradrenergic systems, this vicious cycle may sustain depression 
at least in this set of depressed patients.  
It has been shown that activation of GR in the central nucleus of the amygdala increases rather 
than decreases CRH mRNA levels (Makino et al., 1994; Schulkin et al., 1998). The 
amygdaloid CRH system may have a stimulatory effect on the PVN (Van de Kar et al., 1991). 
Interestingly, a recent report showed that in ADX rats chronic intracerebroventricular infusion 
of corticosterone resulted in increased basal and stress-induced ACTH levels and a tendency 
for increased paraventricular CRH immunoreactivity (Laugero et al., 2002). Although, at 
present, no direct evidence mutually linking hypercortisolemia and amygdaloid CRH 
activation is available, a recent study showed that local implantation of corticosterone into the 
amygdala prolonged the corticosterone response to a behavioural stressor (Shepard et al., 
2003). Within the hippocampus high corticosterone levels acting through GR also appears to 
disinhibit the HPA-axis (Van Haarst et al., 1997). This suggests that under some conditions 
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glucocorticoids may indeed be able to activate rather than inhibit the HPA-axis. High-dose 
RU486 treatment may rapidly reset the balance in facilitatory and suppressive input to the 
PVN, although the mechanism is poorly understood at present. 
 
Although the emphasis of studies on involvement of corticosteroid receptors in depression has 
been put on the role of the GR, an increasing amount of evidence indicates that altered MR 
function may be of relevance as well (Reul et al., 2000b). Post-mortem examination of brains 
of suicide victims with a history of depression revealed a reduction of MR mRNA levels 
without alterations of GR mRNA levels (Lopez et al., 1998). Treatment with antidepressants 
may upregulate MR expression contributing to increased glucocorticoid negative feedback 
(Brady et al., 1991; Reul et al., 1993; Reul et al., 1994). The MR upregulation may precede 
both the antidepressant-induced upregulation of GR and the enhanced negative feedback on 
the HPA-axis (Seckl and Fink, 1992; Reul et al., 1993) and may thus make up the primary 
cause of restoring normal HPA-axis activity in major depression. The importance of 
appropriate MR function is further supported by a study showing that systemic administration 
of antimineralocorticoids impaired the therapeutic effect of the antidepressant amitryptiline 
(Holsboer, 1999). It was recently postulated that chronic stress might impair the normal CRH-
mediated stress-induced upregulation of hippocampal MR leading to a progressively 
deteriorating hippocampal inhibition of HPA-function resulting in a hyperactive HPA-axis 
(Reul and Holsboer, 2002).  
 
Taken together, impaired function of GR and especially MR signalling pathways may play a 
role in the aetiology and pathophysiology of depression. A change in the balance of MR- and 
GR-mediated actions may underlie the progressive reset of the HPA activity in depressive 
disorder (De Kloet et al., 1998), whereas antidepressants may restore HPA-axis activity 
through facilitation of MR function and/or upregulation of MR levels, with subsequent 
beneficial effects on GR function and/or levels. Modulation of corticosteroid transport at the 
BBB by Pgp may be a novel strategy to find new treatments of stress-related disorders.  
Antidepressants, glucocorticoid feedback and Pgp 
An intriguing alternative mechanism of action of antidepressants involving Pgp was recently 
postulated by Pariante et al. (2001) based on in vitro findings. They showed that coincubation 
of dexamethasone or cortisol at low non-saturating concentrations with various 
antidepressants resulted in enhanced GR function without increased GR levels in L929 
fibroblast cells. Coincubation with dexamethasone in presence of a Pgp inhibitor or with 
corticosterone does not lead to a facilitation of GR function, suggesting involvement of 
transport mediated by a steroid membrane transporter like Pgp. Recently, it was indeed 
confirmed that this transporter shows a similar steroid transport profile as Pgp, and RT-PCR 
demonstrated presence of both mdr1a and mdr1b mRNA (Webster and Carlstedt-Duke, 2002).   
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This may imply that antidepressants may inhibit the function of Pgp at the BBB, thus 
increasing uptake of cortisol into the brain and enhancing GR-mediated negative feedback on 
the HPA-axis, decreasing HPA-axis hyperactivity in depression. Acute facilitation of GR 
function may precede upregulation of GR levels, implying that GR upregulation may be the 
consequence of facilitated GR function rather than the cause (Pariante and Miller, 2001). 
However, as stated before, upregulation of MR preceding GR upregulation may also make up 
the primary cause of restoring normal HPA-axis activity in major depression.  
Effectiveness of other glucocorticoids 
The reduced central glucocorticoid feedback after treatment with low-dose dexamethasone 
raises the question whether treatment with low doses of other glucocorticoids may result in a 
similar reduction of total brain glucocorticoid levels. Glucocorticoids like prednisolone and 
hydrocortisone (=cortisol) are Pgp substrates and are able to activate GR as well. Like 
dexamethasone they might be able to suppress the pituitary-adrenal secretion predominantly at 
the pituitary level, while they would simultaneously be hampered to enter the brain leading to 
a low central corticosteroid state. However, there are clear pharmacochemical, 
pharmacokinetic and pharmacodynamic differences among these three glucocorticoids, which 
likely interfere with their ability to create a central ADX-like condition. Clear differences in 
potency to inhibit HPA-axis activity are caused by differences in relative corticosteroid 
receptor affinities, differences in binding to CBG and differences in metabolism affecting 
plasma and biological half-life.  
The plasma half-life of glucocorticoids is much shorter than the duration of their biological 
actions, but for both pharmacological parameters glucocorticoids are arranged in the same 
order. The biological half-life of hydrocortisone is 8-12 hr, whereas the presence of an 
additional double bond (prednisolone and dexamethasone) or a fluorine atom (dexamethasone) 
enlarges the plasma half-life and consequently the biological half-life to 12-36 hr 
(prednisolone) or even 48 hr (dexamethasone) (Jusko and Ludwig, 1992).   
Both dexamethasone and prednisolone bind with very high affinity to the GR (<1nM). 
Hydrocortisone, like corticosterone, binds with very high affinity to the MR (<1nM), whereas 
it has a 4-10 fold lower affinity to GR. Although dexamethasone has some affinity to the MR 
in vitro, it does not exert any agonistic actions via MR in vivo (De Kloet, 1991). Limited 
access to the MR can not fully explain this discrepancy as Pgp is not likely to protect renal 
MR and dexamethasone is not a substrate for renal 11ß-HSD type 2 (Reul et al., 2000b). The 
instability of dexamethasone-MR complexes due to an extremely high dissociation rate of 
dexamethasone may explain its inability to activate MR in vivo (Reul et al., 2000b). Whether 
this phenomenon also applies to prednisolone is not known, but, anyhow, its mineralocorticoid 
potency is less than that of cortisol.  
Plasma protein binding and particularly binding to CBG interferes with biological activity, as 
only non-CBG-bound fraction is available for distribution to receptor sites (Pardridge, 1981; 
Breuner and Orchinik, 2002). Both hydrocortisone and prednisolone, but not dexamethasone, 
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bind to CBG. The degree of plasma protein binding of prednisolone is dose-dependent due to 
the low capacity of CBG (Jusko and Ludwig, 1992). Displacement of cortisol by prednisolone 
due to competition increases the unbound, freely available plasma levels of cortisol (Pugeat et 
al., 1981). All three steroids may suppress hepatic CBG production, which may increase free 
cortisol levels, but dexamethasone is much more potent than prednisolone and hydrocortisone 
(Smith and Hammond, 1992). Of particular importance is the intracellular presence of CBG in 
corticotroph cells of the anterior pituitary (De Kloet et al., 1984b). Here, CBG may sequester 
prednisolone and hydrocortisone limiting their accessibility to the pituitary GR.  
Taken together, the properties of dexamethasone likely make this hormone the most 
favourable glucocorticoid in creating a low corticoid condition in the brain. In addition to its 
ability to be transported by Pgp, its high affinity for the GR combined with its lack of plasma 
and pituitary CBG binding and its long duration of biological activity favours its potency in 
acting at the anterior pituitary to inhibit pituitary-adrenal secretion. Due to CBG binding and 
lower affinity to GR much higher doses (30-70x) of prednisolone and hydrocortisone are 
needed to suppress the HPA-axis to a similar extent (Baumann et al., 1985; Gispen-de Wied et 
al., 1993). The use of these high doses makes it likely that some steroid will enter the brain, 
which in case of hydrocortisone may easily activate MR.  
Concluding remarks and perspectives 
In conclusion, the findings of the studies described in this thesis have made evident the 
importance of corticosteroid transport at the BBB in controlling corticosteroid access to the 
brain. The efflux transporter Pgp may play a crucial role as an intermediate between brain and 
periphery by controlling transport of corticosteroids at the BBB. Pgp is able to hamper 
penetration of various corticosteroids into the brain, particularly when these hormones are 
circulating at low plasma levels. Impaired uptake of synthetic glucocorticoids such as 
dexamethasone and prednisolone, but also of the naturally occurring glucocorticoid cortisol, 
likely results in a reduced occupation of central corticosteroid receptors and thus in a 
diminished response to these glucocorticoids.  
Intriguingly, both mouse and human Pgp do not transport corticosterone in contrast to cortisol, 
which may underlie the increased ratio of corticosterone over cortisol in post-mortem human 
brain samples compared to plasma. Future investigations will reveal whether corticosterone 
rather than cortisol may be the major endogenous corticosteroid in mediating corticosteroid 
actions, particularly via MR, on human brain function, as suggested by the preferential uptake 
of corticosterone into human brain.  
The brain-selective low corticosteroid state created by administration of low-dose 
dexamethasone to rats might be used as an animal model to specifically study central roles of 
corticosterone without the potentially confounding effects of reduced peripheral 
glucocorticoid effects.  
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At the BBB several other efflux transporters are expressed besides Pgp. For instance, several 
members of the multidrug resistance-associated proteins (MRP) have been detected at the 
brain capillaries (Sun et al., 2003). Whether any of these or any yet unknown transporter may 
also transport corticosteroids remains to be resolved. Recently, it was demonstrated that 
MRP1 is able to transport corticosterone and deoxycorticosterone (Webster and Carlstedt-
Duke, 2002), but the presence of MRP1 at the BBB remains controversial (Taylor, 2002; Sun 
et al., 2003). Furthermore, steroid membrane transporters might be present at neuronal cells as 
well, affecting uptake of glucocorticoids directly at the neuronal membrane (Herr et al., 2000; 
Pariante et al., 2003). 
 
Modulation of Pgp-mediated transport of corticosteroids may influence central glucocorticoid 
actions, as exemplified by the inhibition of corticosteroid transport by antidepressants 
(Pariante et al., 2001). Altered uptake of glucocorticoids may reset MR/GR balance and thus 
HPA-axis activity. Therefore, Pgp may provide an interesting new target to regulate 
glucocorticoid feedback to the brain in disorders with disturbed central glucocorticoid 
signalling such as major depression and post-traumatic stress disorder, and possibly also 
chronic fatigue syndrome and fibromyalgia.  
 
Pgp plays a key role in protection against a wide variety of drugs including anticancer and 
antiepileptic drugs and HIV protease inhibitors. These drugs may influence transport of 
endogenous substrates including corticosteroid hormones but also centrally and peripherally 
acting compounds (King et al., 2001; Lam et al., 2001). Particularly, inhibitors of Pgp 
transport may interfere with physiological Pgp function. Some steroids (progesterone, RU486) 
may inhibit Pgp function (Gruol and Bourgeois, 1994). As Pgp impairs the efficacy of 
treatment of (brain) cancer, much effort has been put in finding reversal agents to bypass Pgp 
by inhibiting its transport function. Although some of these Pgp modulators are now in clinical 
trials, the clinical efficacy remains to be established particularly with regard to their potential 
side effects (Van Zuylen et al., 2000). Inhibition of Pgp may have undesired side effects by 
increasing the uptake of cortisol into the brain potentially endangering neuronal survival. 
 
Polymorphisms in the MDR1 gene resulting in altered levels and functionality of Pgp have 
been shown to affect efficiency of this transporter (Hoffmeyer et al., 2000). Regulation of 
expression and post-translational modification of Pgp presumably also affect Pgp efflux 
transport function. Various stimuli that evoke cellular stress responses have been shown to 
affect Pgp expression (Johnstone et al., 2000; Sukhai and Piquette, 2000). However, with 
regard to BBB Pgp, little is known about these features. Epileptic insults have been shown to 
induce Pgp expression in the epileptic lesions in both capillaries and glial cells (Sisodiya et al., 
1999; Rizzi et al., 2002; Seegers et al., 2002b). Whether stress-related disorders have any 
effect on Pgp expression is not yet known. Much work should be done to resolve when and 
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how Pgp operates as a dynamic regulator of the central access of Pgp-substrates including 
glucocorticoids.  
In addition, it should be found out whether corticosteroids can directly affect Pgp 
functionality. Preliminary data suggest that glucocorticoids might be able to increase Pgp 
expression at the BBB (Sérée et al., 1998; Aquilante et al., 2000). This would not only affect 
glucocorticoid access to the brain but also access of other Pgp substrates.  
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The actions of glucocorticoid hormones are essential for healthy functioning of brain and 
body, particularly during stress. Secretion of these hormones by the adrenals is tightly 
controlled through the Hypothalamus-Pituitary-Adrenal-axis (HPA-axis). Activity of the 
HPA-axis follows a circadian rhythm with highest plasma glucocorticoid levels just prior to 
awakening. Furthermore, secretion of glucocorticoids is stimulated after stress. This stress 
response plays an important role in the adaptation to a changing environment.  
Glucocorticoids affect a wide range of processes in both periphery and brain. They regulate 
storage and mobilisation of energy, affect immune and inflammatory responses and act on 
diverse endocrine systems including the HPA-axis. Their effects in the central nervous system 
are particularly potent. Within the brain they modulate synaptic plasticity and regulate 
neuronal function, which likely underlie their effects on behavioural adaptation to stress, 
learning and memory processes and mood.  
Glucocorticoids mainly exert their actions through genomic mechanisms altering gene 
expression. The genomic actions are mediated by two types of receptors, the high affinity 
mineralocorticoid receptors (MR) and the lower affinity glucocorticoid receptors (GR). In the 
periphery glucocorticoid actions are mostly mediated by GR, which is abundantly expressed in 
almost any cell in the body. Within the brain both types of corticosteroid receptors are present 
although with a different localisation pattern. MR and GR mediate different but partly 
overlapping aspects of central glucocorticoid action. 
 
To reach their central target areas glucocorticoid hormones have to enter the brain by passing 
the blood-brain barrier (BBB). The BBB is a dynamic physical and metabolic barrier 
consisting of specialised endothelial cells that protects the brain from blood-borne compounds, 
and plays a role in maintaining brain homeostasis. The BBB can strongly interfere with 
distribution to the brain of endogenous and exogenous compounds. Generally, hydrophilic and 
large lipophilic compounds are not able to penetrate the brain, as they are not able to pass cell 
membranes, whereas small lipophilic compounds can easily cross the BBB by passive 
diffusion through the endothelial cells. However, for a number of highly lipophilic compounds 
including the synthetic glucocorticoid dexamethasone BBB permeability is unexpectedly low. 
The multidrug transporter P-glycoprotein (Pgp) is an important functional component of the 
BBB and various other tissues with a barrier function. It acts like a ‘gatekeeper’ at the BBB 
actively keeping a wide variety of lipophilic, potentially neurotoxic substances out of the 
brain. This transmembrane protein is encoded by the multidrug resistance (MDR) genes, 
mdr1a in rodents and the highly homologous MDR1 in humans. Studies using mdr1a (-/-) 
knockout mice which lack functional Pgp at the BBB, have shown that this efflux transporter 
is responsible for the apparent low permeation of dexamethasone and a wide range of other 
compounds that should easily penetrate the BBB as expected based on their size and their 
sufficient high lipid solubility.  
Although the importance of the actions of glucocorticoids in brain is commonly accepted, 
modulation of glucocorticoid access at the BBB level has hardly been a subject of research as 
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these compounds are considered to readily pass this barrier. Now that it has been demonstrated 
that transmembrane proteins are able to transport these hormones, this issue becomes an 
increasingly interesting subject to study. Any process at the BBB that can influence the 
endothelial crossing of glucocorticoids would directly affect central corticosteroid receptor 
occupancy and the magnitude of the central response to corticosteroids.  
 
The aim of the studies described in this thesis was to examine the interaction of 
glucocorticoids and the efflux transporter P-glycoprotein expressed at the BBB as a possibly 
new level at which access to the brain and thus central corticosteroid receptor function may be 
controlled. Modulation of access of glucocorticoids to the brain may provide a new way to 
restore aberrant corticosteroid signalling associated with hypercortisolemia, glucocorticoid 
feedback resistance or MR/GR imbalance.  
 
In chapter 2, findings regarding the expression of Pgp in the brain at the level of mRNA are 
presented. In situ hybridisation with a riboprobe recognising both murine mdr1 genes (mdr1a 
and mdr1b) demonstrates presence of mRNA in the endothelial cells of brain capillaries 
throughout the rat brain confirming presence of Pgp at the BBB. Surprisingly, expression of 
mdr1 mRNA was also found in granule cells of the dentate gyrus, a subfield of the 
hippocampus highly expressing both MR and GR. Its function at this site has yet to be 
resolved. 
 
In chapters 3 and 4, the interactions of various naturally occurring glucocorticoids and 
synthetic glucocorticoids with Pgp are described particularly with regard to the uptake of these 
hormones into the brain. The hypothesis that endogenous glucocorticoids would easily reach 
the central glucocorticoid target areas, whereas Pgp would protect the brain against exogenous 
synthetic glucocorticoids, was rejected.  
Autoradiographic studies in adrenalectomised mice with a disrupted mdr1a gene confirmed 
that the synthetic glucocorticoid prednisolone like dexamethasone is hampered to enter the 
mouse brain and to reach glucocorticoid receptors. Presence of Pgp did not affect the uptake 
of the endogenous rodent glucocorticoid corticosterone into mouse brain. In sharp contrast to 
corticosterone, the main human glucocorticoid hormone cortisol was hampered to enter the 
brain of mice expressing Pgp at the BBB, but not of mice lacking Pgp.  
Although the absence of cortisol in the normal physiology of the mouse might explain this 
differential interaction with mouse Pgp, the remarkable difference between the cortisol and 
corticosterone transport capability of Pgp was also demonstrated for human Pgp using an in 
vitro model. Pig kidney epithelial cells form monolayers when seeded on filters and when 
stably transfected with human Pgp MDR1 cDNA these monolayers express high levels of Pgp 
at their apical side. Polar translocation of Pgp substrates to the apical side of these monolayers 
is reminiscent of Pgp function at the human BBB. Human Pgp-mediated polar transport of 
cortisol, prednisolone and dexamethasone, but also of the naturally occurring corticosteroids 
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cortisone, 11-deoxycortisol and, although to a lesser extent, aldosterone was demonstrated 
with these monolayers. Inhibition of transport by a selective Pgp blocker confirmed 
involvement of Pgp. In contrast, Pgp did not transport corticosterone in this system.  
To further corroborate the differential uptake of corticosterone and cortisol in human brain as 
suggested by the mouse and monolayer findings, cortisol and corticosterone levels were 
measured in extracts of human post-mortem brain samples and plasma using liquid 
chromatography-mass spectrometry (LC-MS) to determine the ratio of corticosterone over 
cortisol (chapter 3). In contrast to rodents, both cortisol and corticosterone are circulating in 
human plasma, although corticosterone is present at ten- to twentyfold lower levels than 
cortisol. While in human plasma corticosterone concentrations are only 5% of cortisol levels, 
in the brain corticosterone levels are 30% of those of cortisol as determined using LC-MS.  
Thus, in contrast to corticosterone, which readily enters rodent and human brain, 
cortisol, the main endogenous glucocorticoid in human, appears to be partially 
excluded from rodent and human brain.  
 
The differential uptake of corticosterone and cortisol may have important implications for 
glucocorticoid feedback to human brain. The LC-MS data suggest that cortisol levels in 
human brain are 6 times lower than those in human blood. The total glucocorticoid levels in 
human brain may thus be lower than assumed based upon plasma levels.  
Furthermore, the preferential uptake of corticosterone in human brain suggests that this 
endogenous glucocorticoid may play a more prominent role in human brain function than 
hitherto recognised. Due to the differential uptake of cortisol and corticosterone, the human 
glucocorticoid feedback system might be more complex than the rodent system. Whether this 
is actually the case remains to be resolved, but literature data indicate that corticosterone may 
be the more effective glucocorticoid at the human MR, suggesting that corticosterone might 
have a potentially different role than cortisol in brain.  
 
In chapter 5 the data showing the functional consequences of Pgp-mediated exclusion of 
dexamethasone from the brain on central gene expression are presented. It was hypothesised 
that glucocorticoid feedback to the brain would be reduced as a consequence of depletion of 
glucocorticoids from the brain induced by treatment with low-dose dexamethasone. 
Dexamethasone acting at the level of the pituitary potently suppresses corticosterone 
secretion. As dexamethasone poorly enters the brain due to the presence of Pgp at the BBB, 
administration of low amounts of dexamethasone depletes the brain from endogenous 
glucocorticoids, for which dexamethasone does not appropriately substitute. Peripherally, 
dexamethasone replaces corticosterone at the GR. The resulting condition is a brain-selective 
hypocorticoid state.  
To confirm the working hypothesis, dexamethasone was chronically administered to rats for 6 
days or three weeks. As expected, dexamethasone circulating at low concentrations did not 
feed back at several glucocorticoid responsive genes expressed in the hypothalamic 
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paraventricular nucleus (PVN). Stress-induced responses of c-fos mRNA and CRH hnRNA 
were not reduced, whereas CRH mRNA expression was even increased after three weeks of 
treatment. After high-dose treatment dexamethasone turned out to be able to enter the brain in 
sufficient amounts to activate GR. Expression of glucocorticoid responsive genes was strongly 
reduced indicating that the barrier formed by Pgp is not able to completely exclude 
dexamethasone from entering the brain. In contrast, various peripheral glucocorticoid targets 
were strongly affected by dexamethasone independent of the amount administered.  
After low-dose treatment, dexamethasone-induced effects on brain function should 
probably be ascribed to decreased rather than increased central glucocorticoid 
action. 
 
Other glucocorticoids that are substrates of Pgp are less likely to create this central 
adrenalectomy-like condition, as the high affinity to GR, lack of plasma binding and long-
lasting activity favours the potency of dexamethasone to completely inhibit pituitary-adrenal 
secretion at low plasma levels. To suppress pituitary-adrenal secretion to the same extent high 
doses of cortisol (about 70-fold those of dexamethasone) are needed, which will likely reach 
the brain as well activating both MR and GR.  
 
In conclusion, the findings presented in this thesis have made clear the importance of 
glucocorticoid transport at the BBB in controlling glucocorticoid access to the brain. The data 
show that Pgp is able to hamper penetration of various corticosteroids into the brain, 
particularly when these hormones are circulating at low plasma levels. Efflux transporters like 
Pgp may play a crucial role as an intermediate between brain and periphery by controlling 
transport of corticosteroids at the BBB. As exemplified by the dexamethasone study, impaired 
uptake of synthetic glucocorticoids, but also of the naturally occurring glucocorticoid cortisol, 
likely results in a reduced occupation of central corticosteroid receptors and thus in a 
diminished response to these glucocorticoids.  
Intriguingly, both mouse and human Pgp do not transport corticosterone in contrast to cortisol. 
Future investigations will reveal whether corticosterone rather than cortisol may be the major 
endogenous corticosteroid in mediating corticosteroid actions, particularly via MR, on human 
brain function, as suggested by the preferential uptake of endogenous corticosterone into 
human brain.  
The brain-selective low-corticosteroid state created by administration of low-dose 
dexamethasone to rats might be used as an animal model to specifically study central roles of 
corticosterone without the potentially confounding effects of reduced peripheral 
glucocorticoid effects. 
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Stress en glucocorticoïden  
Stress-gerelateerde ziekten zoals depressie gaan vaak samen met overmatige secretie van 
glucocorticoïd hormonen zoals cortisol. Veel symptomen van deze ziekten zijn inderdaad te 
wijten aan deze ‘stresshormonen’, maar dat betekent niet dat glucocorticoïden altijd schadelijk 
zijn. Zij spelen juist een onmisbare rol in de normale fysiologie van mens en dier en met name 
in de respons op stress.  
Het begrip ‘stress’ zoals gebruikt in dit proefschrift houdt meer in dan alleen negatieve 
aspecten. Elke verandering in het lichaam of in de omgeving die de bestaande 
evenwichtssituatie (homeostasis) bedreigt leidt tot een stressreactie. Stress activeert het brein 
en dit leidt via stimulatie van de Hypothalamus-Hypofyse-Bijnier-as (HHB-as) tot een 
verhoging van de concentraties van glucocorticoïden in het bloed (zie figuur 2, hoofdstuk 1). 
In muizen en ratten is dit corticosteron, in de mens is dit zowel cortisol als corticosteron. 
Naast effecten in vele perifere organen, hebben deze corticosteroïd hormonen ook weer 
effecten in de hersenen. In de hersenen beïnvloeden ze genexpressie, moduleren ze het 
functioneren van neuronen en brengen ze veranderingen in gedrag en geheugen teweeg.  
Zonder deze hormonen kunnen mens en dier zich niet staande houden in een omgeving die 
continu verandert. 
 
De werking van glucocorticoïden wordt strikt gereguleerd. Niet alleen door de vele 
hersengebieden die de activiteit van de HHB-as reguleren, maar ook op andere niveaus. Via 
negatieve terugkoppeling op de hersenen en de hypofyse onderdrukken glucocorticoïden hun 
eigen secretie. Een niveau van regulatie dat tot nu toe weinig aandacht heeft gekregen, is de 
regulering van de toegang van glucocorticoïd hormonen tot de hersenen. Om de receptoren in 
de hersenen, via welke het signaal wordt doorgegeven, te bereiken, moeten glucocorticoïden 
de bloed-hersen-barrière (BHB) passeren. Deze barrière schermt de hersenen af van mogelijk 
schadelijke invloeden van buitenaf. Gezien hun krachtige effecten op de hersenen, kan 
regulatie van de toegang van glucocorticoïden tot het centraal zenuwstelsel wel eens van grote 
invloed zijn op de werking van de hersenen.  
 
Lipofiele stoffen zoals corticosteroïd hormonen zouden in principe de BHB moeiteloos 
moeten kunnen passeren. Echter, aan de bloedkant van deze barrière bevindt zich 
P-glycoproteïne, een transporteiwit dat allerlei heel verschillende lipofiele stoffen (waaronder 
veel medicijnen zoals cytostatica en anti-epileptica) tegenhoudt. Het belemmert ook de 
opname van het synthetisch glucocorticoïd dexamethason in het brein.  
Doel onderzoek 
Het doel van de studies beschreven in dit proefschrift was uit te zoeken wat de rol van de 
efflux transporter P-glycoproteïne (Pgp) is in het reguleren van de toegang van endogene en 
synthetische glucocorticoïden tot de hersenen. De verwachting was dat met name synthetische 
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glucocorticoïden uit de hersenen geweerd zouden worden, terwijl natuurlijke hormonen de 
BHB gemakkelijker zouden passeren.   
Expressie P-glycoproteïne  
In hoofdstuk 2 worden experimenten beschreven waarbij gekeken is naar de expressie van het 
Pgp in de hersenen. De aanwezigheid van mRNA van het gen dat codeert voor het Pgp 
(mdr1a) werd aangetoond in de endotheelcellen die de BHB vormen. Ook op eiwitniveau 
werd de aanwezigheid van Pgp in deze cellen bevestigd. Verbazingwekkend was dat mRNA 
ook aangetroffen werd in neuronale cellen van de gyrus dentatus, een subgebied van de 
hippocampus. Deze hersenstructuur speelt een belangrijke rol bij leren en geheugenprocessen 
en is ook erg gevoelig voor glucocorticoïden. Het is nog niet duidelijk wat de rol van het Pgp 
in dit hersengebied is.  
Opname glucocorticoïden  
In experimenten beschreven in de hoofdstukken 3 en 4 is gekeken naar de opname van 
verschillende glucocorticoïden in de hersenen. Hierbij zijn gewone muizen en knock-out 
muizen die, doordat het mdr1a gen is uitgeschakeld, de efflux transporter Pgp missen, 
gebruikt. Deze dieren zijn geïnjecteerd met radioactief gelabelde glucocorticoïd hormonen. Na 
een uur zijn de dieren gedood en de hersenen en andere organen, waarin de radioactiviteit is 
opgenomen, verwijderd. Met autoradiografie waarbij gevoelige films werden blootgesteld aan 
de radioactieve straling in de coupes van de hersenen werden verschillen in de opname van 
radioactiviteit in de hersenen van beide typen muizen bekeken. Radioactiviteit werd ook 
gemeten in homogenaten van de kleine hersenen, andere organen en bloedplasma.  
Deze experimenten lieten zien dat het synthetische hormoon prednisolon, net als 
dexamethason, moeizaam het brein binnendringt door de aanwezigheid van het Pgp op de 
BHB. In de hersenen van gewone muizen was minder radioactiviteit aanwezig dan in hersenen 
van muizen die het Pgp missen. In andere organen en plasma werd geen verschil gevonden.  
Verschil in hersenopname van cortisol en corticosteron 
Verrassend was het grote verschil tussen de opname van het muiseigen hormoon corticosteron 
en het natuurlijke menselijke hormoon cortisol. Opname van cortisol wordt bemoeilijkt door 
het Pgp, maar corticosteron komt gemakkelijk het brein in.  
Beide hormonen lijken erg op elkaar qua molecuulstructuur en affiniteit voor de twee 
verschillende typen corticosteroïd receptoren en grote verschillen in welk opzicht ook zijn niet 
eerder gerapporteerd. Kleine verschillen zijn er echter wel, maar daar is nooit aandacht aan 
besteed. Corticosteron komt ook voor in de mens, zij het in veel lagere bloedconcentraties dan 
cortisol. Gezien hun zeer vergelijkbare eigenschappen wordt altijd aangenomen dat 
corticosteron nauwelijks een eigen rol - naast cortisol - speelt in de mens. Het door ons in 
muizen gevonden verschil wijst echter op een mogelijk verschil in toegang tot de menselijke 
hersenen van beide hormonen. Om uit te zoeken of het verschil in interactie met het Pgp de 
opname van cortisol in het menselijke brein bemoeilijkt terwijl het geen effect heeft op de 
corticosteronopname, zijn twee lijnen van onderzoek gevolgd.  
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Eerst is vastgesteld of het humane Pgp hetzelfde verschil in transport laat zien.  
Varkensniercellen die getransfecteerd waren met MDR1 cDNA coderend voor het humane 
Pgp werden gebruikt om het transport van glucocorticoïden door het humane Pgp te 
bestuderen. Monolayers van deze cellen transporteren Pgp-substraten van het onderste 
compartiment naar het bovenste (zie figuur 10, hoofdstuk1) en zijn een geschikt model voor 
de humane BHB. Deze monolayers en die van niet-getransfecteerde cellen werden gebruikt 
om transport van radioactief gelabelde corticosteroïd hormonen te bestuderen. Uit deze in 
vitro proeven bleek dat ook het humane eiwit niet in staat is corticosteron te transporteren 
maar wel cortisol en ook dexamethason en prednisolon. Er is dus geen verschil in 
substraatspecificiteit tussen het humane en het muizen-Pgp. 
Dit opmerkelijke verschil suggereert dat corticosteron makkelijker in de humane hersenen kan 
worden opgenomen dan cortisol. Deze suggestie wordt verder onderbouwd door resultaten van 
de corticosteroïd-bepalingen in humane postmortem hersenmonsters en plasmamonsters. Met 
behulp van vloeistof-chromatografie/massa-spectrometrie werd vastgesteld dat de 
corticosteron/cortisol ratio in de hersenen zesmaal hoger is dan in het plasma. Er is dus, 
vergeleken met cortisol, relatief meer corticosteron aanwezig in het brein dan in het plasma. 
Dit wijst erop dat corticosteron inderdaad makkelijker het humane brein binnendringt dan 
cortisol. 
Deze preferentiële opname van corticosteron in de hersenen vergeleken met cortisol 
suggereert dat corticosteron een belangrijker rol kan spelen in de menselijke hersenen dan 
totnogtoe aangenomen. In hoeverre dit ook echt consequenties heeft, zal verder onderzoek 
moeten uitwijzen.  
Dexamethason effect op de hersenen 
Een mogelijk gevolg van de aanwezigheid van Pgp op de BHB zou kunnen zijn dat cortisol, 
maar ook synthetische glucocorticoïden als dexamethason en prednisolon, minder sterke 
effecten hebben in het brein dan in de rest van het lichaam. Dit werd verder onderzocht in 
experimenten waarin ratten behandeld werden met lage doses dexamethason (hoofdstuk 5).  
Door de werking van het Pgp zullen lage concentraties dexamethason nauwelijks in het brein 
worden opgenomen en dus nauwelijks een direct effect hebben op het functioneren van de 
hersenen via de daar aanwezige receptoren. Als krachtig glucocorticoïd zal dexamethason 
onder deze omstandigheden echter wel sterke effecten hebben op perifere organen en 
bijvoorbeeld leiden tot een verkleining van de thymus en een afname van het lichaamgewicht.  
In ratten die gedurende drie weken met lage doses dexamethason behandeld werden, waren 
glucocorticoïd effecten in de hersenen inderdaad zwak vergeleken met effecten in de periferie. 
Na behandeling met hoge doses dexamethason werden wel duidelijke directe effecten in de 
hersenen gevonden, wat erop wijst dat bij deze hoge doses dexamethasone in voldoende mate 
het brein binnendringt om daar de receptoren te bezetten. Deze resultaten bevestigen dat 
effecten van dexamethason, mits de dosis niet te hoog is, minder sterk zijn in het brein dan 
daarbuiten. 
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Een zeer interessant bijkomend gevolg van deze behandeling met lage doses dexamethason is 
dat de lage concentraties effectief genoeg om de endogene corticosteron-secretie te 
onderdrukken door de remmende invloed van dexamethason op de HHB-as op het niveau van 
de hypofyse, die buiten de BHB ligt (zie figuur 9, hoofdstuk 1). Dit leidt dit tot een hersen-
selectieve depletie van glucocorticoïden, waarbij in de hersenen zowel corticosteron als 
dexamethason concentraties laag zijn. Deze verlaging van glucocorticoïd concentraties leidt 
tot een vermindering van de effecten van glucocorticoïden in de hersenen. In de periferie 
buiten de BHB daarentegen neemt dexamethason de glucocorticoïd werking van corticosteron 
over. Inderdaad waren, in de ratten die langdurig met lage doses dexamethason behandeld 
waren, sommige effecten op genexpressie in de hersenen vergelijkbaar met effecten van het 
verwijderen van corticosteron door de bijnier weg te nemen (adrenalectomie). Het gevolg van 
de behandeling met lage doses van het sterke glucocorticoïd dexamethason leidt dus, door de 
activiteit van het Pgp op de BHB, tot een paradoxale vermindering van de werking van 
glucocorticoïden in de hersenen. 
Conclusies 
De belangrijkste conclusie die uit de studies zoals beschreven in dit proefschrift getrokken kan 
worden is de efflux transporters P-glycoproteïne op de bloed-hersen-barrière een cruciale rol 
kan spelen als intermediair tussen de hersenen en de rest van het lichaam door de opname van 
glucocorticoïden in de hersenen te belemmeren. Niet alleen synthetische glucocorticoïden 
maar ook het natuurlijke hormoon cortisol komen moeizaam het brein binnen doordat Pgp 
deze hormonen uit het brein weert. Het verschil in opname van cortisol en corticosteron 
suggereert dat het glucocorticoïd systeem van mensen complexer is dan totnogtoe 
aangenomen. Corticosteron, het hormoon waar eigenlijk in humaan onderzoek nooit aandacht 
aan besteed is, kan in de mens naast cortisol wel eens een belangrijke rol spelen in het 
doorgeven van glucocorticoïd signalen naar de hersenen.  
Van grote praktische betekenis is verder dat blootstelling van de hersenen aan overmaat 
cortisol mogelijk beperkt kan worden door behandeling met lage doseringen dexamethason. 
Dit kan leiden tot een nieuwe aanpak van stress-gerelateerde ziekten die gekenmerkt worden 
door verhoogde cortisol secretie, zoals depressie.  
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Abstract 
Psychotic depression is characterised by a high rate of hypercortisolemia. The glucocorticoid 
receptor (GR) antagonist C-1073 (mifepristone or RU486) has recently been demonstrated to 
rapidly relieve patients of both psychotic and depressive symptoms. We hypothesise that 
C-1073 blocks excess cortisol action at the GR level in brain regions involved in cognitive and 
emotional processing. As only very high doses are effective, the question arises whether 
effective blockade of central GR by C-1073 may be impeded by hampered penetration of 
C-1073 into the brain. Alternatively, since C-1073 is known to inhibit the blood-brain-barrier 
transporter P-glycoprotein (Pgp) that transports cortisol, C-1073 may facilitate uptake of 
cortisol into the brain counteracting its own antagonistic action.  
To determine whether C-1073 itself is hampered to enter the brain, Liquid Chromatography-
Mass Spectrometry-Mass Spectrometry steroid profiles were made of brain and plasma 
extracts of rats treated with high doses for several days. Our results show that concentrations 
of the various compounds were similar in brain and plasma both at one hour and at three hour 
after the last administration. Clearance of circulating C-1073 and metabolites was very rapid. 
Levels were very high at one hour but considerably lower at three hours after the last 
administration. 
To investigate whether C-1073 and/or its metabolites are able to inhibit cortisol transport 
mediated by Pgp, we have used monolayers of epithelial cells stably expressing human Pgp.  
Our data show that 10 µM C-1073 alone blocked Pgp-mediated cortisol transport. A mix of 
C-1073 and its three main metabolites at therapeutically relevant concentrations also inhibited 
transport of cortisol.  
In conclusion, penetration of C-1073 and metabolites into the rat brain may not be impaired. 
Central action of C-1073 (and metabolites) may be impeded by rapid clearance and inhibition 
of Pgp-mediated cortisol-efflux. The latter might result in an increased retention of cortisol in 
brain on top of the C-1073-induced disinhibition of cortisol secretion, requiring higher C-1073 
concentrations in brain to overcome the agonistic cortisol action. Additionally, it may result in 
increased activation of the central mineralocorticoid receptor. The resultant enhanced shift of 
the MR/GR balance may reset cognitive and neuroendocrine systems.  
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Introduction 
Disturbances of cognitive, emotional and neuroendocrine functions in affective disorders are 
frequently associated with hypercortisolemia. Since it is hypothesised that excess cortisol 
action in specific brain areas might be causally linked to these dysfunctions (Holsboer, 2001; 
Belanoff et al., 2001a), the use of glucocorticoid receptor (GR) antagonists may provide an 
effective new strategy in treatment of these psychopathologies. Strong evidence supporting 
this hypothesis has recently been provided with regard to psychotic major depression (PMD) 
(Belanoff et al., 2002). PMD is a distinct depressive syndrome different from nonpsychotic 
depression in various aspects including presence of delusions or hallucinations and 
neuroendocrine dysfunction. Patients show high rates of hypercortisolemia (Belanoff et al., 
2001b) and of nonsuppression on the dexamethasone suppression test (Nelson and Davis, 
1997). The GR-antagonist C-1073 (RU486 or mifepristone) was demonstrated to rapidly 
relieve patients from both psychotic and depressive symptoms (Belanoff et al., 2002). After a 
brief 7-day treatment with high doses of 600-1200 mg/day patients showed dramatic 
improvement in their scores on Brief Psychiatric Rating Scale and Hamilton Rating Scale for 
Depression.  
 
We hypothesise that C-1073 blocks excess cortisol action at the GR level in brain regions 
involved in cognitive and emotional processing, e.g. frontal cortex and limbic brain regions. 
As only very high doses are effective, the question arises whether effective blockade of central 
GR by C-1073 may be impeded by hampered penetration of C-1073 into the brain. 
Alternatively, C-1073 may facilitate uptake of cortisol into the brain at the blood-brain-barrier 
(BBB) by inhibition of the efflux transporter P-glycoprotein (Pgp) (Gruol et al., 1994). Since 
we have shown that Pgp transports cortisol out of the brain (Karssen et al., 2001), C-1073 may 
be able to inhibit Pgp-mediated cortisol efflux at the BBB, resulting in enhanced cortisol 
uptake in brain. The subsequently increased cortisol brain levels would require higher brain 
levels of C-1073 to effectively block central GR.  
This counteracting effect will be on top of the C-1073-induced disinhibition of cortisol 
secretion due to blockade of cortisol negative feedback on the HPA-axis at the pituitary and 
hypothalamic levels. Under normal conditions, the latter effect is only seen when GR is 
activated in presence of increased glucocorticoid levels i.e during the circadian peak in both 
humans and animals (Gaillard et al., 1984; Raux-Demay et al., 1990; Van Haarst et al., 1996). 
In hypercortisolemic depressed patients, this effect may be seen during the whole day (Kling 
et al., 1989; Belanoff et al., 2002; Schatzberg unpublished). 
 
For measurement of brain uptake of GR-antagonists LC/MS/MS steroid profiles were made of 
brain and plasma extracts of rats treated with various doses of C-1073. In vivo, C-1073 is 
rapidly converted into three main metabolites, a mono-demethylated (RU42633), a 
di-demethylated (RU42848) and a hydroxylated (RU42698) (Deraedt et al., 1985).  Since 
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these metabolites retain activity as GR-antagonists (Deraedt et al., 1985; Heikinheimo et al., 
1987a), they were also determined in this study.  
To investigate whether C-1073 and/or its metabolites are able to influence cortisol transport 
mediated by Pgp, we have used monolayers of pig kidney epithelial cells (LLC-PK1) stably 
expressing human MDR1 Pgp (Karssen et al., 2001). 
 
Materials and methods  
Animal experiments 
Young adult male Wistar rats (Charles River, Germany) were housed under a 12-12 hour 
light-dark cycle with lights on at 7:00hr in a temperature (21°C) and humidity controlled 
room. Food and drinking water were available ad libitum. Before and during experiments rats 
were handled daily. All experiments were carried out in accordance with the European 
Communities Council Directive 86/609/EEC and with approval from the animal care 
committee of the Faculty of Medicine, Leiden University (The Netherlands). 
 
Animals were treated with various doses of C-1073 for five days. Body weight was monitored 
throughout this period. At the last day after the last injection the animals were killed by 
decapitation. Brain and plasma were collected and frozen until further use. Adrenals and 
thymus were also dissected and weighed. 
C-1073 was subcutaneously administered at a dose of 16 mg/kg once daily or at a dose of 50 
mg/kg twice daily. In a third experiment C-1073 suspended in an aqueous solution containing 
0.25% carboxymethylcellulose/0.2% Tween-20 was administered by gavage once a day. To 
test whether C-1073 disinhibits the HPA-axis the animals where decapitated at the end of the 
day during the circadian rise of corticosterone levels. Groups treated with vehicle were also 
included in all experiments.  
Corticosteroid determination in brain and plasma 
Using Liquid Chromatography-Mass Spectrometry-Mass Spectrometry (LC/MS/MS) steroid 
profiles were made of samples of the cortex and plasma. Samples were prepared for assay by 
dichloromethane/ethanol extraction essentially as previously described (Karssen et al., 2001). 
The brain samples (weighing about 350 mg) were homogenised in 2 ml 0.1 M perchloric acid 
with a Potter-Elvehjem tissue homogeniser (10 times up and down, 1000 rpm). To check for 
differences in recovery 100 ng of dexamethasone was added to each sample. The homogenates 
were transferred with a 4 ml wash of dichloromethane (DCM) to screw-capped glass tubes. 
After adding an extra 4 ml DCM the tubes were shaken on a horizontal reciprocating shaker 
for 30 minutes and subsequently centrifuged at 1000x g at 4°C for 10 minutes. The DCM layer 
was transferred to a clean coned tube and rinsed with 1 ml water, centrifuged at 700x g for 10 
minutes. Then, the DCM-layer was transferred to a long tube and evaporated to dryness under 
nitrogen. To maximise the amount transferred, the extracts were redissolved in 750 µl ethanol 
and after transferring to an eppendorf, evaporated again. The final extracts were resuspended 
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in 100 µl 25% methanol and centrifuged at 13000 rpm for 5 minutes. To avoid potential 
dissimilarities between different extraction methods, 250 µl plasma samples were extracted in 
the same way.  
 
The LC/MS/MS assays were performed on a Triple Stage Quadrupole mass spectrometer 
(ThermoFinnigan TSQ-Quantum, San Jose, USA) with an atmospheric pressure chemical 
ionisation interface. A modification of the method of Van der Hoeven et al. (1997) was used. 
The analysis was performed in positive ionisation mode using selective reaction monitoring of 
C-1073, its three main metabolites, corticosterone and dexamethasone. The [M+H]+ precursor 
ions were fragmented using argon as collision gas. The m/z ratios of the most abundant 
product ions were alternately scanned. The ion-source temperature and the nebulisation heater 
were kept at 200°C and 400°C, respectively. The voltages on the corona needle and on the 
electron-multiplier were set at 10 µA. Each experiment, a new standard series was made in 
25% methanol with concentrations ranging from 1-500 ng/ml of all steroids. Dexamethasone 
(1µg/ml) was used as an internal standard. A Surveyor LC System (ThermoFinnigan) was 
used to inject 20 µl of the standard or extraction samples. A gradient of methanol-water 
(containing 1 g/l acetic acid) changing from 50/50% to 90/10% at a flow rate of 500 µl/min 
separated the steroids on an ADS C18 column. All samples were measured in duplo. The 
detection limit of this assay was 1-5 ng/ml for each steroid.  
Steroid concentrations were calculated from a standard plot of area under the curve versus 
concentration. The standard curves usually displayed an r2 of more than 0.95. Presented data 
are corrected for recovery of dexamethasone, which was in the order of 25-50%. 
Transepithelial transport and inhibition studies 
In order to examine the inhibitory action of RU486 on Pgp-mediated cortisol transport we 
used monolayers of the porcine kidney epithelial cell-line LLC-PK1, and LLC-PK1 cells 
stably transfected with cDNA of the human MDR1 gene encoding P-glycoprotein (LLC-
PK1:MDR1) (Schinkel et al., 1995) as previously described (Karssen et al., 2001).  
During culturing and experiments complete medium, which consisted of DMEM supplied 
with HEPES (25 mM) and glucose (4.5 g/l) and supplemented with penicillin (100.000 U/l), 
streptomycin (100 mg/l), L-glutamine (2 mM) and 10% (v/v) foetal calf serum, was used. The 
cells were seeded on microporous polycarbonate membrane filters (0.4 µM pore size, 12 mm 
diameter; Costar, USA) at a density of 120*103 cells/cm2. Two hours before the start of the 
experiment, the medium was replaced with 800 µl fresh medium at both the apical and basal 
side of the monolayer. One hour later 8 µl of a 100x stock of GR antagonists or vehicle 
(ethanol) was added at the apical side. RU486 was added alone at a final concentration of 10 
or 100 µM. In a separate experiment a mix of RU486 and metabolites at therapeutically 
relevant concentrations was added. At the start of the experiment (t=0), 8 µl of a 100x stock of 
3H-cortisol (Amersham Pharmacia Biotech, UK; specific activity 63 Ci/mmol) in ethanol 
(final concentration 15 nM) was added in triplicate at the apical or basal side respectively. To 
measure the transepithelial transport from the apical to the basal side or from basal to the 
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apical side, the appearance of radioactivity in the compartment opposite that to which activity 
was added, was examined. Over the four hours of study 75 µl samples were taken once every 
hour from this compartment. These samples were counted in a Tricarb ß-counter together with 
eight µl samples of the 100x stock. From the other compartment 75 µl aliquots were removed 
each time to ascertain an undisturbed action of Pgp. Basal to apical and apical to basal 
transport is presented as percentage of total activity added at the beginning of the experiment. 
Transepithelial electrical resistance was measured before and after the experiments to check 
the integrity of the monolayers (Gaillard and De Boer, 2000).  
Statistical analysis  
Data were evaluated by Student’s t-test. The results of the monolayer experiments were 
analysed by Repeated Measures ANOVA. Significance was taken at p < 0.05. 
 
Results 
The steroid profiles of rat brain and plasma made with LC/MS/MS show that three hours after 
the last treatment with 16 mg/kg the C-1073 levels were low in both brain and plasma (figure 
1). Brain levels were 19.7±13 ng/gr tissue, whereas levels in plasma were 12.6±5.5 ng/ml. 
There was, however, quite a large variability in C-1073 levels between animals. In addition, 
plasma levels did not correlate with brain levels. The concentrations of the three metabolites 
were below the detection limit, except for RU42633 levels, which were very low but 
detectable (data not shown).  
Corticosterone levels in brain at the same time point late in the afternoon were about 8-10% of 
plasma levels in both treatment groups (figure 1). Due to the low number of animals no 
significant differences in corticosterone levels in blood plasma or in brain were found between 
FIGURE 1. Steroid levels at 3 hours after last administration of 16 mg/ml C-1073; levels of
C-1073 were in the same range in both brain and plasma (10-20 ng/ml). Brain levels of
corticosterone were 10-12 times lower than plasma levels in both groups. N=2-4, shown is
mean+SEM. Note the difference in scale.
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vehicle and C-1073 treated animals. There was a strong significant correlation between 
corticosterone plasma and brain levels (figure 2).  
Extremely high brain and plasma levels of C-1073 were found in animals treated with a high 
dose of 50 mg/kg at one hour after the last administration in the morning (figure 3). 
After oral treatment….?? (Experiment in progress)  
C-1073 treatment did neither affect adrenal and thymus weight nor body weight after any 
treatment schedule. 
FIGURE  2. Representative example of the strong correlation between corticosterone brain and
plasma levels. At 3 hours after the last administration of C-1073 (8 or16 mg/kg) or vehicle brain
and plasma levels correlated significantly (r2=0.92; p<0.005). 
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FIGURE 3. At one hour after the last administration of 50 mg/kg C-1073, C-1073 were
extremely high in both brain and plasma. For unknown methodological reasons false positive
results were obtained in vehicle treated animals. Although less strong, again a significant
correlation was found between corticosterone brain and plasma levels (not shown).  
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Inhibition of cortisol transport 
Our monolayer data demonstrate that 10 µM C-1073 is able to block Pgp-mediated cortisol 
transport (figure 4). In MDR1-monolayers cortisol was transported in a highly polarised 
fashion. In presence of C-1073 this transport was inhibited. ANOVA followed by post-hoc 
analysis shows that at t=4 in presence of C-1073 MDR1 transfected monolayers were not 
different from untransfected monolayers with regard to transport of 3H-cortisol, while both 
were statistically different from the untreated MDR1 monolayers. 100 µM C-1073 was not 
able to further enhance the inhibitory action on cortisol transport (data not shown).  
At a concentration of 2.5 µM – a therapeutically relevant level – C-1073 inhibited transport to 
a minor extent (data not shown). As the three main metabolites of C-1073 are structurally 
similar to C-1073, they may inhibit Pgp as well. Therefore we tested the ability to inhibit 
cortisol transport of a mix of C-1073 and metabolites at therapeutically relevant 
concentrations. A mix of C-1073, RU42848, RU42698 (2.5 µM each) and 6 µM RU42633 
affected cortisol transport in MDR1 monolayers to a similar extent as 10 µM C-1073 alone 
(figure 5). C-1073 did not affect C-1073 transport in untransfected monolayers (data not 
shown).  
 
Discussion  
We have examined the interactions of the GR antagonist C-1073 at the blood-brain barrier, 
that may affect its action in the brain. Some of our findings may explain why high oral doses 
are needed to see an effect of C-1073 on brain function. Limited access of C-1073 to the brain 
is not likely to occur, as plasma and brain levels in our rats were similar. However, our data 
suggest that C-1073 and its active metabolites may rapidly disappear from the brain. Our data 
further demonstrate that C-1073 and its metabolites are able to inhibit Pgp-mediated transport 
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FIGURE 4. In presence of 10 µM C-1073, transport of 3H-cortisol in MDR1-transfected
monolayers is inhibited and not different from transport of cortisol in nontransfected monolayers.
Data are presented as mean±SEM of three wells. 
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of cortisol. This inhibition would presumably result in increased cortisol brain levels, which 
would require higher C-1073 concentrations in brain to compensate for increased cortisol 
action. Besides rapid clearance and/or facilitation of cortisol uptake, the increased activity of 
the HPA-axis resulting from blockade of glucocorticoid feedback is also likely to be 
responsible for the high systemic doses needed. 
 
When administered systemically, very high doses of C-1073 are needed to be effective in the 
brain as an antiglucocorticoid in both humans (Gaillard et al., 1984; Belanoff et al., 2002) and 
animals (De Kloet et al., 1988; Ratka et al., 1989). Indeed, to effectively block competitive 
binding of endogenous glucocorticoid to central GR, high levels in the brain are needed. 
However, it is intriguing that when administered directly in the brain, a 100,000 fold lower 
dose is enough to effectively block corticosterone action in rats (De Kloet et al., 1988; Ratka 
et al., 1989; Van Haarst et al., 1996). Our findings indicate that impaired penetration of the 
BBB may not explain the poor effectiveness of systemic doses as compared to central doses. 
The similar levels in brain and plasma as shown by us are, however, in contrast to previous 
studies. Shortly after a single oral administration of 5 mg/kg 3H-RU486 total brain levels of 
radioactivity were about 37% of plasma levels, although it was stated that some brain areas 
including cortex were selectively labelled (Deraedt et al., 1985). In another study, Zucker rats 
were orally treated with 10 mg/kg twice a day for 4 days (Heikinheimo et al., 1994). Six hours 
later, brain concentrations were 28% of those in plasma. These discrepancies are presently 
unexplained for, but might be related to dose, route of administration, timing and/or rat strain. 
It is, however, clear that C-1073 is able to cross the blood-brain barrier at least to a 
considerable extent.  
 
Our data may further provide alternative explanations for the high doses needed. Rapid 
clearance and/or preferential uptake into other tissues may account for the large difference 
FIGURE 5. A mix of C-1073 and its three main metabolites at therapeutically relevant
concentrations (see text) inhibits transport of 3H-cortisol in MDR1 transfected monolayers. 
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between the two time points measured in the present study. Whereas at one hour after the last 
injection levels were extremely high, at three hours after the last administration levels were 
very low. Although the different doses administered may explain some of this, a rapid 
clearance from blood and brain due to uptake into other extravascular compartments is a more 
likely explanation. High rate of extravascular diffusion and fast elimination has previously 
been demonstrated after administration of a low dose of 5 mg/kg to rats (Deraedt et al., 1985). 
 
The high variability of C-1073 between animals and the discrepancy between brain and 
plasma found in the present study are difficult to explain, but do not appear to be related to the 
method of detection using extraction and LC/MS/MS measurements. Corticosterone plasma 
levels correlate well with corticosterone brain levels, supporting the applicability of the 
employed method for measurement of steroid levels.  
 
It might be difficult to extrapolate the present findings to humans. C-1073 follows a 
profoundly different pharmacokinetic profile in rat and human (Deraedt et al., 1985). In 
humans, C-1073 has a complex pharmacokinetic profile due to binding to the low 
capacity/high affinity serum binding protein, α1-acid glycoprotein, which binds about 95% of 
circulating C-1073 (Heikinheimo et al., 1987b; Heikinheimo et al., 1989; Philibert et al., 
1991). After the redistribution phase following oral intake of doses of C-1073 higher than 100 
mg the plasma levels of C-1073 and metabolites do not change for over 24 hours. With higher 
doses administered, only the duration of this period of stable levels increases while the plasma 
levels remain unchanged at 2.5 µM.  The saturation of α1-acid glycoprotein probably explains 
the long plasma half-life in human (Deraedt et al., 1985). The rat α1-acid glycoprotein does 
not bind C-1073, which explains the low levels in plasma and also may result in faster plasma 
clearance (Philibert et al., 1991). However, adipose tissue may function as a depot that 
through continuously supplying C-1073 to the circulation may extend the period of activity of 
C-1073 (Heikinheimo et al., 1994). 
It is not known how plasma binding may affect brain uptake of C-1073. One study shows that 
concomitant treatment of rats with C-1073 and the human α1-acid glycoprotein results in a 
decreased first-pass uptake in liver and uterus (Steingold et al., 1990), but the effect of 
prolonged concomitant treatment was not studied. If only free levels would be available for 
uptake into the human brain as might be suggested by the reported low levels in cerebrospinal 
fluid -about 4% of plasma concentration- (Sartor and Figg, 1996), our findings in rat might 
model the human situation quite well. Further studies should shed light on this issue.    
 
Interestingly, our study provides a new alternative mechanism of action not related to the GR 
antagonism of C-1073, but to its potency to block transport of substrates of the efflux 
transporter Pgp. Like other antidepressants (Pariante et al., 2001), C-1073 promotes 
accumulation and intracellular action of Pgp substrates and it inhibits transport of Pgp 
substrates (Lecureur et al., 1994; Gruol and Bourgeois, 1994; Gruol et al., 1994; Gruol et al., 
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2002). Accumulation studies show that C-1073 is probably not transported itself by Pgp 
(Gruol and Bourgeois, 1994).  
The present study shows that C-1073 is able to block transport of cortisol. Due to the presence 
of Pgp at the BBB, uptake of cortisol into the brain is hampered (Karssen et al., 2001) and 
thus C-1073 would presumably be able to increase cortisol brain levels (figure 6). At a 
concentration of 10 µM C-1073 already completely suppressed Pgp-mediated cortisol 
transport. As levels of C-1073 generally do not rise above 2.5 µM, we also tested this 
concentration. Although at this concentration C-1073 alone only minimally reduced cortisol 
transport, a mix of C-1073 and its metabolites inhibited cortisol transport to a much higher 
degree. Since we have chosen concentrations based upon literature data on plasma levels in 
humans after C-1073 treatment (Lähteenmäki et al., 1987), this suggests that Pgp-inhibition of 
cortisol efflux by C-1073 and its metabolites might indeed result in an increased uptake of 
cortisol in brain in vivo. This would require higher C-1073 concentrations in brain to 
overcome the agonistic cortisol action. 
 
FIGURE 6. Hypothesised C-1073-induced facilitation of cortisol brain uptake through
inhibition of the efflux transporter P-glycoprotein. Under normal conditions cortisol is hampered to
enter the brain due to active outwards directed transport at the blood-brain barrier mediated by P-
glycoprotein. In presence of C-1073 (RU486) this efflux is blocked facilitating uptake of cortisol
into the brain. The ensuing increased cortisol concentration will not lead to increased activation of
GR, since this receptor is blocked by the high concentrations of C-1073. However, it may lead to
increased activation of the MR which would affect cognitive performance and neuroendocrine
regulation. 
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Our data may explain the high doses needed in treatment of psychotic depression, but they do 
not explain the rapid onset of action of C-1073. We hypothesise that blockade of GR in 
specific brain areas involved in cognitive and emotional processing is the principal mechanism 
of action. Patients with psychotic depression show specific impairments in prefrontal and 
hippocampal function not found in patients with nonpsychotic depression (Schatzberg et al., 
2000). These abnormalities might be caused by the excessive glucocorticoid activity 
characteristic of these patients, possibly via enhanced prefrontal dopaminergic activity 
(Schatzberg et al., 1985; Schatzberg et al., 2000). This glucocorticoid-induced enhancement 
might be blocked by C-1073 treatment, which may break the vicious glucocorticoid/dopamine 
cycle.  
Blocking the GR also results in increased cortisol levels in brain (both by blocking the 
feedback loop and by facilitation of cortisol brain uptake at the blood-brain barrier). Since 
C-1073 has negligible affinity for the mineralocorticoid receptor (MR) (Philibert, 1984), the 
higher cortisol levels may result in increased activation of this receptor, which exerts an 
inhibitory action on the HPA-axis (Dallman et al., 1987; De Kloet et al., 1998). Furthermore, 
MR and GR do mediate distinctly different and sometimes even opposing actions of 
glucocorticoid hormones on neuronal function and behaviour (De Kloet, 1991; De Kloet et al., 
1998). Treatment with C-1073 will shift the MR/GR balance, which is important for proper 
cognitive and neuroendocrine functioning (Oitzl et al., 1997; De Kloet, 2002). The resultant 
alteration of central glucocorticoid signalling might normalise the set points of hormonal and 
cognitive function in the patients. Further studies examining the effects of C-1073 on central 
GR and MR occupation are presently under way. 
 
Acknowledgements 
Servane Lachize, Heleen Voorwinden and Bertil Hofte are gratefully acknowledged for 
technical assistance during animal handling, cell culturing and LC/MS/MS measurements 
respectively. 
Reference List 
 
 1.  Belanoff JK, Gross K, Yager A and Schatzberg AF (2001a) Corticosteroids and cognition. J Psychiatr Res 
35 (3): 127-145 
 2.  Belanoff JK, Kalehzan M, Sund B, Ficek SKF and Schatzberg AF (2001b) Cortisol activity and cognitive 
changes in psychotic major depression. Am J Psychiatry 158 (10): 1612-1616 
 3.  Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C and Schatzberg AF (2002) 
An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 52 (5): 386-392 
 4.  Dallman MF, Akana SF, Cascio CS, Darlington DN, Jacobson L and Levin N (1987) Regulation of 
ACTH secretion: variations on a theme of B. Recent Prog Horm Res 43: 113-173 
 5.  De Kloet ER (1991) Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 
12 (2): 95-164 
Uptake of C-1073 into brain 
 183
 6.  De Kloet ER (2002) Stress in the brain: implications for treatment of depression. Acta Neuropsychiatr 14 (4): 
155-166 
 7.  De Kloet ER, De Kock S, Schild V and Veldhuis HD (1988) Antiglucocorticoid RU 38486 attenuates 
retention of a behaviour and disinhibits the hypothalamic-pituitary adrenal axis at different brain sites. 
Neuroendocrinology 47 (2): 109-115 
 8.  De Kloet ER, Vreugdenhil E, Oitzl MS and Joëls M (1998) Brain corticosteroid receptor balance in health 
and disease. Endocr Rev 19 (3): 269-301 
 9.  Deraedt R, Bonnat C, Busigny M, Chatelet P, Cousty C, Mouren M, Philibert D, Pottier J and Salmon 
J (1985) Pharmacokinetics of RU 486. In: Baulieu EE, Segal S (eds). The antiprogestin steroid RU 486 and 
human fertility control. Plenum Press, New York, NY: 103-122 
 10.  Gaillard PJ and De Boer AG (2000) Relationship between permeability status of the blood-brain barrier and 
in vitro permeability coefficient of a drug. Eur J Pharm Sci 12 (2): 95-102 
 11.  Gaillard RC, Riondel A, Muller AF, Herrmann W and Baulieu EE (1984) RU 486: a steroid with 
antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of 
day. Proc Natl Acad Sci U S A 81 (12): 3879-3882 
 12.  Gruol DJ and Bourgeois S (1994) Expression of the mdr1 P-glycoprotein gene: a mechanism of escape from 
glucocorticoid-induced apoptosis. Biochem Cell Biol 72 (11-12): 561-571 
 13.  Gruol DJ, Zee MC, Trotter J and Bourgeois S (1994) Reversal of multidrug resistance by RU 486. Cancer 
Res 54 (12): 3088-3091 
 14.  Gruol DJ, King MN and Kuehne ME (2002) Evidence for the Locations of Distinct Steroid and Vinca 
Alkaloid Interaction Domains within the Murine mdr1b P-Glycoprotein. Mol Pharmacol 62 (5): 1238-1248 
 15.  Heikinheimo O, Haukkamaa M and Lähteenmäki P (1989) Distribution of RU 486 and its demethylated 
metabolites in humans. J Clin Endocrinol Metab 68 (2): 270-275 
 16.  Heikinheimo O, Kontula K, Croxatto H, Spitz I, Luukkainen T and Lahteenmaki P (1987a) Plasma 
concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem 26 (2): 279-
284 
 17.  Heikinheimo O, Lahteenmaki PL, Koivunen E, Shoupe D, Croxatto H, Luukkainen T and 
Lahteenmaki P (1987b) Metabolism and serum binding of RU 486 in women after various single doses. 
Hum Reprod 2 (5): 379-385 
 18.  Heikinheimo O, Pesonen U, Huupponen R, Koulu M and Lähteenmäki P (1994) Hepatic metabolism and 
distribution of mifepristone and its metabolites in rats. Hum Reprod 9 Suppl 1: 40-46 
 19.  Holsboer F (2001) Stress, hypercortisolism and corticosteroid receptors in depression: implicatons for 
therapy.  J Affect Disord 62 (1-2): 77-91 
 20.  Karssen AM, Meijer OC, Van der Sandt ICJ, Lucassen PJ, De Lange ECM, De Boer AG and De Kloet 
ER (2001) Multidrug Resistance P-Glycoprotein Hampers the Access of Cortisol But Not of Corticosterone 
to Mouse and Human Brain. Endocrinology 142 (6): 2686-2694 
 21.  Kling MA, Whitfield HJ, Brandt HA, Demitrack MA, Kalogeras K, Geracioti TD, Perini GI, Calabrese 
JR, Chrousos GP and Gold PW (1989) Effects of glucocorticoid antagonism with RU 486 on pituitary-
adrenal function in patients with major depression: time-dependent enhancement of plasma ACTH secretion. 
Psychopharmacol Bull 25 (3): 466-472 
 22.  Lähteenmäki PL, Heikinheimo O, Croxatto H, Spitz I, Shoupe D, Birgerson L and Luukkainen T 
(1987) Pharmacokinetics and metabolism of RU 486. J Steroid Biochem 27 (4-6): 859-863 
 23.  Lecureur V, Fardel O and Guillouzo A (1994) The antiprogestatin drug RU 486 potentiates doxorubicin 
cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett 355 (2): 
187-191 
 24.  Nelson JC and Davis JM (1997) DST Studies in Psychotic Depression: A Meta-Analysis. Am J Psychiatry 
154 (11): 1497-1503 
Addendum 
 184
 25.  Oitzl MS, Van Haarst AD and De Kloet ER (1997) Behavioral and neuroendocrine responses controlled by 
the concerted action of central mineralocorticoid (MRS) and glucocorticoid receptors (GRS). 
Psychoneuroendocrinology 22 Suppl 1:S87-93: S87-S93 
 26.  Pariante CM, Makoff A, Lovestone S, Feroli S, Heyden A, Miller AH and Kerwin RW (2001) 
Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid 
transporters. Br J Pharmacol 134 (6): 1335-1343 
 27.  Philibert D (1984) RU 38486: an original multifaceted antihormone in vivo. In: Agarwal MK (ed). Adrenal 
Steroid Antagonism. Walter de Gruyter & Co., Berlin, Germany: 77-101 
 28.  Philibert D, Costerousse G, Gaillard-Moguilewsky M, Nedelec L, Teutsch G, ournemine C and ique F 
(1991) From RU-38486 towards dissociated antiglucocorticoid and antiprogesterone. Front Horm Res 19: 1-
17 
 29.  Ratka A, Sutanto W, Bloemers M and De Kloet ER (1989) On the role of brain mineralocorticoid (type I) 
and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology 50 (2): 117-123 
 30.  Raux-Demay MC, Pierret T, Bouvier d'Yvoire M, Bertagna X and Girard F (1990) Transient inhibition 
of RU 486 antiglucocorticoid action by dexamethasone. J Clin Endocrinol Metab 70 (1): 230-233 
 31.  Sartor O and Figg WD (1996) Mifepristone: antineoplastic studies. Clin Obstet Gynecol 39 (2): 498-505 
 32.  Schatzberg AF, Posener JA, DeBattista C, Kalehzan BM, Rothschild AJ and Shear PK (2000) 
Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Am J 
Psychiatry 157 (7): 1095-1100 
 33.  Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED and Cole JO (1985) A corticosteroid/dopamine 
hypothesis for psychotic depression and related states. J Psychiatr Res 19 (1): 57-64 
 34.  Schinkel AH, Wagenaar E, Van Deemter L, Mol CAAM and Borst P (1995) Absence of the mdr1a P-
glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and 
cyclosporin A. J Clin Invest 96 (4): 1698-1705 
 35.  Steingold KA, Matt DW, Dua L, Anderson TL and Hodgen GD (1990) Orosomucoid in human pregnancy 
serum diminishes bioavailability of the progesterone antagonist RU 486 in rats. Am J Obstet Gynecol 162 (2): 
523-524 
 36.  Van der Hoeven RA, Hofte AJ, Frenay M, Irth H, Tjaden UR, Van der Greef J, Rudolphi A, Boos KS, 
Marko Varga G and Edholm LE (1997) Liquid chromatography-mass spectrometry with on-line solid-
phase extraction by a restricted-access C18 precolumn for direct plasma and urine injection. J Chromatogr A 
762 (1-2): 193-200 
 37.  Van Haarst AD, Oitzl MS, Workel JO and De Kloet ER (1996) Chronic brain glucocorticoid receptor 
blockade enhances the rise in circadian and stress-induced pituitary-adrenal activity. Endocrinology 137 (11): 
4935-4943 
   

 187
CURR ICULUM V ITAE  
Adriaan Martijn Karssen werd op 5 mei 1972 geboren te Delft. Hij behaalde in 1990 zijn 
VWO-diploma aan het Christelijk Lyceum Dr. W.A. Visser ’t Hooft te Leiden. Aansluitend 
begon hij met zijn studie Biologie aan de Rijksuniversiteit Leiden. In 1996 werd het 
doctoraalexamen met als specialisatierichting Medische Biologie succesvol afgelegd.  
Tijdens deze studie deed hij zijn hoofdvakstage bij de sectie Dynamische Morfologie van het 
Instituut voor Evolutionaire en Ecologische Wetenschappen van de Rijksuniversiteit Leiden 
onder begeleiding van drs. A.J. Tellegen en prof. dr. J.L. Dubbeldam. Hier deed hij een 
neuroanatomische studie van de tectofugale zenuwbanen in de wilde eend, via welke visuele 
informatie de activiteit van craniocervicale spieren kan beïnvloeden. Tevens werd de cursus 
‘Voortplanting, ontwikkeling en veroudering’ aan de Vrije Universiteit te Amsterdam als 
bijvak gevolgd. 
Een tweede onderzoeksstage werd uitgevoerd bij de divisie Medische Farmacologie van het 
Leiden/Amsterdam Center for Drug Research (LACDR) onder begeleiding van drs. O.C. 
Meijer en prof. dr. E.R. de Kloet. Tijdens deze stage onderzocht hij de rol van corticosteron 
als mogelijke mediator van de effecten van de serotonine 1A (5HT1A-) receptor agonist 
flesinoxan op de expressie van  5HT1A-receptor mRNA in de hippocampus. 
In de zomer van 1997 startte hij als gastmedewerker aan de Universiteit Leiden bij Medische 
Farmacologie, waar hij een nieuwe bindingsassay voor corticosteroïd receptor bepalingen 
verder ontwikkelde en uittestte.   
Vanaf januari 1998 tot april 2002 werkte hij als assistent in opleiding aan zijn 
promotieonderzoek bij Medische Farmacologie met als promotor prof. dr. E.R. de Kloet. Dit 
project werd uitgevoerd in samenwerking met de divisie Farmacologie van het LACDR. Het 
resultaat van dit onderzoek staat beschreven in dit proefschrift.  
Vanaf april 2002 is hij op hetzelfde lab werkzaam op een project dat gefinancierd wordt door 
het kleine Californische bedrijf Corcept Therapeutics. Hij verricht onderzoek naar de opname 
in hersenen van de glucocorticoïd receptor antagonist C-1073, een ‘oud’ medicijn met een 
nieuwe toepassing als snelwerkend antidepressivum. Een voorpublicatie van dit werk kan in 
het addendum bij dit proefschrift gevonden worden.  
Vanaf voorjaar 2004 zal hij als postdoc werkzaam zijn aan Stanford University (Californië, 
VS) bij dr. D. M. Lyons en prof. dr. A. H. Schatzberg.  
 
  188
PUBL ICAT IONS  
Book chapters 
AM Karssen, OC Meijer and ER De Kloet (2003) Corticosteroids and the blood-brain barrier. 
In: Steckler T, Kalin NH, Reul JMHM (eds). Handbook on stress, immunology and 
behaviour. Elsevier Science, Amsterdam, The Netherlands, Ch. 3.2.5: (in press) 
AM Karssen and ER De Kloet (2000) Synthetic glucocorticoids. In: Fink G (ed). 
Encyclopedia of Stress. Acadamic Press, San Diego, CA, vol. 3: 566-570 
Full papers  
AM Karssen, OC Meijer, ICJ Van der Sandt, AG De Boer, ECM De Lange and ER De Kloet 
(2002) The role of the efflux transporter P-glycoprotein in brain penetration of 
prednisolone. J Endocrinol 175 (1): 251-260 
AM Karssen, OC Meijer, ICJ Van der Sandt, PJ Lucassen, ECM De Lange, AG De Boer and 
ER De Kloet (2001) Multidrug Resistance P-Glycoprotein Hampers the Access of Cortisol 
But Not of Corticosterone to Mouse and Human Brain. Endocrinology 142 (6): 2686-2694 
AM Karssen, OC Meijer, D Pons, M Catalán Salaberría and ER De Kloet (2003) mRNA 
expression of multidrug resistance P-glycoprotein in brain. In preparation  
AM Karssen, OC Meijer, M Visser, R Sanjuan Piñol and ER De Kloet (2003) Exclusion of 
dexamethasone from the brain leads to a selective central hypocorticosteroid state. In 
preparation 
OC Meijer, AM Karssen and ER De Kloet (2003) Cell- and tissue-specific effects of 
corticosteroids in relation to glucocorticoid resistance: examples from the brain. J 
Endocrinol 178 (1): 13-18 
ER De Kloet, J Grootendorst, AM Karssen and MS Oitzl (2002) Gene x environment 
interaction and cognitive performance: Animal studies on the role of corticosterone. 
Neurobiol Learn Mem 78 (3): 570-577 
JO Workel, MS Oitzl, M Fluttert, HMB Lesscher, AM Karssen and ER De Kloet (2001) 
Differential and age-dependent effects of maternal deprivation on the hypothalamic-
pituitary-adrenal axis of brown norway rats from youth to senescence. J Neuroendocrinol 
13 (7): 569-580 
AJ Tellegen, AM Karssen, TM Rietveld and JL Dubbeldam (1998) A crossed projection from 
the optic tectum to craniocervical premotor areas in the brainstem reticular formation. An 
anterograde and retrograde tracing study in the mallard (Anas platyrhynchos L.). Eur J 
Morphol 36 (4-5): 227-243 
Publications 
 189
Abstracts  
AM Karssen, JK Belanoff, ER De Kloet (2003) Glucocorticoid receptor antagonist C-1073 
(mifepristone/RU486) inhibits P-glycoprotein-mediated efflux transport of cortisol. 
XXXIV congress of the International Society of Psychoneuroendocrinology, New York, 
USA, Sept 7-9 (Abstract) 
AM Karssen, JK Belanoff, ER De Kloet (2003) C-1073 uptake into the brain: implications 
for treatment of psychotic major depression. XXXIII congress of the International Society 
of Psychoneuroendocrinology, Pisa, Italy; March 20-23 (Abstract) 
AM Karssen, OC Meijer, AG De Boer, JK Belanoff, ECM De Lange, ER De Kloet (2002) 
P-glycoprotein, a modulator of glucocorticoid access to the brain. 5th International 
Congress of Neuroendocrinology, Bristol, UK; Aug 31-Sep 4 (Abstract) 
AM Karssen, OC Meijer, AG De Boer, ECM De Lange, ER De Kloet (2001) Exclusion of 
dexamethasone from brain by P-glycoprotein provides animal model for selective 
depletion of brain corticosteroid receptors. Fifth Dutch Endo-Neuro meeting, Doorwerth, 
Netherlands; June 5-7 (Abstract) 
AM Karssen, OC Meijer, AG De Boer, ECM De Lange, ER De Kloet (2000) The multidrug 
resistance 1a P-glycoprotein affects the penetration of various glucocorticoids in the mouse 
brain, but not of corticosterone. Nuclear Receptors in the Brain, Oegstgeest, The 
Netherlands; April 13-14 (Abstract) 
AM Karssen, OC Meijer, AG De Boer, ICJ Van der Sandt, ECM De Lange, ER De Kloet 
(2000) The multidrug resistance 1a p-glycoprotein affects the penetration of 
glucocorticoids, except corticosterone, in the brain. 30th Annual meeting Society for 
Neuroscience, New Orleans, LA; November 4-9, p 152.17, p 419 (Abstract) 
AM Karssen, OC Meijer, AG de Boer, ECM de Lange, ER de Kloet (1999) The multidrug 
resistance 1a P-glycoprotein affects the penetration of synthetic glucocorticoids in the 
brain. Third Dutch Endo-Neuro meeting, Doorwerth, Netherlands; June 2-4 (Abstract) 
AM Karssen, OC Meijer, AG De Boer, ECM De Lange, ER De Kloet (1999) The multidrug 
resistance 1a P-glycoprotein affects the penetration of synthetic glucocorticoids in the 
brain. Fourth ULLA Summer School, Copenhagen, Denmark; June 30-July 9 (Abstract) 
JO Workel, AM Karssen, MS Oitzl, HMB Lesscher, ER De Kloet (1998) Maternal 
deprivation emphasizes individual differences during aging: a lifespan study on HPA 
activity in the Brown Norway rat. Second Dutch Endo-Neuro meeting, Doorwerth, The 
Netherlands; June 3-5 (Abstract) 
 
 
 190
NAWOORD  
Met het afronden van dit proefschrift is dan eindelijk voor mij de eindstreep als promovendus 
in zicht, de doctorstitel. Zover ben ik natuurlijk niet slechts in mijn eentje gekomen. Veel 
mensen hebben, ieder op eigen wijze, bijgedragen aan de totstandkoming van dit proefschrift. 
Het werk zoals beschreven in dit proefschrift is uitgevoerd onder de begeleiding van Ron de 
Kloet. Het project was een samenwerking met Liesbeth de Lange en Bert de Boer van de 
divisie Farmacologie van het LACDR. Vanaf het tweede jaar, na zijn terugkeer uit de 
Verenigde Staten, is ook Onno Meijer er nauw bij betrokken geweest.  
Een fiks deel van het praktisch werk komt voor rekening van analisten. Het dierexperimentele 
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